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ABSTRACT 
 
Ovarian cancer is treated in most cases with a combination of surgery and chemotherapy. 
However, despite the overall improvement in survival rates, over the last 30 years there 
has not been a break-through therapeutic development. Following first-line treatment, 
the majority of patients experience periods of relapse characterised by resistance to 
anticancer drugs. Factors which contribute to ovarian cancer chemoresistance have been 
identified as potential targets for drug discovery, such as the Bcl-2 family of proteins, 
which regulates apoptosis. The strategy of targeting the anti-apoptotic members of the 
Bcl-2 family that are overexpressed in ovarian cancer has led to the discovery of BH3-
mimetics. ABT-737, a selective BH3-mimetic, has been found to be synergistic with 
chemotherapy in ovarian cancer. In this study the activity of navitoclax, an orally available 
analogue of ABT-737 and obatoclax, a pan-Bcl-2 inhibitor, were evaluated in a series of 
ovarian cancer models. Navitoclax demonstrated synergy with both carboplatin and 
paclitaxel. Obatoclax potently inhibited the growth of ovarian cancer cell cultures. In part 
this was due to the anticipated induction of apoptosis, but in other cell lines an additional 
mechanism of cell death was implicated. Surprisingly, obatoclax was neither synergistic 
with carboplatin nor paclitaxel. These observations may be used to inform the design of 
clinical trials of these agents in ovarian cancer. 
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Ithaca 
When you set out for Ithaka 
ask that your way be long, 
full of adventure, full of instruction. 
The Laistrygonians and the Cyclops, 
angry Poseidon - do not fear them: 
such as these you will never find 
as long as your thought is lofty, as long as a rare 
emotion touch your spirit and your body. 
The Laistrygonians and the Cyclops, 
angry Poseidon - you will not meet them 
unless you carry them in your soul, 
unless your soul raise them up before you. 
Ask that your way be long. 
At many a Summer dawn to enter 
with what gratitude, what joy - 
ports seen for the first time; 
to stop at Phoenician trading centres, 
and to buy good merchandise, 
mother of pearl and coral, amber and ebony, 
and sensuous perfumes of every kind, 
sensuous perfumes as lavishly as you can; 
xii 
 
to visit many Egyptian cities, 
to gather stores of knowledge from the learned. 
Have Ithaka always in your mind. 
Your arrival there is what you are destined for. 
But don't in the least hurry the journey. 
Better it last for years, 
so that when you reach the island you are old, 
rich with all you have gained on the way, 
not expecting Ithaka to give you wealth. 
Ithaka gave you a splendid journey. 
Without her you would not have set out. 
She hasn't anything else to give you. 
And if you find her poor, Ithaka hasn't deceived you. 
So wise you have become, of such experience, 
that already you'll have understood what these Ithakas mean. 
 
Constantine P. Cavafy
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Chapter 1: Introduction to ovarian 
cancer 
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1.1 The clinical facts of ovarian cancer 
 
 What is ovarian cancer? 1.1.1
 
The term “ovarian cancer” describes a number of malignant diseases involving the tissues 
of the ovaries [1]. Ovarian cancer spreads predominantly by dissemination to the 
peritoneum and direct extension to the neighbouring organs and there is some evidence 
to suggest additional hematogenous metastasis to the omentum or via the lymphatic 
system to the pelvic nodes [2], [3],[4]. Metastases can be found in the peritoneum, the 
pelvic and abdominal viscera, the diaphragm, the liver and the pulmonary tract or pleural 
surfaces [5], [6]. The progression of ovarian cancer can  lead to the development of 
ascites in the peritoneal cavity in 45-75% of the patients, depending on the histotype of 
the tumour [7]. 
 
The symptoms of ovarian cancer are abdominal discomfort, bloating, feeling full quickly 
after eating, and increased urinary frequency/urgency. Studies evaluating screening tests 
for ovarian cancer have shown that only a small proportion of patients are symptomatic 
of the disease before their diagnosis and they often describe symptoms which overlap 
with those of many more common conditions of the gastro intestinal and urogenital tract 
[8],[9], [10]. The duration of these symptoms prior to a definitive diagnosis is not clear 
and only 21,2% - 32,2% of women are reported to present with symptoms within three 
months from the diagnosis of ovarian cancer [11] . 
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 Types of ovarian cancer 1.1.2
 
The ovaries consist of three types of tissue; epithelial cells cover the ovary, germ cells 
produce the ova (eggs) inside the ovary and stromal cells hold the ovary together and 
produce most of the hormones (Figure 1). 
Depending on the cell of origin, three types of ovarian cancer can be distinguished [12]:  
 epithelial ovarian cancer (EOC) 
 germ cell tumours 
 sex cord stromal tumours.  
Although the ovarian surface epithelium (OSE) cells have traditionally been considered 
the origin of ovarian carcinomas, newer evidence suggests that the majority of ovarian 
tumours arise from non-ovarian tissue [13],[14]. 
 
 
Figure 1: Anatomy of the female genital tract, reproduced from American Cancer Society website.   
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 Subtypes of EOC 1.1.2.1
 
Embryologically, the OSE cells have the same mesodermal origin [15] as the fallopian 
tube, the uterus and the endocervix. There are five different subtypes of EOC (serous, 
endometrioid, mucinous, clear cell and undifferentiated subtype), which exhibit distinct 
histological features, similar to those of the differentiated Mullerian-duct-derived tissues 
(Table 1). 
 
The subtypes of EOC 
Subtype Characteristics Incidence (%) 5-year survival 
Serous Fallopian tube-like 70% 20-35% 
Endometrioid Endometrium-like 10-20% 40-63% 
Mucinous Endocervix-like 5% 40-69% 
Clear cell Mesonephros-like 3-10% 35-50% 
Undifferentiated unknown 1% 11-29% 
Table 1: The histological features, incidence rates and survival of EOC subtypes, reproduced with 
changes from [16],[17], [18]. 
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 Subtypes of germ cell tumours 1.1.2.2
 
Germ cell tumours comprise only 5% of ovarian cancers. They are diagnosed in younger 
women and represent 80% of pre-adolescent ovarian cancers [12]. The histologic 
subtypes of germ cell ovarian tumours are listed in Table 2. 
 
The subtypes of germ cell ovarian tumours 
Dysgerminoma 
Teratoma (Immature/ Mature/ Monodermal highly specialized) 
Endodermal sinus tumour 
Embryonal carcinoma 
Polyembryoma 
Choriocarcinoma 
Mixed forms 
Granulosa cell tumours (Adult type or Juvenile type) 
Table 2: The classification of germ cell tumours. [12] 
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 Subtypes of sex cord stromal tumours 1.1.2.3
 
Sex cord stromal tumours represent only 3-5% of ovarian cancers and they are diagnosed 
in adult women [12]. Their histologic subtypes are listed in Table 3. 
 
The subtypes of sex cord stromal tumours 
Granulosa-stromal cell tumours 
Tumours in the thecoma-fibroma group (Thecoma or Fibroma-fibrosarcoma or Sclerosing 
stromal tumour) 
Sertoli-Leydig cell tumours (androblastomas) 
Gynandroblastoma 
Sex cord tumour with anular tubules 
Unclassified 
Table 3: The classification of sex cord stromal tumours. [12] 
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 The origin of ovarian cancer 1.1.3
 
Although EOC is usually considered to arise from OSE cells, in reality the cell of origin is 
unknown. The models describing the origin of EOC can be divided into two groups. The 
first group supports the notion that the OSE is the site at which EOC originates. The 
second group represents a more recent view that EOC originates in Mullerian-duct-
derived tissue. 
 
 Evidence that EOC arises from OSE cells 1.1.3.1
 
A number of theories have been developed which propose how EOC arises from the OSE 
cells. The incessant ovulation theory proposes that the ovulation-related inflammation 
and cell proliferation leads to ovarian carcinogenesis [19]. This hypothesis is supported by 
epidemiological data showing that birth control, increased number of pregnancies, 
breastfeeding and the use of oral contraceptives reduce the risk of ovarian cancer [20]. 
 
The epithelial mesenchymal transition (EMT) hypothesis suggests that epithelial cells 
undergo metaplasia towards a mesenchymal type with characteristics of the Mullerian-
duct derived tissue. The transformed cells demonstrate different proliferation and 
motility patterns necessary for the ovarian surface remodelling during ovulation [21], 
[22]. Evidence to support the EMT are the expression in EOC of vimentin, N-cadherin and 
smooth muscle alpha-actin, the production of proteolytic enzymes and type III collagen, 
all of which are characteristic of mesenchymal cells [15]. It has been hypothesized that 
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EMT is necessary but not sufficient for the genesis of EOC. 
 
The ovarian surface contains inclusion cysts, lined with OSE cells, which are believed to be 
the site of origin of many tumours and express markers of Mullerian-duct derived tissue 
including CA125 and CA19-9 and are 2-3 times more metaplastic in EOC patients [23].The 
hypothesis that EOC arises from inclusion cysts is complementary to the incessant 
ovulation theory, as higher ovulatory activity results in higher risk for developing inclusion 
cysts and creating favourable conditions for carcinogenesis [24]. In vitro data from animal 
studies where the persistent culturing of ovarian surface cells  resulted in spontaneous 
cancer transformation, support this hypothesis [25], [26], [27]. 
 
The gonadotropins hypothesis offers an alternative view where the high levels of these 
hormones after the menopause stimulate the surface epithelium and generate the 
production of inclusion cysts from where cancer can arise [28], [29], [30].  
 
A further observation, which supports the hypothesis that OSE cells are the cell of origin 
of ovarian cancer and also explains their ability to differentiate into different histological 
subtypes, is that OSE demonstrate features of cancer stem cells. Gene expression profile 
studies [31] concluded that OSE cells have features in common with stem cells. 
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 Evidence that EOC arises from Mullerian-duct-derived tissue 1.1.3.2
 
It has been argued that the transition of epithelial cells to Mullerian-duct like as part of 
the carcinogenesis process contradicts the fundamental concept that cancer cells are less 
differentiated from their original counterparts [32]. This has led to the hypothesis that 
EOC arises from Mullerian-duct derived tissue which migrates to the ovary [33]. The 
evidence to support this can be summarised as follows: 
I. There are common histological features between EOC cells and Mullerian-duct 
derived cells. 
II. There is a correlation of the gene expression of the various cancer histotypes with 
their morphological counterparts in normal fallopian tissue [34]. 
III. Cells clinically identical to ovarian cancer cells have been found in the peritoneal 
cavity years after the removal of the ovaries for non-cancerous reasons [35], [36], 
[37]. 
IV. Mutations in p53 and BRCA genes are very common in ovarian carcinomas 
[38],[39] . Pre-neoplastic changes and mutations of p53 have been discovered in 
the fimbriae of the fallopian tubes of carriers of mutated BRCA [40], [41],[42], 
[43]. In one group of BRCA mutation carriers, p53 mutations were identified in the 
fimbriae of 38% of the population but not in any of the cells of the inclusion cysts 
of the ovarian surface [44]. 
V. Cells from the hilum (the junction between OSE and the fallopian epithelium) 
express stem cell markers and are readily transformed after inactivation of TP53 
and Rb [45] 
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VI. Mutations of the tumour-suppressor gene PTEN have been reported in a 
significant proportion of ovarian cancer cases [46].Deletion of Dicer and PTEN in 
mice leads to the development of fallopian tube tumours which subsequently 
spread to the ovary prior to metastasis throughout the abdominal cavity [47]. 
 
 
It is interesting that one study identified a group of patients who carried p53 mutations in 
the fimbriae of the fallopian tubes and also exhibited risk factors of the incessant 
ovulation theory such as increased maternal age at first pregnancy and lower parity, 
therefore “marrying” the two different models for the cell of origin [48]. It is possible that 
the process of ovulation creates an appropriate environment that allows the cells to 
migrate from the fallopian tube to the ovary [49].   
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 The epidemiology and risk factors of ovarian cancer 1.1.4
 
Ovarian cancer is currently the 5th most common cancer in women in the UK [50]and 
the gynaecological cancer with the highest mortality, with more deaths than all the 
other gynaecological cancers combined[51]. It is the 2nd most common 
gynaecological cancer after endometrial cancer and it was estimated in 2008 that 
there were over 225,000 new cases worldwide [52]. The risk for developing EOC for 
any woman in the general population is 1,3-2%  [53],[54], although this increases 
significantly in less developed countries. In comparison, the yearly adjusted incidence 
rate for germ cell tumours and stromal tumours is 0.00037 % and 0.00022 % 
respectively [12]. The incidence rate of ovarian cancer in the developed countries has 
been slowly rising over the past two decades [55],[51],[56]. 
 
The recognised risk factors for developing ovarian cancer are as follows: 
 
 1) Increasing age: the vast majority of epithelial ovarian cancer cases are diagnosed 
in postmenopausal women. In the UK from 2008 to 2010 53% of cases were 
diagnosed in women above 65 years of age and 75% in women aged 55 and over 
[50].  
 2) Family history: up to 15% of ovarian cancers are familial [55]. The risk of 
developing ovarian cancer is tripled in the presence of a family history of ovarian or 
breast cancer. The life-time risk estimate is 2.5% for the sister and 7% for the mother 
of an ovarian cancer patient [57]. Additionally, the same risk is increased by 39-46% 
for BRCA1 mutation carries and by 12-20% for BRCA2 mutation carriers [58]. The 
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women of this group are usually offered a prophylactic bilateral salpingo-
oophorectomy.  
3) Factors which prolong ovulation: nulliparity and infertility appear to increase the 
risk of a woman for ovarian cancer [59], [19]. 
4) Environmental carcinogens: the use of talc and the escorting chronic inflammation 
has been associated with the development of ovarian cancer [60], [61]. 
The use of an algorithm, which includes seven risk factors for ovarian cancer (age 
over 45, long term genital talc use, family history of ovarian or breast cancer, Jewish 
ethnicity, no use of oral contraceptives, no live births, no breastfeeding, no tubal 
ligation) showed that women with 6 or 7 positive factors were 6 times more likely to 
develop ovarian cancer [62]. 
 
Some prophylactic factors have also been acknowledged that could be protective 
against ovarian cancer. Factors that interrupt ovulation such as pregnancy, 
breastfeeding and using oral contraceptives are amongst them [59]. The use of oral 
contraceptives offers some protection against ovarian cancer as there is a 50% 
reduction in the incidence for women using oral contraceptives for more than 10 
years [63]. Undergoing a prophylactic bilateral salpingo-oophorectomy where both 
fallopian tubes and ovaries are removed appears to be a protective and cost-effective 
approach for high-risk patients; however the alternative of a salpingectomy and 
delayed oophorectomy remains a valid option with improved quality of life [64]. For 
BRCA positive patients a large study showed an 85% reduction of gynaecological 
cancers among women who underwent a prophylactic salpingo-oophorectomy 
compared to women who chose to be monitored regularly [65]. It is interesting that 
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there is still a 0.2% risk of ovarian cancer for women who have undergone an 
oophorectomy [41], as it supports the theory for the origin of EOC being outside the 
ovaries.   
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 Screening for ovarian cancer 1.1.5
 
Ovarian cancer has been described as ‘’the silent killer’’ because of its late clinical 
presentation. Only 20-25% of women are diagnosed with disease limited to the ovaries 
(FIGO disease stage I-II ) [66] while 75-80% of the patients present with evidence of 
metastatic spread (FIGO disease stage III-IV) [67],[68],[5]. The 5-year survival of ovarian 
cancer patients increases significantly when the disease is diagnosed early. It is possible 
that the establishment of an effective screening strategy could be a cornerstone for 
reducing the ovarian cancer mortality. Such a screening test needs to be characterised by 
very high sensitivity for early-stage disease (>75%) and very high specificity (99.6%) to 
secure a predictive value of at least 10% [69]. 
 
The development of such a screening tool is hindered by the following facts: 
 
1) The criteria established by the WHO for designing screening methods are not fulfilled; 
the natural history of the disease from early to advanced stages is not fully known and 
there increasing evidence suggests that the precursor lesion is  not the OSE cells as 
previously thought, but fallopian tube cells [69].  
 
2) Genetic and biomarker profiling has shown that each EOC subtype has a distinct 
“molecular signature” and the Cancer Genome Atlas project further validated this 
observation [70]. A recent immunohistochemical study found that in a group of 20 
candidate biomarkers, each subtype showed a different pattern of expression and when 
the analysis was made subtype specific then two thirds of the markers had no prognostic 
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value [71]. Thus, each subtype may require different screening methods. 
 
3) There is little understanding of the risk factors behind ovarian cancer, apart from age, 
family history and BRCA mutations. As ovarian cancer is mostly diagnosed in women of 
postmenopausal age, it has been suggested that any screening method should be applied 
only to that age group [58].  
 
Biochemical markers such as human epididymis protein-4 (HE4), decoy receptor-3 (DcR3), 
osteopontin,spondin-2, SMRP, CA72-4, ERBB2, inhibin, activin, EGFR,    mesothelin, 
kallikreins and proteomic markers have been considered, but nothing has been validated 
for screening purposes [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84]. 
The use of a panel of four conventional protein biomarkers in serum has detected as high 
as 87-90% of stage I ovarian cancers [85]. The combination of CA125 and HE4 markers in 
one study showed a sensitivity of 77% for early stage disease [86]. A recent study shows 
that a steady increase in the levels of CA125, HE4 and mesothelin can be monitored to 
detect ovarian cancer 1-3 years before the clinical manifestation of the disease [87]. 
However, the lead time required to diagnose ovarian cancer with this method until the 
clinical diagnosis is confirmed is no more than one year and the impact of this on 
mortality remains to be determined. 
 
The most promising development has been a combination of the serum marker cancer 
antigen 125 (CA125) with transvaginal ultrasonography as part of a two-stage screening, 
where abnormal results prompt further imaging studies. A large multicentre trial (PLCO) 
which evaluated the potential for screening for ovarian cancer by combining Ca125 test 
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and transvaginal ultrasonography concluded that there is no benefit from screening for 
asymptomatic patients and did not result in a reduction in deaths from this disease [88]. 
The completion of the subsequent UK Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) is expected to provide definite data, as the first results from this on-going trial 
show an increased detection rate for early-stage disease (48%), with adequate sensitivity 
(89. 4%) and specificity (99. 8%).   
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 Staging of ovarian cancer 1.1.6
 
The spread of ovarian cancer at the point of diagnosis is described by the staging of the 
disease. It is essential to provide correct staging details for a patient as this can affect 
treatment decisions and later stage disease has poor survival compared to earlier stages. 
Currently an international system of staging is used called the FIGO system, after its 
authors - the International Federation of Gynaecology and Obstetrics (Figure 2). The 
staging of ovarian cancer is made following surgery, where a laparotomy is performed 
and all findings of surgical exploration are biopsied to confirm the diagnosis. The stages of 
ovarian cancer are summarized in Table 4. 
 
  
Figure 2: The stages of ovarian cancer. 
(Reproduced from CancerHelp UK) 
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The FIGO staging system of ovarian cancer, 2014 
Stage Description 
IA Tumour limited to 1 ovary, capsule intact, no tumour on surface, negative washings 
IB Tumour involves both ovaries otherwise like IA 
IC Tumour limited to 1 or both ovaries  
IC1 Surgical spill 
IC2 Capsule rupture before surgery or tumour on ovarian surface 
IC3 Malignant cells in the ascites or peritoneal washings 
IIA Extension and/or implant on uterus and/or Fallopian tubes 
IIB Extension to other pelvic intraperitoneal tissues 
IIIA 
( Positive retroperitoneal lymph nodes and /or microscopic metastasis beyond the 
pelvis) 
IIIA1 
Positive retroperitoneal lymph nodes only : 
IIIA1(i) Metastasis ≤ 10 mm                         IIIA1(ii) Metastasis > 10 mm  
IIIA2 
Microscopic, extra pelvic (above the brim) peritoneal involvement ± positive  
retroperitoneal lymph nodes 
IIIB 
Macroscopic, extra pelvic, peritoneal metastasis ≤ 2 cm ± positive retroperitoneal lymph 
nodes. Includes extension to capsule of liver/spleen 
IIIC 
Macroscopic, extra pelvic, peritoneal metastasis > 2 cm ± positive retroperitoneal lymph 
nodes. Includes extension to capsule of liver/spleen 
IVA Pleural effusion with positive cytology 
IVB 
Hepatic and/or splenic parenchymal metastasis, metastasis to extra-abdominal organs 
(including inguinal lymph nodes and lymph nodes outside of the abdominal cavity 
Table 4: The FIGO staging of ovarian cancer [89]. 
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 Grading of ovarian cancer 1.1.7
 
The grading of ovarian cancer describes how active or aggressive the cancer is.  It is done 
by histopathological examination of the tissue and comparison of the cancer cell’s 
differentiation with the well differentiated tumours looking more normal than the poorly 
differentiated. There are three different grades of tumours: well differentiated (low 
grade), moderately differentiated (moderate grade) and poorly differentiated lesions 
(high grade), as well as types where grade cannot be assessed [5]. The tumour grade is 
the most important prognostic factor in stage 1 disease [90]. 
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 Therapy of ovarian cancer 1.1.8
 
When disease is apparently confined to the ovaries and there is no evidence of 
macroscopic spread, primary surgery is the standard treatment.  A study which evaluated 
the outcome of neoadjuvant chemotherapy followed by interval debulking surgery in 
advanced stage disease did not exhibit any inferior survival outcomes compared to the 
traditional primary surgery [91].On occasions, adjuvant chemotherapy is indicated when 
there is microscopic evidence of metastatic spread or other poor prognostic factors such 
histological un-differentiation [92]. 
 
The standard treatment for advanced cancer is surgery and chemotherapy [93]. The 
majority of patients present with advanced disease that cannot be removed completely at 
surgery and in that case chemotherapy is given with intention of cure. On occasions, 
palliative chemotherapy is given to ameliorate symptoms [92].  
 
 
The therapeutic options for the treatment for ovarian cancer are described in Table 5. 
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Therapeutic options in ovarian cancer at presentation 
Treatment Definition 
Surgery alone Surgery as first therapy, patients can be given any further treatment 
Surgery + 
adjuvant 
chemotherapy 
Surgery as first therapy and then chemotherapy within 90 days from the 
date of surgery. Subsequently, patients can be given any further 
treatment. 
Neoadjuvant 
chemotherapy 
+ surgery 
Two to four cycles of chemotherapy as first therapy and then surgery 
within 42 days from the end of chemotherapy. Subsequently, patients 
can be given any further treatment. 
Radiotherapy Radiotherapy is now rarely used and only for solitary lesions in cases of 
recurrent disease. 
Table 5: The treatment options in ovarian cancer, reproduced with changes from [5].  
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 Surgical management of ovarian cancer 1.1.8.1
 
Cytoreductive surgery in ovarian cancer can be performed before or after chemotherapy 
is administered to the patient. The majority of patients receive surgery first, but the 
option of interval debulking surgery can be considered in cases of advanced disease 
following two cycles of chemotherapy [92]. 
 
The surgical management in ovarian cancer is always performed with the intention to 
remove all macroscopic disease, regardless of the timing of surgery in relation to 
chemotherapy. This approach is based on evidence, which shows that in the case of 
ovarian cancer the reduction of the tumour burden offers a survival advantage [94]. 
However, it is debated whether any benefit  seen is due to the surgery and the skills of 
the surgeon or the nature of the disease [92]. The significance of the surgical skills of the 
surgeon has also been investigated and the current knowledge is that optimal 
cytoreduction is better achieved by gynaecological oncologists compared to other 
surgeons [95], [92]. 
 
The current move in ovarian cancer surgical management is towards more extensive 
surgery and in many cases ultra-radical surgery is advocated. This often entails increased 
morbidity risks which should be weighed against any expected benefit for the patient 
[92]. 
 
  
23 
 
 Chemotherapy in ovarian cancer 1.1.8.2
 
The first line of chemotherapy for advanced EOC is a platinum-based drug or a 
combination of this with paclitaxel [96]. At present all cancer subtypes are being treated 
with the same regimes, however subtype-specific trials have been recommended 
especially for clear cell and mucinous carcinoma [97]. 
 
 
Platinum agents such as carboplatin induce DNA damage by the formation of intra- and 
inter-strand cross-links between the DNA molecules which interferes with DNA 
replication and transcription [98]. The resulting DNA damage response stimulates cycle 
checkpoints and subsequently triggers cell death [99]. The survival of subpopulations of 
cancer cells after platinum chemotherapy can be explained by a number of different 
protective mechanisms that cause drug resistance and which are discussed in more detail 
below [100].  
 
Taxanes such as paclitaxel induce their chemotherapeutic effect by blocking the 
functional reorganization of the cellular microtubules [101]. The assembly of the mitotic 
spindle is arrested and this results in failure of the chromosomes to segregate [102]. This 
leads to prolonged M-phase arrest and subsequent cell death. Resistance to the effect of 
taxanes has been associated with mutations in tubulin and transcriptional changes within 
the cancer cell [103].  
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A recent advance in the field of chemotherapy has been the introduction of the 
intraperitoneal administration of cisplatin instead of the intravenous route [104], [105], 
[106]. It has resulted in an increase in the median survival [106], but the resulting toxicity 
remains a limiting factor [107]. The concept of “dose-dense “chemotherapy represents 
another advance in cancer treatment whereby the cumulative drug dose remains the 
same, but the time intervals between doses are shorter. The primary analysis of a 
recently completed trial shows that dose-dense paclitaxel and carboplatin compared to 
conventional regimes results in an improvement in both progression-free and overall 
survival of ovarian cancer patients [108]. 
 
 
 
 
 Radiotherapy in ovarian cancer 1.1.8.3
 
The use of radiotherapy in the treatment of EOC is now rare and limited to cases of 
solitary lesions in recurrent disease.  
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 Chemoresistance in ovarian cancer 1.1.9
 
Following the first line treatment 80% of the patients show a positive response and 
experience periods of remission. Unfortunately almost 70-80% of patients subsequently 
relapse [109], [110]. The chemotherapeutic regimes used in recurrent disease vary 
depending on whether the disease remains sensitive to the initial treatment or resistance 
has been acquired. Additionally to the clinical manifestations of ovarian cancer, the “gold 
standard” for assessing regression and recurrence of the disease is the serum CA125 
(MUC16) levels. However, rising levels of CA125 in otherwise asymptomatic patients as an 
indication for retreatment has not been shown to confer any survival benefit [111]. 
 
The definition of chemoresistance in ovarian cancer is based upon the time when 
recurrent disease reappears[112]  after primary chemotherapy: 
 
De novo or intrinsic resistance.  
At least 20% of patients receiving first-line chemotherapy do not have any clinical 
remission after treatment is completed. Based on the lack of response to chemotherapy, 
these tumours are considered to exhibit intrinsic drug resistance and are platinum 
refractory [113]. 
 
Platinum sensitivity. 
Any patient with progression of disease reported after 6 months from the completion of 
platinum-based treatment is considered to have a chemosensitive tumour. A greater 
interval between primary treatment and recurrent disease is associated with an increased 
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likelihood that the patient will respond to retreatment for a longer period of time. 
Patients whose tumour is considered chemosensitive may again be treated with 
carboplatin and paclitaxel.  
 
For those patients considered to have chemosensitive disease, at present, three different 
combination regimes are considered to be the standard of care. The use of carboplatin 
and paclitaxel shows a survival advantage compared to platinum monotherapy without 
any increased toxicity risks [114]. Alternative combination regimes which favour less 
toxicity include carboplatin combined with gemcitabine and carboplatin combined with 
pegylated liposomal doxorubicin (PLD). Comparison studies showed that there was no 
difference in the overall survival of patients receiving platinum agent monotherapy or the 
combination of carboplatin with gemcitabine. On the contrary, the carboplatin-PLD 
regime showed better progression-free-survival times compared to the carboplatin-
paclitaxel combination but data regarding the overall survival are not conclusive [115]. 
 
Platinum-resistance. 
5% of the patients progress during their first cycle of platinum-based chemotherapy and 
another 17% of patients progress within 6 months of completion of treatment. They are 
considered to have tumours that are platinum-resistant and may be considered for 
second line chemotherapy. 
 
Overall, approximately 80% of patients diagnosed with EOC will relapse after first-line 
platinum-based and taxane-based chemotherapy and may benefit from alternative 
therapies. For chemoresistant patients the second-line therapy should include a 
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nonplatinum-based agent. The results of several trials show that although there is an 
impact of second-line treatment on the overall response and progression-free survival, 
the overall survival is not improved [114]. Existing data support the use of single-agent 
therapy with conventional Topotecan, pegylated liposomal doxorubicin (PLD) or 
gemcitabine [114]. 
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 Ovarian cancer prognosis 1.1.10
 
The prognostic factors that have been recognised in ovarian cancer are the volume of 
residual disease after cytoreductive surgery and the sensitivity to platinum-based agents 
[116]. The use of biomarkers (serum or tissue) as prognostic tools to predict the response 
of a patient to chemotherapy or the expected survival has been investigated [117], but 
larger cohorts of women are required before any suggested marker is fully established. 
 
After treatment, the 5-year survival rates are [54]: 
i. Stage I is >90% 
ii. Stage II  70-80% 
iii. Stage III 20-30% 
iv. Stage IV <5% 
 
It is accepted by many that metastases are more difficult to treat in comparison to any 
primary tumour [118]. For women diagnosed with advanced disease the surgical 
intervention is limited and the prognosis poor  [119]. Serous and endometrioid ovarian 
cancers respond better than clear cell and mucinous cancers to platinum – taxane 
chemotherapeutic regimes [120]. Serous tumours are initially responsive to 
chemotherapy, while clear cell tumours are resistant [121], [122]. 
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1.2 The molecular biology of ovarian cancer 
 
 The genetic abnormalities of ovarian cancer 1.2.1
 
It has been estimated that the process of oncogenesis in solid tumours entails a single cell 
undergoing five or more critical genetic aberrations. In the case of ovarian carcinogenesis 
approximately 30 oncogenes and tumour suppressor genes have been identified that are 
frequently involved. These genetic changes affect proliferation, apoptosis, adhesion and 
invasion, block anoikis and increase motility. The known genetic and epigenetic 
alterations involved in ovarian carcinogenesis are summarized in Table 6. 
 
The cancer genome atlas project has shed light onto the biology underlying serous 
ovarian cancer.TP53 is mutated in the vast majority (96%) of serous ovarian cancers. 
However, the disease is otherwise characterized by somatic copy number alterations, 
rather than mutations, which appear to be the key genetic drivers in other cancers, such 
as renal cancer.  Changes in the Rb, PI 3-kinase and homologous recombination pathways 
are commonly observed (67%, 45% and 51% of tumours, respectively [123]) in serous 
ovarian cancer. These pathways are discussed in more detail below. Furthermore, serous 
cancer could be subdivided into 4 further subtypes, based on gene expression patterns. 
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Table 6. Genetic abnormalities in ovarian cancer 
Event Effect Chromosome Gene 
Gene amplification Activation 
1q22 
3q26 
5q31 
8q24 
19q 
20p 
20q13,2 
RAB25 
PRKCI,EVII & PIK3CA 
FGF1 
MYC 
PIK3RI & AKT2 
ND 
AURKA 
Gene deletion Inactivation 
4q,5q,16q,17p,17q, 
Xp and Xq 
ND 
Mutation Activation NA 
KRAS (15%), BRAF (12%), 
CTNNB1 (12%), 
CDKN2A (10%), 
APC (9%), PIK3CA (8%), KIT 
(7%) and 
SMAD4 (7%) 
Hypomethylation Activation NA IGF2 and SAT2 
Loss of 
heterozygosity 
Inactivation 
17p13 and 17q21 (in 
50% of cases or more) 
1p, 3p, 5q, 5q, 6q, 7q 
and 
8q (in fewer than 30% of 
ARHI, PEG3, PLAGL1, 
RPS6KA2, TP53, 
BRCA1, BRCA2, 
PTEN, OPCML and WWOX 
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cases) 
Mutation Inactivation NA 
TP53 (62%), BRCA1 (5%), 
BRCA2 (<5%) 
and PTEN (3–8%) 
Promoter 
methylation 
Inactivation NA 
ARHI, DAPK1, CDH13, 
MLH1, ICAM1, 
PLAGL1, DNAJC15, 
MUC2, OPCML, PCSK6, 
PEF3, CDKN2A, CDKN1A, 
RASSF1, SOCS1, SOCS2, 
PYCARD and SFN 
Table 6: The known genetic alterations in ovarian cancer, reproduced with changes [120].  
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 Oncogenes in ovarian cancer 1.2.2
 
There are at least 30 oncogenes commonly known to be involved in ovarian 
carcinogenesis (Table 7). The genes encoding 11 of them are amplified [124] while the 
remained are activated through mutation, truncation or rearrangement. 
 
PIK3CA 
PIK3CA encodes the catalytic subunit of PI3-kinase. It is involved in invasion, metastasis 
and the development of chemoresistance [125], [126], [127]. Through activation of the 
Akt pathway, PI3-kinase promotes cell survival and results in oncogenic transformation 
[128],[129]. 
 
CCNE1 
Amplification of CCNE1, which encodes the cyclin-dependent kinase regulator cyclin E1, 
results in increased oncogenesis, in part through increased proliferation, and genetic 
instability [130], [131], [132], [133] and is associated with poor clinical outcome 
[134],[135]. 
 
RAB25 
RAB25 encodes a small GTPase and its amplification induces increased motility and 
aggressiveness and can promote cancer cell survival in response to stress induced by 
treatment [136]. 
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NOTCH3 
Amplification is necessary for the survival of some ovarian cancers, as its inactivation lead 
to decreased proliferation and increased apoptosis[137]. 
EVI1 
EVI1 is a transcription factor which increases proliferation and migration potential [138]. 
MYC 
MYC also encodes a transcription factor and an oncogene whose amplification causes 
increased proliferation and migration and promotes angiogenesis and cell survival under 
hypoxic conditions [139],[140] ,[141] ,[142],[143],[144], [145]. 
KRAS 
KRAS encodes a small GTPase which is activated by several growth factor receptors and 
stimulates the Erk pathway, thereby promoting cell proliferation. Aberrations are 
common in lower grade cancers and have no prognostic value [146]. 
ErbBB2 (or HER2) 
ErbBB2 belongs to the epidermal growth factor (EGF) family of tyrosine kinases receptors. 
Its activation promotes cell proliferation, angiogenesis and metastasis [147], [148], [149]. 
It is frequently found in mucinous ovarian cancer (18.2%) and has not been shown to 
carry any prognostic value [150]. 
AKT2 
AKT2 encodes a protein serine/threonine kinase It is implicated in pathways regulating 
cell survival and tumour progression. Its expression is clinically associated with advanced 
FIGO stage [151]. 
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Some of the genetic alterations in ovarian cancer are of particular interest, and deserve 
further comments, such as the HOX genes and the genes which are responsible for the 
cell DNA repair mechanisms. The HOX family of homeobox genes normally regulate 
Mullerian duct differentiation and are expressed during gynaecological organogenesis. 
They are not expressed by OSE cells. It has been shown that EOC subtypes re-express 
homeobox genes according to their pattern of Mullerian-duct-like differentiation [152] .  
 
BRCA1 and BRCA2 genes are involved in DNA repair. 15% of ovarian cancer cases are 
associated with BRCA1 or BRCA2 mutations and the heritable non-polyposis colorectal 
cancer gene [153], [154].The tumours bearing mutations in these genes are more 
frequently multifocal (contrary to the fact that 90% of epithelial ovarian cancers are 
clonal [155]) and progress faster, but show a greater response to platinum-based therapy. 
BRCA1 and BRCA2 mutations account for 65-85% of hereditary ovarian cancers and 
mutations in another 4 mismatch repair genes ( MLH1, MSH2, MSH6 and PMS2) for 
another 10-15% [156], [153], [157]. 
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Oncogenes associated with epithelial ovarian cancer 
Gene Chromosome 
Percentage of 
cancers in  
which 
amplified 
Percentage of 
cancers in 
 which 
overexpressed 
Percentage 
of cancers in 
 which 
mutated 
Function 
RAB25 1q22 54% 80–89% ND 
Cytoplasmic 
GTPase and 
apical vessel 
trafficking 
EVI1 3q26 ND ND ND 
Transcription 
factor 
EIF5A2   3q26 ND ND ND Elongation factor 
PRKCI 3q26 44% 78% ND 
Cytoplasmic 
serine-threonine 
protein kinase 
PIK3CA    3q26 9–11% 32% 8–12% 
Cytoplasmic lipid 
kinase 
FGF1 5q31 ND 51% ND 
Growth factor 
for cancer and 
angiogenesis 
MYC 8q24  20% 41–66% ND 
Transcription 
factor 
EGFR   7q12 11–20% 9–28% <1% 
Protein tyrosine 
kinase growth 
factor receptor 
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NOTCH3         9p13 20–21% 62% ND 
Cell surface 
growth factor 
receptor 
KRAS  12P11–12 5% 30–52% 2–24% 
Cytoplasmic 
GTPase 
ERBB2  17q12–21 6–11% 4–12% ND 
Protein tyrosine 
kinase growth 
factor receptor 
PIK3R1           19q ND ND ND 
Cytoplasmic lipid 
kinase 
CCNE1  19q12 12–36% 42–63% ND Cyclin 
AKT2 19q13.2 12–27% 12% ND 
Cytoplasmic 
serine–threonine 
protein kinase 
AURKA    20q13 10–15% 48% ND 
Nuclear serine–
threonine kinase 
Table 7: Oncogenes implicated in ovarian cancer carcinogenesis, reproduced with changes  
[158],[159], [160]. 
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 Tumour suppressor genes in ovarian cancer 1.2.3
 
There are 16 candidate tumour suppressor genes identified in ovarian cancer to date. 
Three of those genes are known to be imprinted; ARHI (DIRAS3), PLAGL1 (LOT1) and 
PEG3. 
 
ARHI 
ARHI encodes a small GTPase in the Ras superfamily. Its expression is associated with 
prolonged progression-free survival. It is down regulated in 60% of ovarian cancers and 
re-expression of ARHI results in reduced proliferation, motility and angiogenesis. It also 
induces autophagy. 
 
PLAGL1 
PLAGL1 encodes a transcription factor with antiproliferative activity. It is down regulated 
in 39% of ovarian cancers and re-expression inhibits cancer cell proliferation. 
  
PEG3  
PEG3 is down regulated in 75% of ovarian cancers and its re-expression inhibits growth 
and induces apoptosis. Recent evidence supports the view that it is involved in the p53/c-
myc apoptosis pathway [161]. 
 
TP53 
Undoubtedly, however, the key tumour suppressor gene associated with ovarian cancer is 
TP53. This gene has been named “guardian of the genome” and is the most commonly 
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mutated gene in human cancers [162]. The p53 protein is a transcription factor which is 
activated in response to cellular stress, particularly DNA damage. Activation of p53 results 
in the transcription of the gene encoding the cell cycle regulator p21, which inhibits 
cyclin-dependant kinases resulting in cell cycle arrest. In addition, p53 can induce the 
expression of pro-apoptotic genes (discussed below). Thus, p53 can be considered to 
promote genomic integrity by causing the elimination of cells with damaged DNA. 
Mutation of p53 inactivates this function, and in some cases allows p53 to act as an 
oncogene. 60-80% of sporadic and familial ovarian cancers carry a mutated TP53 gene. 
Mutation of TP53 is associated with a higher metastatic potential [163], [164]. There does 
not appear to be a statistically significant correlation between mutation of TP53 and the 
chemoresistance of ovarian cancer [165].The restoration of the p53 function has been 
tested and although in a cellular level the effects were promising, there were no 
significant clinical results [166], [167]. 
 
MDM2 is an E3 ubiquitin ligase that binds to p53, catalyses the ubiquitination of p53 and 
targets p53 for degradation. Hdm2 (the human homolog of Mdm2) is overexpressed in 
one third of ovarian cancers. The inhibition of MDM2 with small molecular mass 
compounds in leukaemia patients with wild-type p53 resulted in increased apoptosis and 
p53 stability [168]. However, it is doubtful whether this strategy will be broadly effective 
in ovarian cancer, because only a small proportion of tumours retain wild-type TP53.  
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MLH1  
MLH1 encodes a protein involved in DNA mismatch repair gene. Platinum resistance has 
been linked to CpG methylation of this gene and in preclinical models this was reversed 
with demethylating agents [169]. 
 
PTEN 
PTEN is the 2nd most commonly mutated tumour suppressor gene [170], [171]. 
PTEN encodes a phosphatase which converts the lipid phosphatidylinositol trisphosphate 
(PIP3) to phosphatidylinositol bisphosphate PIP2. PIP3 is necessary for the activation of the 
Akt signalling pathway which promotes cell survival. Consequently, mutation of PTEN 
leads to the activation of the Akt signalling pathway. Mutations in PTEN are found in 3-8% 
of sporadic ovarian cancers, of the endometrioid histotype. 
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 Genetic alterations in ovarian cancer subtypes 1.2.4
 
Investigations of the mechanisms leading to ovarian cancer have not yet revealed genetic 
abnormalities uniquely characteristic for a particular subtype of disease. However, some 
molecular abnormalities have been recognised as being more frequent in certain 
subtypes. 
 
Serous carcinoma  
Mutations of the p53 gene are very common in high grade serous carcinoma with more 
than 95% of tumours carrying an inactive p53 [172]. The TCGA project also found that 
21% of patients carry germline or somatic mutations in their BRCA genes[173], [70]. The 
PI3K pathway is often activated in these cancers conferring a survival benefit [174].On the 
other hand the less “aggressive” low grade serous carcinoma is characterised by 
mutations in the KRAS and BRAF pathway [175] or ERBB2 [176]. 
 
Endometrioid carcinoma 
Endometrioid carcinoma is characterised by mutations in the gene encoding β catenin 
[177],[178] which is involved in two biological processes, signal transduction [179] and 
cell to cell adhesion [180]. These are present in 38-50% of cases [181]. Mutations of PTEN 
are also very common (43%) in this subtype [182]. 
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Mucinous carcinoma 
Mucinous carcinomas are often characterised by mutations in KRAS [183], [184]. 
 
Clear cell carcinoma 
Clear cell carcinoma is interestingly characterised by the lack of TP53 mutations [185] , 
[186]. The expression of HER2 is twofold higher that other subtypes [187]. 
 
Hereditary ovarian cancer 
The frequently involved oncogenes in the development of hereditary ovarian cancer 
include c-ERBB-1 (EGFR), c-ERBB2 (HER2/NEU), MYC, K-RAS, β-catenin (CTNNB1) [188]. 
Tumour suppressor genes which are involved include TP53, PTEN, BRCA1 and BRCA2 
[189]. 
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 Signalling pathways in ovarian cancer 1.2.5
 
The consequence of gene copy number changes and gene mutations is the activation of 
several signalling pathways. Although a diverse range of genetic changes have been 
identified, many of these map to a discrete set of signalling pathways that are activated in 
ovarian cancer. Estimates of the number of pathways activated vary, and are likely to 
change as function is assigned to genes whose role is currently poorly understood. Thus 
far, seven signalling pathways have been identified which are activated in more than half 
of ovarian cancers.  
 
The PI3K-Akt-mTOR pathway.  
This pathway is a key regulator of proliferation, growth, survival and metabolism of cells 
[190]. It is activated in up to 70% of ovarian cancers (although this varies between 
histological type and different reports) and contributes to chemoresistance [120] to 
conventional cytotoxic agents and EGFR inhibitors [191]. The mechanisms which lead to 
the activation of this pathway in ovarian cancer include amplification or mutation of 
PIK3CA, loss of PTEN function or AKT amplification. Inhibitors of PI3K have been shown to 
increase the sensitivity of ovarian cancer cells to paclitaxel [192]. 
 
The Ras-MAPK pathway.  
This pathway is a signal transduction pathway, which regulates cell growth, 
differentiation, survival and death. In ovarian cancer this pathway is activated by 
mutations in HER2, KRAS and BRAF [193], although the overall frequency of activation is 
thought to be less than 50% of ovarian cancers [120]. 
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The IL-6 pathway.  
IL-6 activates the IL-6 receptor which then triggers a number of signalling cascades. The 
downstream pathways involved include Jak2/STAT3, Ras/MAPK and PI3K–Akt pathways 
[194]. JAK2 is a kinase activated by the IL-6 receptor which subsequently phosphorylates 
and activates the transcription factor STAT3. In ovarian cancer this results in higher 
proliferation, enhanced angiogenesis and inhibition of apoptosis [120]. This pathway has 
been estimated to be activated in approximately 70% of ovarian cancers [120]. 
 
Signalling through Src.  
Src is a tyrosine kinase which is highly expressed in several cancers and can be activated 
by several receptor types including growth factor receptors and integrins. It can regulate 
proliferation, invasion and migration [195], [196]. It has been estimated to be activated in 
more than 50% of ovarian cancers [120]. 
 
The lysophosphatidic acid (LPA) pathway. 
 It is thought that the activation of this pathway contributes to both cell cycle progression, 
cell survival and metastatic spread of ovarian cancer. LPA is a bioactive lipid that activates 
a family of G-protein coupled receptors. LPA increases the levels of the cell-cycle-
regulator cyclin D1 [197] and the growth factors VEGF [198] and IL-8 [199] and 
contributes to platinum chemoresistance [200] . It has also been demonstrated that LPA 
promotes the production of IL-6, thus activating that pathway [201]. Autotaxin, an 
enzyme which catalyses the production of LPA, is overexpressed in ovarian cancer and it 
has been shown that it delays apoptosis caused by carboplatin [202]. It has thus been 
implicated in chemoresistance. Levels of LPA are frequently elevated in patients with 
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ascites, in which it can reach concentrations up to 80μM.  It is perhaps not surprising, 
then, that this pathway has been estimated to be activated in 90% of ovarian tumours 
[120]. 
 
The MEKK3- IKK - NF-kB pathway. 
 More than 50% of ovarian cancers are characterised by an active MEKK3 pathway [120]. 
The kinase MEKK3 activates the IKK complex, which in turn phosphorylates and 
inactivates IκB, an inhibitor of the transcription factor NF-κB [203],[204]. This 
transcription factor promotes the expression of antiapoptotic genes and cell growth 
[120]. 
 
The Mullerian inhibitory substance (MIS) receptor. 
 More than 50% of ovarian cancers and stable cell lines are characterised by the presence 
of MIS receptors [120] . The MIS is responsible for the regression of foetal Mullerian ducts 
in males and constitutes a possible therapeutic target for ovarian cancer as it has been 
shown to inhibit ovarian cancer cell growth in vitro [205]. 
 
The PKCι pathway. 
 This pathway has been estimated to be activated in 78% of ovarian cancers [120]. Protein 
Kinase C (PKC) represents a family of kinases which regulate multiple cancer signalling 
pathways. Although its function is not fully understood, PKCι suppresses apoptosis, in 
part by providing an activating link between Src and the NFκpathway. This may explain 
recent data suggesting that it also plays a role in the development of ovarian cancer 
chemoresistance [206].  
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 The role of malignant ascites in ovarian cancer 1.2.6
 
Approximately two thirds of ovarian cancer patients present with ascites [7],[207]. The 
collection of fluid in the peritoneal cavity of ovarian cancer patients is the result of 
increased vascular permeability. Factors that increase vascular permeability such as the 
vascular endothelial growth factor A (VEGFA) [208] play a role in this process. There have 
been clinical studies which show that treatment with antibodies against VEGFA resulted in 
a reduction in the developing ascites [209], [210]. 
 
The formation of ascites in ovarian cancer patients contributes to pathogenesis through 
at least two mechanisms: Firstly, the collection of peritoneal fluid contributes to the flow 
of malignant cells within the peritoneal cavity and facilitates metastatic spread. Secondly, 
the secretions of tumour cells in ascites contain factors that inhibit the immune system 
and favour carcinogenesis [211], [212], [213], [214], [215], [216], [217], [218]. MUC16 has 
been shown to protect ovarian cancer cells by blocking the formation of synapses 
between NK cells and cancer cells [219]. Additionally, MUC16 changes the phenotype of 
NK cells in the peritoneal fluid to cells with less cytotoxic features [211]. As noted above, 
ascites contains significant quantities of the pro-survival factor LPA. 
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 The molecular mechanisms of ovarian chemoresistance 1.2.7
 
Escaping cell death is considered one of the hallmarks of cancer [220]. Our knowledge of 
the molecular mechanisms underlying the development of platinum resistance in ovarian 
cancer is incomplete. However, it is clear that it is multi-factorial (Table 8). The 
cellular/molecular events contributing to drug-resistance are described below.  
 
 
Limited availability of drug to the intracellular environment due to increased efflux 
 
The uptake and efflux of cisplatin in ovarian cancer cells is associated with the emergence 
of chemoresistance. ATP7A and ATP7B are copper transporting enzymes which are highly 
expressed in chemoresistant cancer cells. These enzymes reduce the intracellular 
accumulation of platinum through increased efflux [221],[222],[223]. Real time 
polymerase-chain reaction (RT-PCR) studies identified a higher expression of ATP7B in 
resistant compared to sensitive ovarian cancer cells [224].  The combination of siRNA 
ATP7B silencing with cisplatin therapy in platinum resistant mouse models demonstrated 
a 70-80% reduction in tumour growth [225]. ABCC2, another exporter protein has been 
linked to clinical chemoresistance and is also considered to promote increased efflux of 
the drug[226]. However, trials of inhibitors of P-glycoprotein P, a drug pump associated 
with drug resistance, have so far not been effective. 
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Limited availability of drug to the intracellular environment due to drug inactivation 
 
There are sulphur-containing molecules (such as glutathione) in the intracellular 
environment which show a higher reactivity than the DNA towards platinum-based 
compounds. The exposure of cancer cells to cisplatin has been shown to cause an 
increase in the levels of glutathione and a subsequent inactivation of the drug, leading to 
the development of progressively higher degrees of drug resistance [227], 
[228],[229],[230]. 
 
 
Increased DNA repair activity in cancer cells 
 
Cisplatin interacts with DNA, forming adducts which modify its structure and deregulate 
its ability for transcription. Increased repair of the DNA through the nucleotide excision 
repair (NER) pathway by removal of cisplatin adducts is considered to contribute to the 
chemoresistance of ovarian cancer to cisplatin [231], [232],[233].  The excision repair 
cross-complementation group 1 (ERCC1) protein mediates the NER pathway and is found 
to cause in vitro resistance to cisplatin [234]. 75% of patients with chemoresistant disease 
have positive ERCC1 expression and siRNA silencing of ERCC1 expression increased the 
sensitivity of platinum-resistant stable cell lines [235]. 
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Bypass of DNA damage 
 
Poly ADP-ribose polymerase (PARP) is an enzyme which is essential for the repair of single 
strand DNA breaks [236] Loss of function of this mechanism results eventually in double 
strand breaks. These may be repaired by homologous –recombination repair mechanisms 
in which BRCA1 and BRCA2 are major regulators. Studies in animal models showed that 
the combination of a PARP inhibitor with chemotherapy resulted in improved survival 
[237] while in phase I clinical trials the inhibition of PARP had an improved clinical 
outcome and stabilized disease [238], [239].PARP inhibitors are also being evaluated as 
monotherapy. In patients whose tumours have a defect in homologous recombination, 
for example those with BRCA defects, DNA repair depends on PARP, and consequently 
these tumours are highly sensitive to PARP inhibition. This is referred to as “synthetic 
lethality” – because inhibition of either BRCA or PARP on its own is ineffective, but is 
lethal when both the BRCA and PARP are non-functional. In these cells, double strand 
break repair is dependent on non-homologous end joining which is highly error prone and 
subsequently leads to cell death.  
 
There is evidence to suggest that platinum-resistant ovarian cancer cells exhibit a 
replicative bypass activity against the DNA adducts formed by cisplatin. Such an activity 
was not observed when these cells were exposed to UV light stress or a different 
chemotherapeutic agent, suggesting that it is specific to the lesions induced by cisplatin. 
Thus, although DNA damage still occurs in response to cisplatin, it does not result 
immediately in cell death and so manifests itself as drug resistance. 
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Deregulation of apoptosis in cancer cells 
 
A mechanism which confers to the development of chemoresistance is the inhibition of 
apoptosis that is otherwise induced following DNA damage. The AKT signalling pathway 
conveys protection to cancer cells from cisplatin  through several mechanisms, including 
by inhibiting the x-linked inhibitor of apoptosis (XIAP), blocking caspase 3 activity and 
subsequent apoptosis [240] . It also acts by blocking other proapoptotic proteins [241], 
[242]. 
 
Aurora kinases are involved in cell cycle regulation and they are considered to contribute 
to drug resistance [243]. Aurora-A was found to be overexpressed in 83% of EOC patients 
[244] and there is evidence to suggest that it promotes cell survival by activating the AKT 
pathway and deregulating the cell cycle checkpoint mechanisms [245], [246]. Inhibition of 
the Aurora-A activity in chemoresistant ovarian cancer cells lead to reduced tumour 
growth and the  combination of Aurora inhibitors with cisplatin demonstrated synergistic 
effects [247]. 
 
The BCL2L1 gene encodes the anti-apoptotic protein, Bcl-XL. In ovarian cancer Bcl-XL 
expression is associated with shorter disease-free interval after therapy and 
chemoresistance, [248], [249], [250],[251],[252]. Inhibition of Bcl-XL by “BH3-
mimetics”has been shown to increase sensitivity to cytotoxic agents [253], [254], [255] 
and these are discussed in more detail below (Figure 3) [256]. 
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Figure 3: Apoptosis signalling pathways implicated in drug resistance in ovarian cancer 
,reproduced from [257], [258]. 
Changes to the tumour microenvironment 
Many of the genes which are involved in the organization of the extracellular matrix 
(ECM) are activated in chemoresistant ovarian cancer cells [259]. It has long been 
suggested that the ECM interacts with tumour cells and confers protection against 
chemotherapy [260] .The production of collagen VI from cancer cells has been reported 
to be contributing to their chemoresistance [261] and studies where cisplatin sensitive 
cells were cultured in collagen VI containing conditions resulted in the emergence of 
cisplatin resistance [259]. This may in part reflect the ability of integrins, receptors for 
extracellular matrix, to activate cell survival pathways. 
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Genes and molecular pathways implicated in ovarian cancer drug resistance 
Function Gene or pathway 
DNA damage 
and repair 
the nucleotide-excision repair system-ERCC1 gene (NER), DNA mismatch 
repair (MMR)- MLH1 gene, BRCA1/2 genes 
Apoptosis 
regulation 
caspase inhibitor XIAP, BCL-2 family anti-apoptotic members, FLIP 
apoptosis inhibitor 
Growth 
factor 
receptors 
IGF-R, TrkB, EGF  receptor  family, HER-2 
Cell 
proliferation-
migration 
Src 
Cell survival Akt-PI3-kinase pathway, PTEN,  
Table 8: Genes and molecular pathways implicated in ovarian cancer chemoresistance[238].  
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1.3 The role of apoptosis in ovarian cancer 
 
 What is apoptosis? 1.3.1
 
The phenomenon of cell death in multicellular organisms is an essential part of the 
natural cell turnover process. It helps promote homeostasis by controlling normal cell 
numbers during development and disease. If damaged cells were to accumulate as a 
result of injury, infection or stress then the functional capacity of tissues would be 
impaired. One form of controlled and programmed cell death is known as apoptosis 
[262]. The first medical use of the word “apoptosis” is found in Hippocrates’s book 
“Mochlicon” to describe the “falling off of the bones” and Kerr & Wylie reintroduced it in 
1972 with its current meaning. 
 
Apoptosis is characterized by specific morphological changes (Figure 4) which include 
cellular shrinkage and fragmentation into apoptotic bodies, which are subsequently 
opsonized for cleavage by macrophages [263], [264].  
 
Figure 4: Overview of the process of apoptosis, reproduced from [265].  
53 
 
The cell death machinery which initiates apoptosis operates by having sensor molecules 
which detect cellular stress or damage through transcriptional mechanisms [266]. The 
biochemical changes that underpin apoptosis are mediated by a family of cysteine 
proteases (caspases) initially expressed as inactive zymogens which are proteolytically 
processed to their active state by an apoptotic signal [267] (Figure 5). Caspase proteins 
exist as inactive silent pro-enzymes and are activated by proteolytic cleavage in 
hierarchical order. The initiator caspases (caspases -6, -8, -9 and -10) are activated first 
which then activate downstream effector caspases (-2, -3 and -7). The release of 
cytochrome c from mitochondria in the intrinsic apoptosis pathway results in the 
activation of caspase-9 and the formation of the apoptosome which confirms the 
commitment of the cell to programmed death. The evasion of apoptosis is considered a 
hallmark of cancer which can explain the survival of cancer cells after chemotherapy and 
the development of chemoresistance [220], [268]. 
 
Figure 5: The caspase cascade at apoptosis, reproduced from [269]. 
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 The cellular pathways that activate apoptosis 1.3.2
 
Apoptosis signalling can be initiated from outside the cells via plasma membrane 
receptors ( referred to as the extrinsic pathway) or through stress that originates from 
within the cell (referred to as the intrinsic pathway) [270], [271]. The extrinsic pathway is 
triggered when either receptors for Fas or TRAIL are activated by their ligands [272]. This 
leads to the formation of a death-inducing signalling complex which in turn activates 
caspase-8 and 10. Mutations and deletions of the Fas gene have been found in 
haematological malignancies [273], [274]. The intrinsic pathway, also referred to as the 
mitochondrial pathway is characterized by the mitochondrial outer membrane 
permeabilization (MOMP) and the release of cytochrome-c, an enzyme normally found in 
the space between the inner and outer mitochondrial membrane (OMM) [275]. This 
pivotal event represents a “point-of-no-return” step because once it is passed it 
constitutes an irreversible decision to commit cellular suicide (Figure 6).  
 
 
Figure 6: Overview of the apoptotic pathways, reproduced from [276]. 
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 The role of the Bcl-2 family of proteins in apoptosis 1.3.3
 
The intrinsic apoptosis pathway is controlled by the Bcl-2 family of proteins [277].This 
family comprises evolutionary related proteins with possess either pro-apoptotic or anti-
apoptotic action. There are four different classes of proteins in this family; the 
proapoptotic “effectors” (Bax, Bak), the anti-apoptotic “inhibitors” (Bcl-2, Bcl-XL, Bcl-W, 
Mcl-1, Bfl/A1, Bcl-B), the proapoptotic “activators” (Bim, Bid, Puma [2-4], possibly Bmf 
and Noxa [5]) and the pro-apoptotic “sensitizers” (e.g. Bad, Bmf, Noxa) (Figure 7). 
 
 
Figure 7: The division of the Bcl-2 family of proteins to anti- and pro-apoptotic members. 
  
• Bax            Bcl-2-associated X protein  
• Bak            Bcl-2 antagonist killer 1  "Effectors" 
• Bcl-2         B-cell lymphoma 2 
• Bcl-XL       Bcl-2 like 1 
• Mcl-1       Myeloid cell leukemia-1 
• Bfl/A1 
• Bcl-B 
• Bcl-W      Bcl-2 like 2 
"Inhibitors" 
• Bim         Bcl-2 interacting mediator of cell death 
• Bid          BH3-interacting-domain death agonist 
• Puma      p53-upregulated modulator of apoptosis 
" Activators" 
• Bad                   Bcl-2 associated death promoter 
• Noxa "Sensitizers" 
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The members of the family are defined by their unique α-helical composition of up to 4 
Bcl-2 homology domains termed BH1,BH2,BH3 and BH4 (Figure 8).  The genetic 
background of the Bcl-2 control of apoptosis was first discovered when mutants of the 
organism Caenorhabditis elegans were observed to cause failure in apoptosis to cells 
which normally undergo this procedure during development [278]. The proteins 
responsible for blocking apoptosis were found to share homology with mammalian 
proteins including B-cell CLL/lymphoma 2(Bcl-2) [279]. The BCL-2 gene was originally 
identified at the chromosomal breakpoint of the translocation of chromosome 18 to 14 in 
follicular non-Hodgkin lymphoma [280] and is considered the founding member of the 
family.  The study of the function of BCL-2 revealed its contribution as preventing cell 
death rather than promoting cell proliferation [281]. 
 
Figure 8: The Bcl-2 family of proteins, reproduced from [282].  
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The pro-apoptotic “effector” molecules of the Bcl-2 family 
 
The pro-apoptotic “effector” molecules of the family include the Bcl-2 antagonist killer 1 
(Bak) and the Bcl-2-associated X protein (Bax). These proteins contain BH domains 1 to 4 
[283]. Bak and Bax can independently permeabilize the OMM [284], [285], [286, 287]. Bax 
and Bak are essential since mitochondria deficient for Bax and Bak fail to release 
cytochrome c [288]. The loss of Bax or Bak renders cells resistant to permeabilization 
caused by BH3-only proteins [289].  
 
 
The pro-apoptotic BH3-only proteins of the Bcl-2 family; “activators” and “sensitizers” 
 
The BH3-only proteins are defined by the presence of a single BH domain in their 
molecule, the BH3 domain. They include the “activators” such as the Bcl-2-interacting 
mediator of cell death (Bim), the BH3-interacting-domain death agonist (Bid) and the p53-
upregulated modulator of apoptosis (Puma) and the “sensitizers” such as the Bcl-2-
associated death promoter (Bad) and Noxa (the latin word for damage; also known as 
PMAIP1). All these BH3-only proteins can be activated by various different stimuli via 
several mechanisms including transcriptional up regulation, subcellular localization 
and/or post-translational modifications [290]. 
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The anti-apoptotic “inhibitors” of the Bcl-2 family 
 
The anti-apoptotic “inhibitors” currently known are Bcl-2, Bcl-XL (Bcl-2 like 1), Mcl-1 
(myeloid cell leukemia-1), Bfl/A1, Bcl-b and Bcl-W (Bcl-2 like 2) and they contain BH 
domains 1 to 4. They all share a conserved hydrophobic groove formed by 6 alpha (α) 
helices and which binds to the BH3 domain. The structure of the groove varies slightly 
from one member to the other and these molecular variations can explain how different 
pharmacologic inhibitors that target these anti-apoptotic BCL-2 “inhibitors” have different 
binding affinities for various family members. 
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 The regulation of apoptosis in ovarian cancer 1.3.4
 
The exposure of a cell to stress or any other pro-apoptotic treatment triggers 
transcriptional and post-translational regulation of individual members of the Bcl-2 
family. It is the dynamic equilibrium between the opposing functions of the pro- and anti-
apoptotic members that affects the integrity of the outer mitochondrial membrane.  
 
The activation of Bak and Bax involves a conformational change which exposes the N-
terminus of the proteins that is otherwise hidden [291]. Bak is localized primarily in the 
OMM with only a small fraction sited at the endoplasmic reticulum (ER). Bax is cytosolic 
and once a death stimulus has been received it migrates to the OMM and becomes an 
integral membrane protein that can induce permeabilization [292]. The homo-
oligomerization of Bax and Bak leads to MOMP through the formation of proteolipid 
pores on the mitochondrial surface. This causes the release of mitochondrial proteins 
such as the cytochrome c and second mitochondria-derived activator of caspase (SMAC 
also known as DIABLO) from the mitochondrial intermembrane space into the cytosol, 
where they interact with caspases and activate them. 
 
Two competing models have been proposed for how Bax and Bak are activated, but 
recent data supports a “direct activation” model in which the BH3-only “activators” bind 
directly but transiently to the “effectors” Bax or Bak to activate them [293]. The 
alternative “indirect” model envisages that the effectors” do not require any activation 
and are continuously sequestered by the “inhibitors”. Apoptosis is induced indirectly by 
the BH3-only proteins as they bind to the “inhibitors”, allowing for the “effectors” to be 
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released fulfilling their pro-apoptotic potential. Other variations of both of these models 
have been suggested and it is possible that aspects of both of them are correct. 
 
The anti-apoptotic “inhibitors” preserve the integrity of the outer mitochondrial 
membrane by binding to both the “effectors” and the BH3-only “activators”. When the 
BH3 domain of Bax or Bak is sequestered by antiapoptotic Bcl-2 family proteins their 
apoptotic function is lost. However, the binding of the “sensitizers” through their BH3 
domain to the hydrophobic BH3-binding groove of the “inhibitors” can reduce their 
capacity to sequester the “activators” or the “effector” molecules. The overall reduction 
in the cellular reservoir of the “inhibitors” results in the effective transmission of pro-
apoptotic signalling from the “activators” to the “effectors” Bak and Bax (Figure 9). 
 
Many types of cancer including ovarian cancer, haematological malignancies and 
gastrointestinal cancers are characterised by an elevated expression of various 
prosurvival proteins [250], [294]. In more than 70% of ovarian cancers the expression of 
anti-apoptotic proteins Bcl-2, Bcl-XL and survivin is increased compared to normal ovarian 
tissue [295]. High levels of Bcl-XL have been linked to resistance to platinum and taxane 
therapy and disease recurrence [248], [296]. Altered expression of survival proteins is 
often due to translocation, gene amplification or mechanisms non-related to genomic 
alterations. In leukemia cell lines chemoresistance was induced in vitro by the 
overexpression of Bcl-XL [251]. Overexpression of Bcl-XL also contributes to the resistance 
of other types of cancer such as pancreatic [249] .   
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Figure 9: The regulation of the intrinsic apoptosis pathway by the Bcl-2 proteins.  
Apoptosis is triggered by the formation of a pore in the mitochondrial outer membrane formed 
from the effectors. This is controlled by the activator molecules (Bid, Bim, Puma, labelled “A”) 
which directly stimulate the effectors (Bak and Bax). A pro-apoptotic signal (such as oncogene 
stress or chemotherapy) induces the expression of apoptosis activators and sensitizers. The 
activators may be sequestered by the inhibitors (labelled “I”, e.g. Bcl-2, Bcl-XL, Mcl-1) and this 
prevents apoptosis. However, sensitizer molecules (labelled “S”, eg Noxa, Bad) or BH3 mimetics 
(e.g. ABT-737, labelled “ABT”) can occupy the inhibitors, preventing them from binding the 
activators. In cells in which the inhibitors are already primed with an activator, the effective 
displacement of the activator from the inhibitor by ABT-737 induces apoptosis.
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The interaction between pro- and anti-apoptotic proteins of the Bcl-2 family is also 
regulated by the different binding capacity between the “inhibitors” and their ligands. 
Some BH3-only proteins can bind to all the apoptosis inhibitors, whereas other BH3-only 
proteins exhibit specificity for a subset of the apoptosis inhibitors. For example, Bad bind 
preferentially to Bcl-2, Bcl-XL and Bcl-W [7, 8], whereas Noxa binds preferentially to Mcl-1 
[7, 8] and possibly Bfl/A1 [7]. The BH3-only apoptosis activators Bim and Puma are each 
able to bind to all the apoptosis inhibitors whereas Bid has a more restricted binding 
profile [7, 9]. Whether the induction of a BH3-only protein leads to apoptosis depends on 
whether the repertoire of apoptosis inhibitors expressed is adequate to dampen the pro-
apoptotic signal arising from the activation of BH3-only proteins (Figure 10). 
 
 
Figure 10: The binding specificity of BH3 only proteins. The activators (denoted with an “A”), Bim 
and Puma bind to all the apoptosis inhibitors (denoted with an “I”). However, tBid and the 
sensitizers (denoted with an “S”) bind to a subset of the apoptosis inhibitors. There are some 
discrepancies in the literature (e.g., whether Bmf binds Mcl-1) and it is important to note that this 
diagram summarizes interactions (adapted from [7-9] in a binary fashion (interaction or no 
interaction) whereas in reality the interactions are better described by a range of binding 
affinities.  
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The Bcl-2 family is also responsible for interacting with non-apoptotic cell-death 
machinery such as that which regulates autophagy [297]. Autophagy is a type of cell 
death characterised by the formation of double-membrane vacuoles called 
autophagosomes [298],[299] which merge with lysosomes and degrade the cellular 
components [300]. Bcl-2 family proteins also bind to the endoplasmic reticulum, where 
they modulate autophagy, another important pathway regulating cell survival and death 
[294]. The proteins Bcl-2 and Bcl-XL can sequester beclin 1 (BECN1), a tumour suppressor 
protein which activates autophagy. Bcl-2 and Bcl-XL bind the BH3 domain of the molecule 
of beclin and inhibit autophagy [301]. The addition of a BH3-only protein or a drug which 
binds to the Bcl-2 family inhibitors can reverse this and induce autophagy [302]. 
Autophagy plays  a dual role in cell survival as it can provide the cell with energy at times 
of starvation or, when there are excessive stress conditions can become a suicide 
pathway [303]. 
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 The use of BH3 mimetics as treatment for ovarian cancer 1.3.5
 
The introduction of platinum-based compounds and taxanes over the last forty years has 
resulted in an improvement in survival for patients diagnosed with ovarian cancer but it 
appears likely that conventional chemotherapy has achieved its maximum potential 
(although incremental improvements are being explored with differing schedules such as 
dose-dense chemotherapy and different routes such as intraperitoneal administration). 
Standard chemotherapy could however be used in tandem with a type of targeted 
therapy that acknowledges the different molecular abnormalities which characterize 
every subtype of EOC [181].  
 
It has been shown that where the anti-apoptotic Bcl-2 “inhibitors” are overexpressed the 
apoptotic cell death is prevented. In some cancer cells, constitutive expression of pro-
apoptotic BH3-only proteins renders the cells dependent on BH3-only proteins for 
survival. Such cells have been described as being “primed for death”. Alternatively, 
treating cells with pro-apoptotic stimuli such as chemotherapy can increase the 
expression of BH3-only proteins. In both cases, the cells become dependent on the 
expression of Bcl-2 family inhibitors for survival. Evidence in support of this hypothesis 
was provided by the observation that a modified peptide derived from the BH3-only 
protein Bid displayed anticancer activity in haematological malignancies and xenografts 
[304]. 
 
In the last two decades our progress in understanding the function of the Bcl-2 family of 
proteins has contributed to the development of drugs, which prevent Bcl-2 family 
65 
 
inhibitors from binding the BH3-only pro-apoptotic proteins. There are several agents of 
this category that have been developed so far. The first drug (oblimersen sodium) 
targeting Bcl-2 was a Bcl-2 antisense oligodeoxynucleotide which showed 
chemosensitising effects when combined with chemotherapy drugs in chronic 
lymphocytic leukaemia (CLL) patients[305]. However, this molecule has failed to progress 
in clinical trials and any efficacy observed may reflect off-target effects. Other small 
molecule inhibitors have recently been developed. These include molecules that affect 
expression of anti-apoptotic Bcl-2 members (e.g. sodium butyrate, depsipeptide, 
fenretinide, flavopiridol).  
 
BH3-mimetics are a recently described class of molecules. These are drugs which bind to 
the same binding site as the BH3 domain of pro-apoptotic Bcl-2 family members, thereby 
diminishing the capacity of the “inhibitors” to sequester the pro-apoptotic proteins. 
These drugs are termed BH3-mimetics because they bind to the hydrophobic groove of 
the anti-apoptotic Bcl-2 proteins. These BH3-mimetics antagonise the Bcl-2 family 
apoptosis “inhibitors” and are expected to induce apoptosis in cancer cells that are 
primed for death by liberating pre-bound BH3-only “activators”. This can explain why 
BH3-mimetics have exhibited remarkable single agent activity in primed cancer cells 
[306]. Alternatively, in cells treated with chemotherapy, the expression of BH3-only 
proteins is usually increased. BH3 mimetics effectively lower the threshold at which cells 
undergo apoptosis because they prevent the Bcl-2 family “inhibitors” from sequestering 
the BH3-only proteins. Consequently, BH3-mimetics have shown synergy with several 
chemotherapeutic agents that induce BH3-only proteins in cells that are not primed 
already with a BH3-only activator [307]. In both cases (primed cells or cells in which BH3-
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only proteins have been induced), the BH3-mimetics elicit their effect because the cancer 
cells become dependent on Bcl-2 family proteins for survival. Thus, BH3-mimetics are not 
thought to directly induce apoptosis on their own, but require the induction of the pro-
apoptotic BH3-only proteins. This suggests that targeting the Bcl-2 family could be an 
effective way to facilitate cancer cell death either as single agent or combination therapy 
[308]. 
 
Gossypol is the first compound that demonstrated inhibition of Bcl-2,Bcl-XL and Mcl-1 and 
was originally discovered  during the 1950s [309]. Its analogue, apogossypol is still being 
developed and seems to possess less systemic toxicity and target Bcl2- and Mcl-1 better 
[310]. 
 
ABT-737 is a selective inhibitor of Bcl-2, Bcl-XL and Bcl-W [311]. Nuclear magnetic 
resonance–based screening and structure-based design targeting the Bcl-2 family of 
proteins was employed for the development of this compound, with linking of two 
different molecules of modest affinity into a single molecule of high affinity [310]. 
Preclinical studies have shown in ovarian cancer cells that it increases the sensitivity to 
carboplatin [312]. As a single agent ABT-737 showed limited potency in ovarian cancer 
[312], in contrast to its activity against lung cancer and leukaemia cells. This may in part 
be attributed to the fact that it binds to Mcl-1, an anti-apoptotic Bcl-2 protein expressed 
in several ovarian cancer cell lines, with a weak affinity [312]. Mcl-1 has become 
recognized as one of the key mediators of resistance to ABT-737. Alternatively, ovarian 
cancer cells may not be “primed” for death. However, ABT-737 lacks adequate oral 
bioavailability, and this prompted the development of ABT-263 (navitoclax), an orally bio-
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available analogue of ABT-737. ABT-263 has similar pharmacological properties to ABT-
737, including relatively poor affinity for Mcl-1. 
  
In contrast to this, GX15-070 (Obatoclax) is a pan-Bcl-2 inhibitor that inhibits all of the 
anti-apoptotic Bcl-2 proteins. This overcomes the potential for resistance due to 
expression of Mcl-1. It has been shown to induce features of apoptosis even without the 
activation of the intrinsic apoptosis pathway because cell death is reduced (but not 
prevented) in cells lacking Bax or Bak. It is possible that its activity involves additional 
targets relating to mitochondrial damage [313]. It is being assessed in phase I and II 
clinical trials for haematological malignancies. It is discussed in more detail in chapter 4. 
 
HA14-1 is another small-molecule inhibitor of the anti-apoptotic Bcl-2 proteins which was 
developed by structure-based screening [314]. It seems to be potent both as single agent 
and in combination with other chemotherapeutics and has a very high binding affinity for 
Bcl-2 [314]. Other “BH3 mimetics” such as BH3 inhibitor-1 and -2 and Antimycin A [315] 
are still in preclinical development and appear to possess other, additional mechanisms of 
restoring the “pending” apoptosis of primed cancer cells. However, several of these drugs 
induce cell death in cells lacking Bax and Bak. Apoptosis is critically dependant on the 
latter two proteins, suggesting that these compounds induce cell death through some 
additional undefined mechanism and are not “pure” BH3-mimetics. 
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Table 9 summarizes the various BH3-mimetics currently being evaluated in preclinical and 
clinical development [310]. 
Agents targeting anti-apoptotic BCL-2 family proteins 
Agents Target Proteins Sponsor Stage 
Apogossypol Bcl-2, Bcl-XL, Mcl-1 Burnham (NCI) Preclinical 
HA-14 Bcl-2 Maybridge Chem Preclinical 
Antimycin A Bcl-2, Bcl-XL University of 
Washington 
Preclinical 
BH3Is Bcl-XL Harvard University Preclinical 
Oblimersen sodium Bcl-2 Genta Phase III 
Gossypol (AT-101) Bcl-2, Bcl-XL, Bcl-2, 
Mcl-1 
Ascenta (NCI) Phase I/II 
ABT-737 (ABT-263) Bcl-2, Bcl-XL, Bcl-w Abbott Phase I 
GX15-070 Bcl-2, Bcl-XL, Bcl-w, 
mcl-1 
GeminX Phase I 
Abbreviations: BH3Is, BH3 inhibitors; NCI, National Cancer Institute; Maybridge Chem, Maybridge 
Chemical Co. Ltd; U, University 
Table 9: Various BH3-mimetics currently being evaluated reproduced with changes from [310]. 
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The foregoing discussion has highlighted the need for new therapies to treat ovarian 
cancer. When this study was commenced, ABT-737 had been shown to increase 
sensitivity of ovarian cancer cells to carboplatin both as a single agent and also in 
combination with carboplatin [312]. These studies demonstrated activity in vitro (cell 
lines and primary cultures) as well as in vivo (xenografts) and also suggested that 
apoptosis was induced faster by this drug. However, it had not been investigated in 
combination with carboplatin and paclitaxel, the therapy most commonly used to treat 
ovarian cancer. Furthermore, although it was anticipated that navitoclax would also show 
synergy with carboplatin, this had not formerly been demonstrated. Thus, one goal of this 
work was to further investigate the potential for navitoclax in ovarian cancer. 
 
The realization that Mcl-1 and A1 conferred resistance to ABT-737 suggested that ABT-
263 might only be effective in tumours where these Bcl2 family proteins were not 
expressed. Obatoclax represented a newly described panBcl2- family inhibitor. Therefore, 
a further goal of this work was to investigate the potential for obatoclax in the treatment 
of ovarian cancer. 
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1.4 Models of ovarian cancer disease 
 
 Permanent cancer cell lines 1.4.1
 
A cell line is defined as a permanently established cell culture that will proliferate 
indefinitely given appropriate medium and conditions. It differs from a cell strain in that it 
has escaped the Hayflick limit and has become immortal [316]. The Hayflick limit is the 
number of times a normal human cell population will divide until cell division stops. The 
current body of research on ovarian cancer has been predominantly based on the use of 
ovarian cancer derived cell lines. Their use is invaluable considering their advantages, 
such as the long lifespan and high proliferation rate.  
 
However, it is argued that these models are not without weaknesses and consequently do 
not represent the drug resistance in ovarian cancer adequately. This argument becomes 
particularly important when one considers the diversity of ovarian cancer as a disease and 
that the future of cancer treatment potentially lies in individualised care with novel 
“targeted” therapies rather than traditional chemotherapy [67]. Permanent cell lines are 
known to be different genomically from primary cultures of the same origin as they have 
acquired genetic alterations over the length of time [317],[318],[319], [320], [321], [322] . 
This is related to the fact that they have been cultured for years in non-physiological 
conditions and have been exposed to oxidative stress. Additionally, their drug resistance 
does not necessarily correlate with the clinical response of the tumours they were 
derived from [323]  but is much more dynamic and can be influenced even by the method 
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of drug administration [324]. It is also impossible to compare their chemosensitivity to 
that of the tissue of origin and establish a link with the clinical chemoresistance. Thus, the 
existing repertoire of ovarian cancer cell lines do not, on their own, provide an adequate 
experimental model of ovarian cancer. 
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 Primary cultures from ascites of ovarian cancer patients 1.4.2
 
The heterogeneity of ovarian cancer emphasizes the significance of an unmet need to 
develop a plethora of models which can adequately represent the diverse nature of this 
malignancy and allow for the optimal evaluation of new anticancer drugs. One model that 
has been used by many researchers is to test drugs on primary cultures of patient 
tumours, with the expectation that the growth of the cells in culture provides a 
reasonable model of clinical disease. Our group has previous experience of establishing 
primary cultures of ovarian cancer cells (PCOCC) from ascitic fluid and ethical approval 
was obtained for this study to use samples of ascites drained from ovarian cancer 
patients at the University Hospital of North Staffordshire [312]. The sensitivity of these 
cultures to obatoclax was evaluated under standard laboratory conditions (21% O2). 
Although this is often referred to as normoxia, this is significantly higher than the oxygen 
tension in cancer tissue, which often experiences an O2 tension of 2% or lower [325]. This 
is often (inaccurately) referred to as hypoxia. To approximate physiological conditions and 
compare this to routine laboratory conditions, it seemed appropriate to test drug activity 
in both 21% and 2% O2.This is particularly relevant to drug evaluation, because O2 tension 
can have profound effects on cancer cell biology [326]. 
 
The growing body of evidence regarding the validity of permanent cancer cell lines has 
resulted in a search for  improved models of ovarian cancer disease which more closely 
resemble the tumour subtypes [1], [327]. Our group has previous experience of primary 
cultures of ovarian cancer cells (PCOCC) as a model to study drug resistance in EOC [312]. 
The ascites in ovarian cancer patients is an exudative fluid with a cellular fraction. It 
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contains mainly ovarian cancer cells, mesothelial cells and lymphocytes [328]. The cancer 
cell fraction is a mixture of single cells and aggregates or spheroids. These spheroids have 
been shown to contribute to the dissemination of the disease by adhering to the 
extracellular matrix [329] and the ascitic fluid contains both angiogenic factors and 
growth factors [328] and is thought to be playing a role in the tumour microenvironment. 
There are several protocols for establishing primary cultures of ovarian cancer cells 
(PCOCCs) from malignant ascites with the simplest one being seeding culture vessels 
directly with ascitic sample, which leads to cultures of EOC cells [318]. The current 
experience is that once established these cells usually proliferate for 6-8 passages before 
reaching senescence [330] and so any planned experiments should optimally be done with 
low passage number cells. The process of distinguishing EOC cells from other 
contaminating cells in the cultures is based on the use of a combination of appropriate 
markers as there is no unique marker for EOC cells. Potential contaminating cells include 
fibroblasts, endothelial and mesothelial cells and other ovarian type cells. Leucocytes, red 
blood cells and platelets are of minor concern as they do not survive or are removed from 
the culture at first passage. These distinguishing markers are summarised in Table 10. 
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Marker Distinguishing cells 
keratins 7, 8, 18, and 19 other ovarian cell types 
17b-OH steroid dehydrogenase and 
mucin 
extraovarian mesothelial cells 
Laminin/ keratin stromal fibroblasts 
  absence of factor VIII and Ulex lectin 
receptors 
morphologically similar endothelial cells 
Table 10: Distinguishing markers of epithelial ovarian cancer cells. 
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 Three dimensional (3D) cell cultures 1.4.3
 
Drug discovery in oncology relies heavily on animal testing, an expensive practice neither 
completely representative of the human body behaviour towards the drug nor without 
ethical concerns. Traditionally two-dimensional cell culture models have been used in 
vitro, but the configuration of cells on a flat surface remains unnatural and cannot 
adequately predict how the tumours in the human body will react to a drug [331]. The 
two-dimensional environment lacks the ability to create areas of hypoxia with 
extracellular matrix influences, heterogeneous cell populations with different replication 
phases and the effects of soluble signalling molecules and nutrients/waste transport 
[332]. Additionally, it has previously been observed that chemoresistant tumour cancer 
cells show greater sensitivity to chemotherapy when cultured in monolayers [333]. All the 
above can at least explain why drug discovery in cancer very often fails in the clinical 
phase despite the promising pre-clinical assessments. 
 
Three-dimensional cell cultures can bridge the gap between the in vitro and in vivo 
methods and create a microenvironment that more closely resembles the human 
physiological conditions [1]. At present a number of techniques have been described to 
allow for such models to be created. Previous studies on mesothelioma cancer have 
shown that 3D models set up from either cell lines or tumour cells exhibit a higher 
expression of Bcl-2 molecules and develop a degree of apoptotic resistance [334], which 
can be overcome by the addition of the BH3-mimetic ABT-737. This observation confirms 
that the involvement of the Bcl-2 family in the development of multicellular resistance to 
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chemotherapy [334]. Therefore, in this study ovarian cancer cell spheroids were 
developed as three-dimensional models in order to evaluate the effect of anticancer 
agents and BH3 mimetics. These were grown from the existing stock of permanent 
ovarian cancer cell lines. 
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 Xenograft studies 1.4.4
 
 
Xenograft studies can be performed by implanting human cancer cells into animal 
models. The use of murine models as preclinical cancer models in ovarian cancer to study 
the activity of any compound is a well-established practice and can be considered 
complementary to the in vitro human tumour cell lines, the three-dimensional cell 
cultures and the primary ascitic cultures[335],[336],[337],[338]. Human tumour 
xenografts are the most widely used models where human cancer cells are transplanted 
into immunocompromised mice so that they are not rejected. The tumours are 
transplanted subcutaneously, intraperitoneally or orthotopically regarding the organ 
specific for the type of cancer. Once these tumours are developed the response to a 
certain therapeutic regime can evaluated by measuring tumour size. 
 
These models have been shown to resemble both the histological characteristics and the 
degree of differentiation observed in the patient’s tumours [339],[340]. Any limitations in 
their clinical predictive value are thought to be associated with the immunodeficiency of 
the hosts and the differences in the tumour microenvironment and drug metabolism 
[339],[340]. 
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1.5 Aims & objectives 
 
 
Overcoming the chemoresistance of ovarian cancer poses a major challenge for 
researchers today and is the main focus of my project.  The major goal of the research 
presented in this thesis was to provide the preclinical data necessary to support the 
clinical development of navitoclax and obatoclax in ovarian cancer. The following 
hypotheses were tested. 
 
I. Navitoclax will have weak single agent activity, but will enhance the cytotoxicity of 
carboplatin and paclitaxel, both in double and triple combinations. 
II. Obatoclax may have significant single agent activity but will sensitize ovarian cancer 
cells to carboplatin and paclitaxel. 
III. Furthermore, these studies would be conducted where possible using additional 
experimental models other than monolayer cultures maintained in 21% O2. 
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Chapter 2: Materials & Methods 
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2.1 Ovarian cancer permanent cell lines 
 
The ovarian cancer cell lines used in these studies were A2780, cisA2780, Ovcar-3, Ovcar-
4, Ovcar-5, Ovcar-8, Igrov-1 and Sk-Ov-3 cells and were purchased at the beginning of the 
study from the American tissue culture collection (ATCC). 
A2780, cisA2780, Ovcar-4, Ovcar-5, Ovcar-8, Igrov-1 and Sk-Ov-3 cells were grown in 
Roswell Park Memorial Institute medium (RPMI 1640; Lonza) supplemented with 10% 
fetal bovine serum (FBS; Lonza) ,2mM L-Glutamine (Lonza) and penicillin/streptomycin 
(Lonza, 50 U/ml). 
Ovcar-3 cells were grown in RPMI supplemented additionally with 0,01mg/ml insulin 
(Lonza) and 1mM sodium pyruvate (Lonza). 
Cells were incubated in a water jacketed incubator, at 37 °C in a humidified 5% CO2 
atmosphere. cisA2780 cells were periodically (once per month) treated with Cisplatin 
(1μM for 1 week, from a 1 mM DMSO stock) to maintain their chemoresistance. 
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 Trypsinization  2.1.1
 
Cells were grown in T25 or T75 cell culture flasks (Triple red). Cells were routinely sub-
cultured in sterile conditions twice weekly. Confluency was confirmed microscopically and 
flasks more than 80% confluent were deemed to require sub-culturing. 
To passage the cells, the cultures were washed with 5 ml phosphate buffered saline (PBS, 
Lonza) and then treated with 1ml 0.01% trypsin/1 mM EDTA (Lonza) in PBS at 37°C. Cells 
were agitated to encourage them to detach. The trypsin was neutralized by the addition 
of equal volume of growth medium containing 10% FCS. The re-suspended cells were 
transferred to a sterile 15ml polypropylene tube (Triple red) and collected by 
centrifugation at 150 g for 2 minutes at room temperature. The supernatant was 
aspirated and the cell-pellet was resuspended in fresh medium. 
 
 Cell counting 2.1.2
 
Cell counting was performed with the use of the improved Neubauer hemocytometer 
Cells were resuspended at an estimated concentration of between 105 and 106 cells per 
ml. At least 100 cells were counted to determine cell number. 
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 Cryopreservation 2.1.3
 
Cells were grown in T75 culture flasks to 50% confluence. Only cells of low passage 
number which appeared microscopically to be healthy and were growing in logarithmic 
phase were considered appropriate for cryopreservation. 
 
The cells were collected by trypsinization (see section 3.1.1) and quenched with 5 ml 
growth medium. The freezing medium comprised complete growth medium containing 
8% (v/v) sterile DMSO (Sigma Aldrich) The pellet was resuspended in 1 ml of freezing 
medium (estimated 2-4 million cells per ml). 200μl aliquots of this cell suspension were 
transferred into 2ml cryovials (Triple Red). The cells were frozen slowly (approximately      
-1°C per minute) by being placed inside an insulated box in a -70°C freezer overnight. The 
next day the cryovials were transferred to the liquid nitrogen tank (-196°C) for long-term 
storage. 
 
 Reviving cryopreserved cells 2.1.4
 
To revive the frozen cells the frozen cells are thawed rapidly by immersing in a water bath 
at 37°C. The content of each vial was diluted in 10 ml of pre-warmed culture medium. In 
the case of Ovcar-3 cells, the cells are washed at this stage once by centrifugation (150g, 3 
minutes) in 10 ml growth medium to immediately remove DMSO. Other cells are directly 
seeded into T25 culture flasks. The medium was changed the following day to remove any 
residual DMSO and dead cells that have not attached to the bottom of the culture dish.  
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2.2 siRNA interference studies 
 
The siRNAs used in these experiments were obtained as siGENOME SMARTpool reagents 
(Dharmacon) and were complementary to mRNA encoding Atg-5 or Beclin. A non-
targeting SMARTpool was used as a negative control as well as an individual non-targeting 
control siRNA. The siGENOME SMARTpool siRNAs consist of four distinct RNA 
oligoduplexes per target gene.  
The optimal conditions for transfection have previously been determined by work in the 
laboratory [312]and afforded more than 95% transfection efficiency. Cells were collected 
by trypsinization, seeded in 96-well plates at 5,000 cells/well  for all cell lines, except 
Ovcar-8, A2780 and CisA2780  where 2,500 cells/were used. The cells were seeded in 80μl 
of antibiotic-free RPMI medium containing 10% FCS and the culture vessels were 
incubated overnight as described (see section 3.1). 
The next morning cells were transfected with siRNA with the use of the transfection 
reagent Dharmafect-1. The siRNA were diluted in optimum (Invitrogen) to 10 times the 
desired final concentration. In parallel, a 1% Dharmafect-1 solution in Optimem was 
prepared. The two solutions were mixed and incubated at room temperature for 20 
minutes to allow the formation of siRNA liposome complexes. During this time, the 
medium on the cells was replaced with 80 µl of fresh growth medium containing 10% FCS. 
Subsequently 20 µl of the liposome siRNA complex was added to the cells.  The cells were 
returned to the incubator and medium was changed after 24 hours.  
The reduction in the expression of the target genes was confirmed by Q-PCR and western 
blotting. 
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2.3 Cell cytotoxicity studies 
 
In drug development the study of pharmacodynamics to evaluate the physiological and 
biochemical effects on human cells can be performed with a number of techniques. The 
toxicity testing methodology applied in our studies is described here. 
 
 Drug preparation 2.3.1
 
Navitoclax (Chemitek) and paclitaxel (Sigma) were dissolved in DMSO at 20 mM and 10 
mM respectively and carboplatin (Sigma) was dissolved in PBS (13.5 mM). Obatoclax 
(GeminX) was dissolved in DMSO at 5mM. 
 
 SRB colorimetric assay 2.3.2
 
The sulforhodamine B (SRB) assay was used to measure the growth of cultures of ovarian 
cancer cells [312]. Cells were collected by trypsinization and were seeded in 96-well 
plates (Triple red). 5,000 cells were seeded per well for all cell lines except 2,000 cells per 
well for Ovcar8, cisA2780 and A2780 cells) in 80 µl of growth medium. The cells were 
incubated for 24 hours at 37 °C in 5% CO2 in a humidified atmosphere before drugs were 
added. For dose response curves, 18 different drug concentrations were prepared (and a 
control containing only the drug solvent) at 5 times the desired final concentration.  20 µl 
of these drug dilutions was added to the cells. After further 72-hr incubation the medium 
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was removed and the cells were fixed in 100 μl of cold 10% trichloroacetic acid on ice for 
30 minutes. The plates were then washed in water, air dried and then stained in 0.4% 
sulforhodamine B for 30 minutes. Excess SRB was removed by washing with 1% acetic 
acid (3x100μl) and the dye was solubilized in 100μl of 10mM Tris (pH 10). The optical 
density was measured at 570nm with a microplate reader. In samples in which the 
measure absorbance exceeded 2.0, a fraction of the sample was removed, and the 
sample supplemented with Tris before remeasuring at A570.  
 
 Non-linear regression for IC50 value determination 2.3.3
 
The IC50 concentration of drugs in cell growth assays using ovarian cancer cell lines was 
determined from the dose-response curves. In every dose-response curve a certain drug 
concentration (independent variable) led to a certain degree of growth inhibition 
(dependent variable). Only data from complete dose–response curves were used. The 
data were analyzed by non-linear regression using the Graphpad Prism software to ﬁt a 4 
parameter (also called Hill-equation) sigmoidal dose–response curve. The averages IC50 
values from all experiments are reported together with the standard deviation. 
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 Drug Combination Studies 2.3.4
 
For drug combinations, carboplatin and paclitaxel were combined at the ratio of their 
IC50s. Where navitoclax was included, a fixed concentration estimated from preliminary 
IC50 determinations on its own to inhibit proliferation by 5 % was used while the 
concentration of the chemotherapeutic agent was varied. The fixed concentrations of 
navitoclax were: A2780, 3.3 μM; cisA2780, 1.5 μM; Ovcar-3, 1.2 μM; Ovcar-4, 2.1μM; 
Ovcar-5, 0.7 μM; Ovcar-8, 1.5 μM; Igrov-1, 0.4 μM; Sk-Ov-3, 0.6 μM. Using a fixed 
concentration overcomes problems associated with drug insolubility that can occur at 
high concentrations if a drug that has a high IC50 is included in combination at a fixed 
ratio. Drugs were prepared at 6x the final drug concentration, and 20 µl of each drug 
added to the cells in 80 µl of growth medium. After incubation for 72 hours, the cells 
were stained with SRB as described (2.3.2) and IC50 values determined (2.3.3).  
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 Combination Index (CI) value determination 2.3.5
 
The concept of the Combination Index (C.I.) was introduced by Chou and Talalay [341] for the 
quantification of synergism or antagonism between two drugs. It can be defined as a 
quantitative  measure based  on  the  mass-action  law,  of  the  degree  of  drug interaction in 
terms of synergism and antagonism for a given endpoint  of  the  effect  measurement [341]. 
The equation for calculating the Combination Index can be seen at Figure 11. 
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Figure 11: The Combination Index (CI) equation. 
 
 
 In the denominator, (Dx)1 is for Drug 1 “alone” that inhibits a system x%, and (Dx) 2 is for Drug 
2 “alone” that inhibits a system x%. The (D x) 1 and (D x) 2 values can be calculated from the 
results of non-linear regression obtained from fitting a Hill equation to the dose-response data. 
In the numerators, (D)1 (D)2 represent the concentrations of drug 1 and drug 2 respectively in 
the combination that also inhibit by x%. If the sum of these two fractional terms is equal to 1, 
an additive interaction is indicated.  If the C.I. value is smaller than 1, synergism is indicated, 
and if the C.I. value is greater than 1, antagonism is indicated [341]. 
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In our drug combination studies with Obatoclax, Carboplatin and Paclitaxel the Combination 
Indices or “C.I. values” were calculated to measure the combined effect of the drugs in doublet 
combinations. The drugs were combined in a fixed ratio of their respective individual IC50 values 
measured in preliminary experiments with the single agent using every cell line separately. The 
C.I. values described represent the averages from the experiments with the associated standard 
deviation. 
 
In the studies with navitoclax, for each single agent, double or triple drug combination, 
complete dose-response curves were determined in every experiment, using 18 different drug 
concentrations to establish IC50 values and Hill coefficients. For drug combinations of 
carboplatin and paclitaxel, the drugs were combined at the ratio of their IC50s. Where 
navitoclax was included, a fixed concentration estimated from preliminary IC50 determinations 
on its own to inhibit cell growth by 5 % was used while the concentration of the 
chemotherapeutic agent was varied. The fixed concentrations of navitoclax were: A2780, 3.3 
μM; cisA2780, 1.5 μM; Ovcar-3, 1.2 μM; Ovcar-4, 2.1μM; Ovcar-5, 0.7 μM; Ovcar-8, 1.5 μM; 
Igrov-1, 0.4 μM; SkOv-3, 0.6 μM. Using a fixed concentration overcomes problems associated 
with drug insolubility that can occur at high concentrations if a drug that has a numerically high 
IC50 is included in combination at a fixed ratio (ref 4).  The C.I. values are quoted at fraction 
affected = 0.5 (i.e. the concentration at which the combination affected 50% of the cells). 
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 Trypan Blue viability studies 2.3.6
 
Trypan blue is a vital dye which is used to determine cell viability. The chromophore is 
negatively charged and only penetrates the damaged membrane of dead cells. It is used 
to stain dead cells or tissue and exclude them from live cells. Under microscopy, the 
cytoplasm of dead cells is stained blue while the viable cells have a clear cytoplasm. 
 
12-well plates were seeded with 50,000 cells/well and after 24hr obatoclax was added at 
multiples of the IC50 ( 0x,1x,3x,6x,10x,20x) previously measured in 72 hour cell growth 
assays. After an incubation period of 72 hours the adherent cells were collected by 
trypsinization (see section 3.1.1) with 1.2ml trypsin/EDTA and combined with the non-
adherent floating cells. The cells were then collected by centrifugation at 150 g for 3 
minutes and the pellet was resuspended in an appropriate volume of 0.4% Trypan Blue. 
The viable and non-viable cells were then counted with a hemocytometer as described 
(see section 3.1.2). 
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 Measurement of drug sensitivity after siRNA transfection 2.3.7
 
To measure the effect of knockdown of Atg-5 or Beclin on the sensitivity of cells to 
obatoclax, cells were transfected with siRNA as described (section [2.2]). 24 hours after 
the transfection the medium was replaced with fresh antibiotic-free 10% FCS/RPMI 
medium. After a further 24 h, the cells were treated for 48 hours with the indicated 
concentration of carboplatin, paclitaxel or obatoclax. The drug sensitivity assay was 
performed as described (section 3.3.2). 
 
 Colony formation assay 2.3.8
 
100,000 cells from the Ovcar-5 and Ovcar-8 cell lines were seeded in 6-well plates in 1 ml 
of growth medium. The next day the cells were treated with obatoclax at multiples (0, 
1,3,6,10,20 x IC50) of the IC50 measured in cell growth assays. The cells were incubated in 
the presence of the drug for 48 hours. The cells were collected by trypsinization and 
counted using a hemocytometer. Cells were then reseeded at multiple densities 
(10,100,1000,10,000,100,000 cells per well) in a 6-well plate The cells were kept in a 
humidified 5% CO2 atmosphere at 37°C for 15 days. The colonies were stained with 1 ml 
of 0.5% methylene Blue in 50% ethanol, before washing with water. Colonies larger than 
1 mm in diameter were counted macroscopically. 
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 Spheroid assays 2.3.9
 
To measure the activity of drugs using spheroids, cells were resuspended in complete 
medium (2 x 106 cells/ml) and 20 μl pipetted on the up-turned lid of a 48 well plate. Only 
the inner ‘wells’ of the lid were used and 20 μl of medium was placed in the remaining lid 
‘wells’. 300 μl of PBS were placed in the well beneath the lid to ensure a humid 
atmosphere. After 1 week, the spheroids were exposed to drug by addition of 5 μl of 
RPMI containing the drug or solvent. After a further 72 hours, the spheroids were 
collected with a wide bore pipette into a 96 well plate and 25 μl of Cell-titer Glo 
(Promega) reagent were added to measure ATP. Microscopic inspection confirmed that 
this method fully lysed the spheroids, avoiding issues of the reagent penetration into the 
spheroid affecting the measurement. For IC50 measurements, the data were analyzed 
using Graphpad Prism to fit a four parameter Hill equation using non-linear regression. In 
drug combinations, single concentrations of each drug were tested. To compare the 
observed effect of the drug combinations in these experiments with the expected effect, 
the Bliss independence criterion was used to calculate the expected effect of the 
combination from the effect of the individual single agents [342].  
E Expected = EA + EB - EAEB 
Where EExpected is the expected effect of the combination assuming Bliss additivity, EA and 
EB represent the effect of drugs A and B when used on their own. The actual effect of the 
combination (the “observed effect”) was then compared to the expected effect using a 
paired t-test.  
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 Caspase 3/7 assays 2.3.10
 
To measure caspase 3/7 activity, cells were collected by trypsinization, counted and 5,000 
cells were seeded per well of a 96 well plate in 80 µl of growth medium. The following day 
cells were exposed to the indicated concentration of drug by addition of 20 µl of drug at 
5X times the desired final concentration. After 30 hours the cells were collected by 
centrifugation (150 g, 1min) to collect any floating cells at the bottom of the well and 75µl 
of the supernatant was removed. Caspase activity was measured by addition of 25µl using 
Caspase 3/7 Glo (Promega), incubating for 30 min and measuring luminescence using a 
luminometer. 
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2.4 Molecular biology methods 
 
 Gene expression analysis 2.4.1
 
To confirm effective knockdown of gene expression by siRNAs, Q-RTPCR studies were 
performed on parallel samples prepared at the same time as the siRNA experiment that 
was used to measure changes in drug sensitivity. Alternatively, protein was isolated and 
expression measured by western blotting. 
 
 Total RNA extraction from cell lines 2.4.2
 
Cells were plated for siRNA studies as described (section [2.2]).  To isolate RNA for QPCR 
studies, RNA was isolated from 4 wells in a 96 well plate (a minimum of 105 cells) 96 hours 
after transfection with siRNA. Cells were lysed in 350 µl RLT buffer before isolation of 
RNA), according to the manufacturer’s protocol (Qiagen RNAeasy kit).   
The RNA concentration was determined spectrophotometrically by absorbance at 260 nm 
and the purity of RNA samples was assessed by the 260/280 nm ratio. 
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 cDNA synthesis 2.4.3
 
For the production of cDNA, 11.5μl of RNA were mixed with 1.5μl (2.5 μg/μl) anchored 
oligodT primer (Invitrogen) and heated at 65 °C for 5 minutes to denature the secondary 
structure of the RNA before being placed on ice. A “master mix” was prepared comprising 
(per sample) 4 µl Transcriptor reverse transcriptase buffer (Roche) 2µl of 
deoxyribonucelotides (10 mM) and 0.5 µl reverse transcriptase (Roche). 7 μl of the master 
mix were added to each sample. The reaction was incubated at 55 °C for 30 min to allow 
cDNA synthesis and then at 85 °C for 5 minutes to inactivate the reverse transcriptase. 
Each sample was diluted 5-fold by adding RNA free water and stored at -20 °C. 
 
 Semi quantitative RT-PCR 2.4.4
 
qRT-PCR was performed using SybrGreen (Abgene) according to the manufacturer's 
instructions using a 7900HT Fast Real-Time PCR machine. 7.5μl per well of a master mix 
consisting of primers (GAPDH, Atg5 and Beclin respectively) & SYBR Green were prepared 
by mixing 6.25μl SYBR Green with 0.125μl 10 μM primers (final concentration 100nM) 
and 1.13μl H20. 5μl of 5-fold diluted RT reaction cDNA was added to the mix which was 
then centrifuged to remove any bubbles from the bottom of the wells. The qRT-PCR 
reaction was performed with dissociation stage setting to check for non-specific PCR 
product.  
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For each primer set, the efficiency of each primer was measured using 4 serial 2-fold 
dilutions of the template. Data were analyzed by plotting log [DNA] versus Ct and the 
slope of the resulting graph determined by linear regression. Efficiency for each round of 
amplification was calculated as 
                          
 
100% efficiency amplification corresponds to two copies of each template being 
synthesized per amplification cycle. To calculate knockdown following siRNA transfection, 
QPCR reactions were performed for the target gene and for GAPDH on each sample (cells 
transfected with non-targeting control siRNA, and cells transfected with siRNA designed 
to the gene under investigation).This efficiency was then used during the calculation of 
the “fold-knockdown” with siRNA. 
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Primers for Atg5 and Beclin1 autophagy genes were designed using the NCBI Entrez Gene 
database and the Primer3 software. The sequences for primers used were as follows: 
forward1 Beclin, 5′-AGATGCGTTATGCCAGAC- 3′; reverse1 Beclin 5′-
GATTGTGCCAAACTGTCCAC- 3′; forward2 Beclin, 5′- CAGGCTGAGGCTGAGAGAC- 3′; 
reverse2 Beclin 5′-TTCAGCTCATCATCCAGCTC - 3′; forward1 Atg5, 5′- 
GCATCAAGTTCAGCTCTTCC - 3′; reverse1 Atg5 5′- GATGGACAGTGCAGAAGGTCT- 3′; 
forward2 Atg5, 5′-CAGATGGACAGTTGCACACA  - 3′; reverse2 Atg5 5′- 
TGTTGGCTGTGGGATGATAC- 3′ (Sigma). 
 
 Transfection of GFP-LC3 2.4.5
 
Cells (5000 cells per well) were seeded in 96 well plates in 100µl antibiotic-free RPMI 
containing 10% FCS. After 16 hours the cells were transfected with 0.1 µg DNA (pCI-neo-
GFP-LC3) encoding GFP-LC3 and 0.2µl Lipofectamine 2000 in 50 μl Optimem as described 
[343]. Cells transfected with the vector were included as a control on every 96-well plate. 
After 6 hours the cells were washed once with PBS and placed in fresh medium.   
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 Western Blotting 2.4.6
 
Cell extracts were either prepared from T25 flasks or from 6 well plates. For the 
extraction of cellular proteins following siRNA transfection a sample was obtained by 
combining 6 wells of a 96 well plate that had been transfected using 5,000 cells/well and 
which were cultured in a 96-well plate for 96 hours after transfection. Cells were washed 
with PBS, and then lysed with modified RIPA (“radioimmune precipitation assay”) buffer 
(use 1 ml for every 100 cm2 of culture vessel). The modified RIPA comprised 20 mM 
Hepes, 150 mM NaCl, 2 mM EDTA, 0.5% sodium deoxycholate, 1% NP40 adjusted to 
pH7.0 with NaOH and freshly supplemented with 100 µM leupeptin and 15 µM pepstatin. 
The samples were cleared by centrifugation (15,000g, 10 min, 4°C) before the 
supernatant was collected. Protein concentration was estimated with a bicinchoninic acid 
(BCA) assay and samples were stored at -70°C. 
 
The BCA assay (Sigma Aldrich) was used to determine protein concentration. Bovine 
serum albumin (BSA, Sigma Aldrich) was used to construct a calibration curve (0.1, 0.25, 
0.5, 0.75, 1.0, 1.5, 2.0 mg ml-1 BSA). 10 µl of the sample or standard were treated with 
100 µl of the BCA assay reagent comprising bicinchoninic acid solution (containing 
bicinchoninic acid, sodium carbonate, sodium tartrate, and sodium bicarbonate in 0.1 N 
NaOH with final pH 11.25; Sigma-Aldrich) mixed with  4% (w/v) CuSO4 • 5H2O solution in 
a ratio of 50:1. The samples were incubated for 30 min at 37°C and A570 determined 
spectrophotometrically. The sample protein concentration was calculated following linear 
regression analysis of the standard curve of the sample. 
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For electrophoresis protein samples (10-20μg) were denatured at 70°C in NuPAGE sample 
buffer (Invitrogen) containing 5% β-mercaptoethanol for 15 minutes and subjected to gel 
electrophoresis using 3–12% BisTris gels (Invitrogen)  using Hepes running buffer (100 
mM Tris, 100mM Hepes, 1% SDS)  in an XCell surelook minicell (Invitrogen) . Protein 
markers (Invitrogen) were included on every gel.  The separated proteins were 
electrotransferred to nitrocellulose membranes (Hybond-ECL, GE Healthcare, 
Buckinghamshire, UK) in using 25mM Tris, 200 mM Glycine 0.075% SDS in 10% methanol 
at 30 V for 1 hour. The blotted membranes were incubated in blocking solution (5% non-
fat dry milk in TBST (0.02 M Tris hydrochloride, pH7.5, 150 mM sodium chloride, 0.1% 
Tween) for 1 hour at room temperature and incubated overnight with the antibody at 
1:1000-1:2000 dilutions. The membranes were then exposed to secondary antibody at 
1:2500 dilution for 1 hr.  
Chemiluminescence was detected using an ECL Chemiluminescent Substrate kit as per the 
manufacturer’s instructions. 
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2.5 Flow Cytometry 
 
Cells in the G1 phase of the cell cycle have diploid DNA while cells in G2/M phase have 
doubled this DNA content. Propidium iodide (P.I.) is a fluorescent stain which binds to 
DNA and RNA and so can be used to measure progression through the cell cycle. The 
fluorescence emission is proportional to the DNA content of the cell, therefore G1 cells 
fluorescence with half the intensity of cells in G2 or M phases. Cells in the S phase will 
exhibit intermediate fluorescence intensities. Apoptotic cells have reduced DNA content 
and exhibit a hypodiploid peak (sub-G1 peak) when stained with P.I. and analyzed by flow 
cytometry. That is due to the partial loss of DNA resulting from the effect of endogenous 
nucleases and the diffusion of low-molecular weight DNA out of the cells. 
 
 Ovarian cancer cell line were seeded in 6-well plates at a density of 105 cells per well in 
2ml of growth medium. The following day an appropriate volume of 25 μM obatoclax 
solution was added to each well to a final drug concentration equal to a 1x, 3x, 6x, 10x or 
20x multiple of the  IC50 measured in 72 cell growth assays. Control cells were treated 
with solvent alone.  Cells were incubated for 48 hours at 37°C in a 5% CO2 humidified 
atmosphere. At high drug concentrations some cells detached, so both detached and 
adherent cells were collected. The culture supernatant was removed and the adherent 
cells collected by with 0.5 ml trypsin EDTA (section [2.1.2]) before being recombined with 
the culture supernatant. The cells were then collected by centrifugation (150g, 3 min).  
The supernatant was removed and the cells in the pellet fixed by dropwise addition of ice-
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cold 70% ethanol while vortexing the sample. The cells were stored for up to 2 weeks at 
4°C.  
For flow cytometry, the ethanol was removed by centrifugation (200xg, 10 min, 4°C) and 
the cells washed twice with 5 ml ice-cold PBS by centrifugation. The cells were 
resuspended in 0.5 ml PBS and stained by addition of 50 µl propidium iodide/RNAse (0.5 
mg/ml heat treated RNASE, 500 µg/ml Propidium Iodide) for 15 minutes in the dark. Flow 
cytometry data were acquired using a BD FACsort flow cytometer with CellQuest software 
and data collected on the FL2 channel. Cells were gated to exclude small fragments using 
the forward scatter/side scatter plot and to exclude doubles using the FL2 doublet 
discrimination module plot of FL2 area versus FL2 width plot. FACS data were analyzed 
with the use of Cyflogic software. 
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2.6 Primary cultures from malignant ascites 
 
In this study we collected ascitic fluid from untreated patients diagnosed with ovarian 
cancer at the University Hospital of North Staffordshire, who attended the Radiology 
Department to have ultrasound-guided drainage. This was done strictly anonymously and 
was approved by the South Staffordshire Research Ethics committee 
(reference 09/H1203/61). All the patients were consulted and provided with an 
information leaflet and about the purposes of the study and the processing of the ascitic 
fluid. The process of the aspiration itself was not modified in any way from the usual 
protocols. A signed consent form was required in order for the samples to be collected 
and processed. The patient’s respective GPs were later informed by letter regarding the 
participation of the patients in this study and their right to access more information or 
withdraw.  
 
Primary cultures were established by the method described by Nachtigal et al [318]. Equal 
volumes of medium and ascitic fluid were seeded in T75 flasks and after 24 hours the 
supernatant was removed and replaced with fresh medium. For the primary cultures the 
media used was a 1:1 mix of MDCB105 and M199 (both from Sigma Aldrich), 
supplemented as described above [Section2.1.1]. Cells were used between passages 2 
and 8.  
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 Fluorescence microscopy of primary cultures 2.6.1
 
 
Cells were grown on glass coverslips and fixed with 3% paraformaldehyde for 20 min. 
After washing 3 times with PBS the cells were incubated for 1 hour with Hoechst-33342 or 
anti cytokeratin antibody clone MNF116 (Dako) diluted 1:500 in PBS. The cells incubated 
with the antibody were then washed three times with PBS before incubating with FITC-
anti-mouse antibody (1:1000). After washing a further three times, the cells were 
mounted in Vectorshield and viewed with a fluorescent microscope. 
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2.7 Tumour xenograft experiments 
 
 
Due to lack of appropriate facilities and licensing at Keele University, the xenograft 
experiments were performed by Suzanne A. Eccles at the Institute of Cancer Research, 
Sutton, United Kingdom in accordance with the U.K. Home Office regulations under the 
Animals (Scientific Procedures) Act 1986 and the U.K. Coordinating Committee on Cancer 
Research guidelines for animal experimentation [344]. 
 
In brief, tumors were established from cultured Ovcar-8 cells harvested from culture 
vessels after trypsinization, wash, and resuspension in PBS. Cells were injected s.c. 
bilaterally in mice. Dosing commenced when tumors were well established (f5-6 mm 
diameter). Obatoclax was prepared in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 
5% dextrose. Animals received either vehicle alone or obatoclax (5mg/kg) intravenously 
every day for the first 5 days of the study. Animals were observed daily, weighed, and 
tumors measured thrice weekly. Tumors were measured across two perpendicular 
diameters and volumes calculated from the following formula: 
       [
     
 
]
 
 
 
as previously described [345]. 
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Chapter 3: Evaluation of navitoclax in 
ovarian cancer 
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3.1 Aims & Objectives 
 
The BH3-mimetic ABT-737 has previously been shown to enhance the cytotoxic effects of 
chemotherapy in ovarian cancer cells. However, ABT-737 has poor oral availability and 
this has led to the development of its successor, navitoclax, which has sufficient 
bioavailability to justify its entry into clinical trials. However, the effect of navitoclax in 
ovarian cancer cells had not yet been assessed. The goal of the research presented in this 
chapter was to investigate whether navitoclax was also synergistic with the 
chemotherapy used to treat ovarian cancer.  
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3.2 Introduction 
 
A common assumption in cancer studies is that the over-expression of a gene in a large 
fraction of tumours indicates that the encoded gene product supports tumorigenesis. The 
intrinsic apoptotic pathway provides an example of this, and is considered to be central to 
the survival of cancer cells in which anti-apoptotic proteins which regulate this pathway 
are overexpressed.  This is profoundly important in ovarian cancer where the emergence 
of resistance to drug treatment is a major hurdle that must be overcome. The discovery 
of the Bcl-2 family of proteins (Chapter1) in the last 20 years and the clarification of the 
functions of its different family members has contributed significantly to identifying new 
targets for cancer therapy. The development of molecules which can effectively 
antagonize the Bcl-2 family apoptosis “inhibitors “has made considerable progress and 
has delivered agents such as the “BH3-mimetics” to the clinic. These drugs are able to 
bind the hydrophobic groove of anti-apoptotic Bcl-2 proteins mimicking BH3-only 
proteins. A number of agents has been developed and entered clinical trials and these 
innovative drugs have shown synergy with several chemotherapeutic agents [307]. 
 
 
ABT-737 was discovered by Abbott Laboratories in the mid-2000s using nuclear magnetic 
reasonance-based screening and structure-guided design to exploit the hydrophobic 
binding groove of the prosurvival proteins Bcl-2 and Bcl-XL which binds to the BH3 domain 
of pro-apoptotic proteins. By occupying the hydrophobic grove, the apoptosis inhibitors 
are no longer able to sequester the pro-apoptotic BH3-only protein, thereby increasing 
their propensity to induce apoptosis [346],[347],[348]. ABT-737 binds with high affinity to 
107 
 
Bcl-2, Bcl-XL and Bcl-W (IC50<10nM), but is far less potent against Mcl-1 and A1 [349]. It is 
a selective inhibitor that requires functional Bax and Bak to induce apoptotic cell death by 
disrupting the interactions between antiapoptotic and proapoptotic proteins [349] . Thus 
it does not directly induce apoptosis, rather it sensitizes cell to other pro-apoptotic stimuli 
which induce the expression of pro-apoptotic BH3-only proteins. 
 
ABT-737 has been shown to be a potent single agent in lymphoma and small cell lung 
cancer [311], AML [350],[351], multiple myeloma [352], CLL [353] and acute 
lymphoblastic leukemia [354]. Although this may seem in contradiction with the 
foregoing discussion of ABT-737 as an apoptosis sensitizer, in fact it reflects pre-existing 
pro-apoptotic stimuli in these cells. In many of these cells the constitutive expression of 
BH3-only proteins does not lead to cell death because they are sequestered by Bcl-2 
family inhibitors. ABT-737 displays potent single agent activity in these cells because they 
are “addicted” to Bcl-2 family inhibitors to survive. ABT-737 liberates the proapoptotic 
proteins and thereby induces cell death. In other cells where BH3-only proteins are not 
constitutively expressed, the cells are not dependant on Bcl-2 family apoptosis inhibitors 
for continual survival and ABT-737 shows weak single agent activity. 
 
Our group has shown that in ovarian cancer ABT-737 has modest potency as a cytotoxic 
single agent in in vitro assays using ovarian cancer cell lines [312]. In ovarian cancer, 
combination with carboplatin resulted in a shortening of the time to apoptosis and an 
increase in cell growth inhibition, especially when cells were treated with ABT-737 after 
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exposure to chemotherapy [312]. In xenograft studies in mice the combination of both 
drugs showed enhanced efficacy. Other workers have found that combinations of ABT-
737 with paclitaxel in ovarian and breast cancer cell lines successfully enhanced the 
observed cell death [355], [356]. Thus, ABT-737, and other BH3-mimetics, has the 
potential to increase the sensitivity of ovarian cancer cells to chemotherapy. This is 
particularly important in ovarian cancer where the development of drug resistance 
prevents effective treatment. Bcl-2 family apoptosis inhibitors have been shown to be 
over-expressed in drug resistant disease [357].This suggests that BH3-mimetics might be 
considered for use in patients whose disease has become resistant to chemotherapy. 
 
The potential for ABT-737 to be used in patient therapy is limited by its poor oral 
bioavailability. The prospect of administering it intravenously is also hampered  by its low 
aqueous solubility [358]. The structural characteristics of ABT-737 which were considered 
responsible for these liabilities were identified and then analogues were designed with 
modified structures in an attempt to allow oral administration without adversely affecting 
the drug’s pharmacodynamics activity [358]. Navitoclax is a second-generation BH3-
mimetic with considerably higher oral bioavailability which was developed from ABT-737 
and has the same pharmacological profile and inhibits the same members of the Bcl-2 
family. Navitoclax has low plasma clearance values and low volumes of distribution in 
animal models with near 50% bioavailability in lipid-based formulations [358]. The 
selectivity of navitoclax for Bcl-2 family members resembles that of ABT-737 as well as 
that of the BH3-only protein BAD [349]. Navitoclax displays a high affinity for Bcl-2, Bcl-XL 
and Bcl-W and binds less to Mcl-1 an A1. Extensive studies have confirmed that its 
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cytotoxicity is, as with ABT-737, mechanism based and dependant on the mitochondrial 
apoptotic pathway [358]. Unsurprisingly it has been described already that cells 
overexpressing Mcl-1 show resistance to navitoclax. 
 
The evaluation of navitoclax in pre-clinical studies has shown that it causes cell death in a 
panel of leukemia and lymphoma cell lines and tumour regression in xenograft models 
[359]. Additionally, it  enhances the therapeutic effect of chemotherapy for B-cell 
lymphoma and multiple myeloma xenograft models [358]. Combinations of navitoclax 
with rapamycin in lymphoma cells showed enhanced cell killing when compared to the 
effect of each single agent [359]. In ovarian cancer, combinations of navitoclax with 
paclitaxel or gemcitabine exhibited synergistic effects across a number of cell lines 
[360].So far, navitoclax has been evaluated in phase I and II studies in small-cell lung 
cancer, haematological malignancies and other solid tumours [361], [362]. Although there 
was no evidence of efficacy in lung cancer, 35% of patients with chronic lymphoid 
leukemia achieved a partial response and 27% showed stable disease for 6 months [363]. 
These observations encouraged us to extend the observations previously made with ABT-
737 in ovarian cancer cells to navitoclax. This led to the hypothesis that navitoclax would 
synergize with carboplatin in ovarian cancer cells. 
 
The current gold-standard therapy for ovarian cancer patients consists of the combination 
of carboplatin and paclitaxel. This has been extensively reviewed for its haematological 
toxicity and found to be overall well tolerated by patients with high response rates. 
Thrombocytopenia remains a clinical challenge which often affects the quality of life and 
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causes treatment dose reductions or treatment delays. Carboplatin has been shown to 
cause thrombocytopenia and leukopenia and is associated with the need for transfusional 
support. It causes dose-dependent myelosuppression and this may occur in patients with 
renal impairment or patients concurrently receiving other myelotoxic drugs. Paclitaxel 
also possesses dose-dependent myelotoxicity, but is less associated with 
thrombocytopenia. Rather, paclitaxel is known to have “platelet-sparing” activity and 
reduce the thrombocytopenia induced by carboplatin [364],[365],[366]. 
 
The use of ABT-737 on mice has also shown the induction of rapid and reversible 
thrombocytopenia due to accelerated cell death of platelets (especially of the older cells), 
but no bone marrow toxicity [367]. This is a result of the inhibition in platelets of the 
prosurvival Bcl-2 proteins by the drug, directly causing an apoptotic-type of cell death. 
Despite the reduction in platelet counts,  in other animal models plasma concentrations 
of ABT-737 several folds higher than the efficacious level were well tolerated [358].  
 
Navitoclax similarly causes dose -dependent thrombocytopenia and T-lymphopenia. The 
levels of endogenous Bcl-XL have been found to play a critical role in vivo for the survival 
of platelets and the high affinity of navitoclax for this molecule can explain the observed 
platelet apoptosis. It is interesting that unlike conventional chemotherapy where 
myelosuppression is observed, the selective action navitoclax only affects the circulating 
platelets. The reduction in the number of circulating cells is rapid, but multiple daily 
dosing in animal models did not significantly reduce the cells to levels lower from the 
initial first-dose effect [358]. This could be explained by the ability of the animal to 
111 
 
produce more platelets or by the possibility of separate platelet populations with distinct 
sensitivity to navitoclax. It has also been shown that navitoclax interferes with the 
mechanism of calcium signalling in platelets and contributes to the depletion of the 
cellular calcium stores and this may also affect the observed thrombocytopenia.  
 
Despite these concerns, all the available evidence from phase 1/2 clinical studies of 
navitoclax at the time this study was initiated showed that navitoclax was safe and well 
tolerated with minimal systemic toxicities  [368],[369], [361]. Thus, it still appeared 
reasonable to evaluate the hypothesis that navitoclax would synergize with carboplatin. 
However, the thrombocytopenia observed with both carboplatin and navitoclax raised 
the concern that these drugs might display additive toxicity. Bearing in mind that 
paclitaxel has “platelet sparing” activity, and that combinations of carboplatin and 
paclitaxel are the current standard of care in ovarian cancer, the hypothesis was modified 
to evaluate whether navitoclax would synergize with combinations of carboplatin and 
paclitaxel. Paclitaxel might also have platelet sparing activity when added to the 
carboplatin-ABT-263 combination and ameliorate the anticipated additive 
thrombocytopenia. However, previous work from our group failed to find significant 
synergy between paclitaxel and ABT-737 and several groups have published preclinical 
work which has demonstrated an antagonistic interaction between carboplatin and 
paclitaxel [370], [371]. This made the outcome of the navitoclax carboplatin-paclitaxel 
combination unpredictable. Therefore all the pairwise combinations of carboplatin, 
paclitaxel and navitoclax were investigated alongside the triple combination of all three 
agents. 
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3.3  Results  
 
 Single agent studies of carboplatin, paclitaxel and navitoclax 3.3.1
 
In order to evaluate the combined effect in vitro of carboplatin, paclitaxel and navitoclax 
on ovarian cancer cell lines, studies were first performed to assess the activity of the 
drugs as single agents. This information was subsequently used to select the 
concentrations of drugs to use in combination studies. The IC50 values for carboplatin and 
paclitaxel measured in the panel of cell lines in this study (Tables 11 & 12) were 
comparable to those previously reported by our group [312]. The navitoclax single agent 
studies demonstrated that the growth of cell cultures was inhibited in all 8 cell lines with 
IC50 values ranging from 3-8μM (Table 13). This was comparable to the potency of ABT-
737 against the same cell lines measured previously by our group, although navitoclax 
was approximately, 2-fold more potent than ABT-737 [312]. 
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Cell Line IC50 (μM) 
A2780 10.9 ±1 
cisA2780 108.5 ±15.9 
Ovcar-3 4.6 ±0.9 
Ovcar-4 25.2 ±11.9 
Ovcar-5 63.6 ±10.1 
Ovcar-8 69.6 ±10.7 
Igrov-1 20.8 ±3.8 
Sk-Ov-3 30 ±4.1 
Table 11: The IC50 values (mean ± S.D., n=3) of carboplatin as evaluated in single agent studies 
against 8 different ovarian cancer cell lines. Cells were treated with indicated drug for 72 hours 
after which relative cell number was estimated by staining with SRB. 
 
Cell Line IC50 (nM) Hill Slope Number of experiments 
A2780 2.7 ±0.78 -4.1 ±0.9 n=13 
cisA2780 2.8 ±1.9 -3.7 ±1.1 n= 10 
Ovcar-3 5.1 ±6 -3.3 ±1.2 n=11 
Ovcar-4 8.6 ±6.7 -3.8 ±1.1 n=8 
Ovcar-5 6.7 ±1.7 -3.9 ±1.1 n=9 
Ovcar-8 4.8 ±1.3 -3 ±0.9 n=10 
Igrov-1 6.2 ±7.8 -2.7 ±1.7 n=9 
Sk-Ov-3 7.9 ±4.1 -1.8 ±0.3 n=8 
 
Table 12: The IC50 values (mean ± S.D., n=3) of paclitaxel  as evaluated in single agent studies 
against 8 different ovarian cancer cell lines. Cells were treated with indicated drug for 72 hours 
after which relative cell number was estimated with SRB. 
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Cell line IC50  (μM) n 
A2780 6.8 ± 2.5 9 
cisA2780 4.7 ± 2.0 5 
Ovcar-3 5.9 ± 0.4 3 
Ovcar-4 5.9 ± 3.5 6 
Ovcar-5 3.2 ± 1.3 10 
Ovcar-8 5.3 ± 1.5 13 
Igrov-1 8.5 ± 5.7 16 
Skov-3 5.2 ± 1.5 6 
Table 13: Single agent potency of navitoclax. 
Cells were treated with a range of concentrations of navitoclax for 72 hours, stained with SRB and 
the IC50 (mean ± S.D.) calculated from the indicated number (n) of experiments. 
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 Combination Studies 3.3.2
 
Pairwise drug combination studies of carboplatin and paclitaxel, carboplatin and 
navitoclax, paclitaxel and navitoclax as well as the triple combination of all three agents 
were performed. In these studies navitoclax was used at a fixed concentration that is 
comparable to the levels observed in phase 1 clinical trials with navitoclax [361],[372]. 
 
In agreement with previous reports describing antagonism between carboplatin and 
paclitaxel, data consistent with modest antagonism (C.I. > 1) between these two drugs 
was obtained in all of the cell lines.  [370],[371]. However, this only reached statistically 
significant in two cell lines (Figure 12). 
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Figure 12: The effect of drug combinations containing navitoclax on ovarian cancer cells . A. The 
indicated cells were treated with carboplatin, paclitaxel or navitoclax drug combinations. 
Carboplatin and paclitaxel were evaluated at 18 different concentrations, combined at a ratio of 
the respective single agent IC50s. Where navitoclax was included, a fixed concentration was used 
(see methods). The C.I values (mean ± S.D., n= 3-8) are quoted at fraction affected fa=0.5 and are 
significantly different from C.I.= 1.0 where indicated (*, P < 0.05, t-test). The CI values obtained 
with carboplatin/navitoclax (¥) or paclitaxel/navitoclax (#) differed significantly from the values 
observed with carboplatin/paclitaxel combination (Kruskal-Wallis test, P < 0.05) and the CI 
obtained with carboplatin/paclitaxel (§) differed significantly from 
carboplatin/paclitaxel/navitoclax where shown. B. Igrov-1 cells were treated with the indicated 
combinations of carboplatin (50 µM), paclitaxel (20 nM) or navitoclax (0.4 µM) for 30 hours and 
caspase activity measured. The results (mean ± S.D, n=6) were normalized for cell number by 
staining duplicate samples with SRB and are expressed as a fraction of the caspase activity 
measured in cells treated with carboplatin alone. The results were statistically different where 
indicated (P < 0.05, 1-way ANOVA). Error bars represent S.D. 
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Our group has previously observed synergy between ABT-737 and carboplatin. In this 
study synergy was observed between navitoclax and carboplatin in 4 of 8 cell lines 
evaluated (C.I. < 1; (Figure 12). This was most prominent in Igrov-1 cells, the cell line in 
which synergy between carboplatin and ABT-737 was most evident in previous studies 
[312]. Antagonism was observed between carboplatin and navitoclax in the A2780 cell 
line and its platinum-resistant daughter cell-line cisA2780. These observations are 
consistent with the previously observed antagonism between carboplatin and ABT-737 
[312]. Why antagonism is observed in these two related cell lines is unclear, although, of 
the cell lines evaluated, they are the least genetically related to authentic serous ovarian 
cancer [373]. The carboplatin-navitoclax combination performed significantly better 
(smaller C.I. value) than the standard-of-care doublet combination of carboplatin-
paclitaxel in 5 of the 8 cell lines evaluated. 
 
Previous studies from our group demonstrated an additive rather than a synergistic 
interaction between ABT-737 and paclitaxel in cell proliferation studies. Those 
experiments were performed using the same methods used here - by measuring a 
combination index after 72 hour cell proliferation assays [312]. In contrast, Wong et al 
observed a more than additive effect between navitoclax and paclitaxel in ovarian cancer 
cell lines [312]. In those studies a 72 hour cell growth assay was also used, but a 
combination index was not reported, rather the Bliss independence criterion was used to 
identify super-additive effects.  In the studies presented here (which used the 
combination index method), consistent with the work previously published by our group, 
additivity was observed between navitoclax and paclitaxel in most of the cell lines 
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examined, although modest synergy between navitoclax and paclitaxel was observed in 
one cell line (Ovcar-5, Figure 12). 
 
When the triple combination of carboplatin, paclitaxel and navitoclax was evaluated the 
pattern of synergy and antagonism across different cell lines matched that observed with 
the carboplatin and navitoclax doublet combination. In Igrov-1 cells, in which synergy 
between carboplatin and navitoclax was observed, the triple combination was also 
synergistic. In A2780 and cisA2780 cells antagonism was again evident (Figure 12). In 
addition, in all of the cells in which synergy between carboplatin and navitoclax had been 
observed, the C.I. value for the triple combination was less than that obtained with the 
standard-of-care doublet combination of carboplatin and paclitaxel. In Igrov-1 cells, 
where navitoclax and carboplatin showed the most synergy, the triple combination was 
also the most synergistic. Importantly, in those cells where antagonism was observed 
between carboplatin and paclitaxel, antagonism was no longer evident when navitoclax 
was included.  This suggests that in cells in which navitoclax is synergistic with 
carboplatin, navitoclax is able to improve upon the activity obtained with the standard-of-
care carboplatin/paclitaxel combination. 
 
 
To confirm these observations using an endpoint other than cellular biomass, caspase 3/7 
activity was measured in cells exposed to single, double or triple combinations of 
carboplatin, paclitaxel and/or navitoclax.  For these experiments Igrov-1 cells were used 
because this is the cell line in which the most significant synergy between carboplatin, 
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paclitaxel and navitoclax was observed. Relatively short term exposure (30 hours, 
compared to 72 hours used in the cell proliferation studies) was used because the signal 
from this assay eventually decays after cell death has occurred. Carboplatin increased 
caspase 3/7 activity, and this was enhanced by inclusion of navitoclax, consistent with the 
synergy seen between these two agents in the cell growth studies using this double 
combination. In agreement with the work of Wong and co-workers [360], navitoclax also 
enhanced the caspase 3/7 activity measured after 30 hours exposure to paclitaxel. 
However, this was not consistent with the lack of synergy observed between navitoclax 
and paclitaxel in the cell proliferation studies presented here. One potential explanation 
is that navitoclax accelerates apoptosis induced by paclitaxel when it is measured after 30 
hours drug exposure but has a relatively modest effect on the potency of paclitaxel 
measured after 72hr drug exposure.  Alternatively, measuring caspase 3/7 activity may be 
a more sensitive means to detect modest synergy. The results with the triple combination 
were, however, consistent with the data obtained in cell proliferation studies. The 
caspase-3/7 activity induced by the combination of carboplatin, paclitaxel and navitoclax, 
was significantly greater than that in cells exposed to the carboplatin and paclitaxel 
doublet combination. 
 
To confirm further these observations, the activity of the drug combinations was 
measured using Igrov-1 cells grown as spheroids. Firstly, the activity of the single agents 
was evaluated. Carboplatin inhibited the survival of spheroids (assessed by measuring 
cellular ATP) with only a modest (3-fold) decrease in potency compared to that measured 
using monolayer cultures (Figure 13). In contrast, the sensitivity of cells in spheroids to 
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navitoclax was increased approximately 5-fold. Strikingly, the spheroids were 
approximately 2000-fold more resistant to paclitaxel than the cells grown in monolayer 
cultures (Figure 13).  
 
 
 
Figure 13: Evaluation of navitoclax, carboplatin and paclitaxel in Igrov-1 spheroids.  The potency 
of navitoclax, carboplatin and paclitaxel against Igrov-1 cells was compared against monolayer 
and spheroid cultures. The results (mean ± S.D., n=7-11) are expressed as a fraction of the ATP 
measured in cells treated with drug vehicle alone. Error bars represent S.D. 
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The effect of the drug combinations was then evaluated. For these experiments, the Bliss 
independence criterion was used to assess drug interactions. Although evaluating synergy 
by measuring a combination index is a robust approach, it is best supported by 
performing a full dose-response analysis which is technically challenging using spheroids 
due to the difficulties in obtaining sufficient data points. Instead single drug 
concentrations were used and chosen to inhibit survival on their own by approximately 
50% (25% for paclitaxel due to its poor potency in spheroids).  These concentrations were 
comparable to drug concentrations achieved in patients [361],[372],[374],[375].The Bliss 
independence criterion has been used by other workers to analyse drug interactions in 
the absence of complete dose-response curves e.g. [360]. In these studies, antagonism 
between carboplatin and paclitaxel was not observed with Igrov-1 spheroid cultures. 
However, when navitoclax was included with either carboplatin, or with paclitaxel, or 
with the combination of carboplatin and paclitaxel, a more than additive interaction was 
observed. The number of cells surviving in each case was significantly fewer than that 
anticipated for the corresponding drug combination estimated from the Bliss 
independence criterion and the effects of each drug as a single agent (Figure 14).  
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Figure 14: Evaluation of navitoclax drug combinations in Igrov-1 spheroids.  
Igrov-1 spheroids were treated with the indicated combinations of 30 μM 
carboplatin, 2 μM navitoclax and 1.2 μM paclitaxel. The results (mean ± S.D., n=4-5) 
are expressed as a fraction of the ATP measured in cells treated with drug vehicle 
alone. Drug combinations were compared to the expected effect (shown with a 
dashed line for each drug combination) calculated from the measured effect of the 
individual drugs in each individual experiment and assuming Bliss independence. *, 
significantly different from the Bliss expected effect (t-test, P < 0.01). Error bars 
represent S.D. 
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3.4 Discussion 
 
Platinum agents and taxanes are at the core of our current gold standard for treatment of 
ovarian cancer. Carboplatin induces its effect by forming DNA adducts at any phase of the 
cell cycle, although the response to this is cell cycle-dependent and platination causes 
arrest of cells in S-phase [16, 26]. In contrast, paclitaxel causes M-phase arrest and exerts 
its activity by preventing normal microtubule dynamics. The strategy of targeting the 
intrinsic apoptosis pathway in cancer cells with the use of BH3-mimetics which bind to the 
Bcl-2 family of proteins has yielded new drugs which have shown enhanced toxicity when 
combined with traditional chemotherapeutics[376]. Various BH3-mimetics are currently 
undergoing further pre-clinical and clinical assessment as single therapy and in drug 
combinations for different types of cancer. The work in this chapter explored 
combinations of these drugs. 
 
The addition of navitoclax to combinations of carboplatin and paclitaxel in monolayer and 
spheroid cultures appears to increase their potential therapeutic effect. Several studies, 
including the results presented here, have reported antagonism between platinum based 
compounds and taxanes in monolayer cultures. The antagonism between carboplatin and 
paclitaxel has been proposed to be due to carboplatin causing arrest, preventing cells 
from reaching M-phase when they are sensitive to paclitaxel [16, 17]. However, 
carboplatin can still attach to DNA in cells that are first exposed to paclitaxel and which 
have arrested in M-phase.  Thus, pre-exposing cells to paclitaxel has generally been found 
to be less antagonistic than other schedules of administration. However, in clinical 
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practice, patients may receive carboplatin and paclitaxel on the same day of treatment. 
Thus, the simultaneous exposure to both carboplatin and paclitaxel in our experiments 
approximates common clinical practice. In several cell lines the inclusion of navitoclax 
with either carboplatin or paclitaxel in monolayer led to combination indices significantly 
lower those obtained with the carboplatin and paclitaxel combination. Whether 
antagonism occurs between carboplatin and paclitaxel in the clinic is unclear. Two 
chemotherapeutic drugs, even if mutually antagonistic, may elicit more cell kill than 
would occur if either agent were used on its own so antagonism per se does not 
necessarily prohibit the combination of two drugs. However, the results presented here 
suggest that the inclusion of navitoclax with the carboplatin-paclitaxel combination may 
increase the therapeutic effect. 
 
After these studies were completed, clinical trials of navitoclax were suspended due to 
the thrombocytopenia induced by navitoclax. This is a particular concern in the present 
study, because carboplatin also causes thrombocytopenia, raising the potential for 
additive toxicity when these drugs are combined. Abbott, the company that discovered 
navitoclax, has subsequently developed a new analogue of navitoclax “ABT-199”, which 
lacks appreciable affinity for Bcl-XL [377]. The development of ABT-199 from Abbott is 
expected to resolve the problem of thrombocytopenia [378]. This agent has been 
developed from the re-engineering of navitoclax and on-going studies confirm that it 
possesses weak ex vivo activity on platelets [377]. Clinical studies have demonstrated 
efficacy against haematological malignancies and show an improved toxicity profile [377], 
[379]. Unfortunately, previous work from our group suggests that Bcl-XL is a key mediator 
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of chemoresistance in ovarian cancer cells, suggesting that ABT-199 is unlikely to be 
useful in ovarian cancer. 
 
The reduced sensitivity of spheroids to chemotherapeutic agents has been previously well 
characterized. In our experiments, the spheroid cultures were much less sensitive to 
paclitaxel than cells in monolayer culture. In part, this may be due to poor penetration of 
paclitaxel into tumour spheroids [27]. This is unlikely be the sole explanation for the 
reduced sensitivity because paclitaxel can penetrate cultured tumour fragments within 24 
hours [27] and in our experiments spheroids (and monolayers) were exposed to drug for 
72 hours. Furthermore, the spheroids retained their sensitivity to both carboplatin and 
navitoclax, suggesting that drug penetration is not completely prevented. Alternatively, a 
more likely explanation may be that the relatively low mitotic index of cells in spheroid 
culture may reduce the potency of cell cycle specific drugs such as paclitaxel [28]. Cells 
which proliferate slowly are likely to be relatively resistant to agents such as paclitaxel 
whose mechanism of action depends on cells progressing through the cell cycle. This 
reduced potency of paclitaxel may also contribute to the lack of antagonism observed 
between carboplatin and paclitaxel in spheroid culture. The spheroids were modestly less 
sensitive to carboplatin than were cells in monolayer. In contrast, the spheroids were 
somewhat more sensitive to navitoclax. This latter observation may reflect the change in 
expression of Bcl-2 family members. The expression of Bcl-2 and Bcl-XL, both of which are 
sensitive to inhibition by navitoclax, is increased in spheroids [29-32]. In contrast, 
expression of the navitoclax insensitive family member Mcl-1 is decreased [29, 30]. The 
expression of the BH3-only protein Bim is also increased [33] which would effectively 
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neutralized Bcl-2 apoptosis inhibitors. This may indicate a greater dependence of 
spheroid cultures for survival on Bcl-2 family members that are sensitive to navitoclax. 
These observations underline the value of using different experimental models to 
measure drug sensitivity and interactions. It also suggests that studies which seek to 
identify drugs which restore the sensitivity of cells to paclitaxel should consider using 
spheroid culture rather than monolayers, as these may provide a better model. 
 
Our group has previously reported synergy between carboplatin and ABT-737 in a number 
of ovarian cancer cell lines [8]. ABT-737 was also found to augment the inhibition of the 
growth of Igrov-1 xenografts. In the studies presented here, synergy was also observed 
between navitoclax and carboplatin. Our group initially reported additivity between 
paclitaxel and ABT-737 in several ovarian cancer cell lines [5]. In contrast, Wong and co-
workers [15] observed a more than additive interaction in an even broader panel of 
ovarian cancer cells. Combining navitoclax with paclitaxel is an attractive approach, 
because paclitaxel does not cause significant thrombocytopenia. One possible 
explanation for the discrepancy between the work presented here and that of Wong et al  
is the different methods of analysis of cell proliferation assays used by us (calculation of 
Combination Index) and by Wong and co-workers (comparison of the observed effect 
with the effect expected estimated from the Bliss independence criterion). However, in 
the work presented here and that of Wong and co-workers, an increase in caspase 
activity was identified when navitoclax was included with paclitaxel for relatively short 
periods (24-30 hours). These observations may suggest that navitoclax can potentiate the 
activity of paclitaxel against ovarian cancers, but it is less pronounced when measured in 
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72 hour cell proliferation assays using monolayer cultures. It also raises an issue of the 
clinical relevance of these observations If ABT-737 or navitoclax, when combined with 
paclitaxel, simply accelerate cell death without affecting the number of cells that die, is 
there likely to be any clinical benefit? Navitoclax appears to accelerate apoptosis induced 
by paclitaxel [15] and ABT-737 has previously been observed to accelerate apoptosis 
induced by carboplatin. Nonetheless, navitoclax was able to increase the effectiveness of 
the carboplatin-paclitaxel combinations. Thus it wold seem sensible to prioritize the 
clinical evaluation of carboplatin-paclitaxel-navitoclax over paclitaxel-navitoclax 
combinations. 
 
The binding of navitoclax to Bcl-XL affects platelet survival and causes mechanism-based 
predictable transient thrombocytopenia, with a dose-limiting relationship [363], [380]. At 
present the majority of clinical trials assessing navitoclax have been completed and the 
focus is on the adverse effects on the patients. In the present study, navitoclax improved 
the activity of carboplatin and paclitaxel combinations, making it desirable to evaluate 
this combination in clinical trials. It will be essential to determine if paclitaxel is able to 
reduce the impact on platelets of the carboplatin and navitoclax. These studies still 
appear worthwhile, if the thrombocytopenia can be carefully monitored, because of the 
lack of suitable treatment options in patients with drug-resistant disease. Thus, it remains 
important to be determined if navitoclax can be tolerated in ovarian cancer patients. 
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In summary, navitoclax improved the activity of the carboplatin/paclitaxel combination, 
the doublet combination that most closely matches the current standard of care, both in 
monolayer and spheroid cultures. Combined with our previous studies demonstrating 
synergy between ABT-737 and carboplatin [8], and those of Wong [15] showing more 
than additive interaction between paclitaxel and navitoclax, this leads to the conclusion 
that navitoclax warrants clinical evaluation in ovarian cancer, but the platelet effects of 
the combination must be carefully monitored.  One set of patients likely to benefit from 
this combination are those whose tumours express high level Bcl-XL. High expression of 
Bcl-XL correlates with a poor response to paclitaxel [15] and Bcl-XL is also a key 
determinant of synergy between carboplatin and ABT-737 [15]. However, multiple factors 
determine sensitivity to navitoclax [5] and other patient groups, such as those with 
elevated expression of BH3-only proteins, may also benefit from inclusion of navitoclax. 
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Chapter 4: Evaluation of obatoclax in 
ovarian cancer 
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4.1 Aims & objectives 
 
In this study the efficacy of obatoclax was evaluated in models of ovarian cancer to 
explore the potential for this agent as a treatment for patients with ovarian cancer. This 
study was performed using established ovarian cancer cell lines and primary cultures 
established from patients with varying degrees of chemoresistance. The mechanism(s) of 
action of this drug were also investigated as part of this analysis. 
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4.2 Introduction 
 
 
The induction of apoptosis has been identified as a therapeutic strategy for drug 
discovery in oncology. Molecules such as the BH3-mimetics were designed to target 
cancer cells considered “primed” for apoptotic cell death because of their “addiction” to 
overexpressed pro-survival Bcl-2 “inhibitors” or cells in which BH3-only proteins were 
induced by chemotherapy [306]. These drugs are thought to elicit their effect by 
liberating BH3-only proteins which are apoptosis activators thereby causing the activation 
of Bax and Bak and subsequently MOMP [381], [353]. A number of these drugs has been 
developed and these differ in their binding capacities for the anti-apoptotic members of 
the Bcl-2 family of proteins [376], [382]. The overexpression of the apoptosis inhibitor 
Mcl-1, which does bind neither ABT-737 nor navitoclax with high affinity, has emerged as 
a mechanism of resistance to the aforementioned drugs [376], [351], [349].  
 
Obatoclax mesylate (GX15-070) is a prodiginine derivative with an indole ring developed 
through structure-activity relationship studies of the pyrrolic ring A of GX15 [383]. It is a 
pan-Bcl-2 protein inhibitor originally developed by GeminX (Montreal, Canada) and 
having the ability to bind to all pro-survival Bcl-2 protein, obatoclax is not anticipated to 
suffer from the same resistance mechanisms that limits the activity of ABT-737[384]. In 
the foregoing chapters, the efficacy of ABT-737 and navitoclax in models of ovarian 
cancer has been discussed. These initial studies provided proof-of-principle for the 
therapeutic targeting of the prosurvival Bcl-2 family of proteins in ovarian cancer. 
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However, the anticipated broader activity of obatoclax warranted its evaluation in ovarian 
cancer. 
A number of preclinical in vitro studies have examined the activity of obatoclax in several 
types of cancer and demonstrated that this drug possesses significant single agent 
efficacy. The most prominent activity of obatoclax has been demonstrated against a 
number of haematological malignancies including acute myeloid leukemia (AML), mast 
cell leukemia, acute lymphoid leukemia (ALL), chronic lymphocytic leukemia (CLL), 
lymphoma and multiple myeloma [385]. The spectrum of the published  IC50 values in 
these studies lies primarily in the nanoMolar range, spanning 150 nM for sensitive lines to 
5 μM relatively resistant cell lines [386], [387], [388], [389], [390], [391], [392]. Breast 
cancer cell lines with increased Bcl-2 expression showed increased apoptosis when 
treated with obatoclax on its own or combined with radiotherapy, suggesting that these 
cells were dependant on Bcl-2 for survival [393],[394]. In neoplastic mast cells obatoclax 
exhibited potent activity against primary cultures established from patients as well as 
permanent cell lines [395]. In head and neck squamous cell carcinoma (HNSCC), a cancer 
with very poor prognosis, obatoclax showed potent monotherapeutic activity, which was 
enhanced by the addition of chloroquine, an autophagy inhibitor [396]. In 
cholangiocarcinoma, a type of malignancy where the cancer cells are not considered 
“primed” for apoptotic death, obatoclax was also potent as single agent treatment and its 
activity has been associated with the activation of Bax [397]. In hepatoblastoma cells 
obatoclax was able to augment apoptosis and additionally inhibit tumour cell migration 
[398]. Thus, there is a significant body of evidence demonstrating the single agent activity 
of obatoclax in a range of cancer cell types. 
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The use of obatoclax in drug combinations has also been examined in vitro and these 
combinations have shown an overall increased effectiveness in a number of malignancies. 
In haematological malignancies such as acute myeloid leukemia, sensitivity to bortezomib 
was enhanced by the inhibition of Mcl-1 by obatoclax [399] and in Hodgkin lymphoma 
cells synergy was seen when obatoclax was combined with entinostat [400]. In colon 
cancer cells obatoclax showed synergy with chemotherapy to induce apoptosis [401]. In 
hepatoblastoma cells obatoclax demonstrated an additive effect when it was combined 
with cisplatin, etoposide, irinotecan, paclitaxel, or doxorubicin [402]. The use of the 
obatoclax derivative SC-2001 together with bortezomib in acute leukemia to inhibit the 
action of Mcl-1 protein or as single agent against hepatocellular carcinoma cells, restored 
the sensitivity of cancer cells to treatment [403], [404]. In pancreatic tumours the 
combination of obatoclax with the multikinase inhibitor sorafenib and histone 
deacetylase inhibitors sensitized the cells to treatment [405]. Melanoma cells underwent 
apoptosis with greater sensitivity when treated with the endoplasmic reticulum stress 
inducer tunicamycin when it was combined with obatoclax [406]. Pretreatment of central 
nervous system cancer cells with obatoclax increased their sensitivity to lapatinib and 
resulted in prolonged host survival in xenograft studies [407]. Similarly, orthotopic 
xenograft studies of obatoclax in mouse models have assessed this drug in 
hepatoblastoma and cholangiocarcinoma cells and tumour size reduction and increased 
survival were also observed [398], [397]. Thus, there is also a significant body of evidence 
demonstrating the activity of obatoclax in combination with several other drug classes in 
a range of cancer cell types. 
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The efficacy of obatoclax demonstrated through in vitro preclinical studies, either as 
monotherapy or in combinations with chemotherapy, has justified and led to the clinical 
evaluation of obatoclax. Phase I clinical trials of obatoclax aiming to detect a safe dose 
range and assess possible side effects were conducted with patients with haematological 
malignancies [408],[387],[409]. Other phase I trials have evaluated the combination of an 
obatoclax infusion over 3 hours or 24 hours with carboplatin and etoposide in patients 
with small cell lung cancer (SCLC) or the combination of obatoclax with topotecan for 
(other) solid tumours [410]. In all of the trials obatoclax was administered intravenously 
and it was seen that steady-state levels of the drug were easily achieved [387]. The half-
life of obatoclax appears to range from 39 to 60 hours [408]. The trials demonstrated that 
obatoclax is safe for use in humans and the most commonly occurring adverse events 
were grade 1/2 central nervous system symptoms such as somnolence, euphoria and 
ataxia, which rapidly resolved at the end of the infusion. Neuropsychiatric side effects 
have been found to be related to the dose and frequency of administration and these can 
be reduced by increasing the duration of drug infusion from 1 hour to 3 hours [409]. This 
is a strong indication that the drug can cross the blood-brain barrier, and the adverse 
effects may reflect the high levels of Bcl-XL expressed in neurons [409]. 24 hour infusions 
have also allowed dose escalation without dose limiting toxicity being observed [387]. A 
further study found that the incidence of CNS events was reduced with 24 hour compared 
to 3 hour infusions. However, the data were consistent with greater efficacy when the 
drug was infused for 3 hours (81% response rate with 3 hour infusion, 44% response rate 
with 24 hour infusion) although relatively small numbers of patients were treated [411]. 
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The successful completion of a number of phase I trials of obatoclax was followed by 
respective phase II studies. In patients diagnosed with relapsed or refractory classical 
Hodgkin lymphoma obatoclax was very well tolerated, but showed limited clinical activity. 
No objective responses were observed and consequently this study did not complete the 
plans for enrolment beyond the initial small number of patients (ten patients). Adverse 
events were all limited to grade I severity and half of the patients showed signs of stable 
disease while the remaining experienced disease progression within 8 weeks [412]. In 
relapsed SCLC patients the addition of obatoclax to 2nd line topotecan treatment after 1st 
line platinum therapy did not result in an improved response rate and for this reason the 
sample population was not expanded [413]. This study recruited 9 patients of which 5 had 
stable disease for the duration of treatment while the remaining developed progressive 
disease. No partial or complete responses were noted and the median progression-free 
survival was 2 months (range 2-5 months). The main adverse events noted were similar to 
those described previously with neurologic symptoms of somnolence and ataxia being the 
most frequent ones. These were transient and occurring during the period of the actual 
drug infusion and resolved within 2 hours after completion of treatment. In relapsed non-
small-cell lung cancer the combination of obatoclax with docetaxel showed minimal 
response [414]. 11% of the patients showed a partial response and the median duration 
of response was 4.8 months with a median progression-free survival of 1.4 months. Due 
to two episodes of dose-limiting toxicities, the intended maximum dose was not reached. 
Neutropenia was the most common adverse event described. Monotherapy with 
obatoclax infusion in patients diagnosed with myelofibrosis did not exhibit significant 
clinical activity [415]. None of the 22 patients enrolled for this trial showed complete or 
partial response, though one patient exhibited clinical improvement which was 
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maintained for 4 cycles of therapy. Low-grade ataxia and fatigue were common adverse 
events in half of the patients. A phase II trial of obatoclax in combination with carboplatin 
and etoposide versus conventional chemotherapy for SCLC patients has been reported at 
the world conference on lung cancer 2011 (and abstract published, [416]). The final 
publication of this data is eagerly anticipated because a trend for improved ORR, PFS and 
overall improved survival was claimed. Obatoclax appeared to reduce the rate of 
refractoriness during the first six chemotherapy cycles by 37%. In this trial, obatoclax was 
administered as a 3-hour infusion, rather than a 24-hour infusion [411]. It is interesting to 
note that all the other obatoclax phase II trials that were apparently less successful used 
either 1-hour or 24-hour infusion rates for obatoclax and the participants had been 
heavily pre-treated with chemotherapy, making them intrinsically less likely to respond. It 
is therefore possible that the 1-hour infusion may have prevented sufficiently high doses 
being used and the 24-hour infusion might have prevented sufficiently high plasma 
concentrations being achieved. Controlling the rate of drug administration may be critical 
to obtain a satisfactory therapeutic window. 
 
The adverse effects observed in phase II trials reflected those in previous studies .The 
most common adverse events described during the phase II trials of obatoclax were 
haematological such as neutropenia, thrombocytopenia and anaemia or neurological like 
ataxia, fatigue and somnolence [413],[414]. 
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Thus, there is a sound rationale based on previous studies of BH3-mimetics by our group 
and a significant body of evidence, both preclinical and clinical, supporting the evaluation 
of obatoclax in ovarian cancer. Many of the clinical trials cited above were published after 
the current research commenced, but they suggest that adverse effects might be 
managed using appropriate infusion schedules and doses which achieve a balance 
between efficacy and toxicity. It still seems reasonable, therefore, to investigate the use 
of obatoclax in ovarian cancer. 
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4.3 Results 
 
 Single agent studies of obatoclax 4.3.1
 
To investigate the sensitivity of ovarian cancer cells to obatoclax the drug was initially 
evaluated in single-agent cell growth studies. For the purposes of these studies 8 ovarian 
cancer cell lines were used: A2780, cisA2780, Ovcar-3, Ovcar-4, Ovcar-5, Ovcar-8, Igrov-1 
and Sk-Ov-3. Obatoclax inhibited the growth of cultures of all of the ovarian cancer cell 
lines with nanoMolar potency (Table 14 and Figure 15). 
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Cell Line IC50 (nM) Hill Slope Number of experiments 
A2780 59 ± 30 -3.6 ± 1 n=17 
cisA2780 72 ± 39 -3.9 ± 0.8 n= 15 
Ovcar3 35 ± 28 -2.1 ± 1.1 n=11 
Ovcar4 140 ± 130 -1.9 ± 0.7 n=10 
Ovcar5 78 ± 29 -3.1 ± 0.9 n=15 
Ovcar8 97 ± 35 -4.3 ± 1.1 n=15 
Igrov-1 150 ± 78 -4.7 ± 2.6 n=15 
Skov-3 220 ± 92 -1.6 ± 0.4 n=9 
Table 14: Single agent activity of obatoclax  against eight ovarian cancer cell lines. The activity of 
obatoclax against ovarian cancer cell lines was evaluated in cell growth assays. IC50 and Hill 
coefficients (mean ± S.D.) were determined by the SRB assay following 72 hours exposure to 
obatoclax. Error bars represent S.D. 
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Figure 15: Activity of obatoclax in cell growth assays. The activity of obatoclax against ovarian 
cancer cell lines was evaluated in cell growth assays by the SRB assay following 72 hours exposure 
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to obatoclax. The figures show representative experiments, the results of which are summarized 
in Table 14. “C” denotes cells treated with vehicle alone. 
 
The evaluation of the single agent activity of obatoclax in the same eight ovarian cancer 
cell lines was repeated in preliminary experiments in 2% O2 to mimic those found 
physiologically (Table 15). Although these experiments were only performed once, in 2% 
O2 obatoclax mostly retained activity in all of the cell lines although the IC50 increased 
modestly, on average 2.4-fold across all 8 cell lines (range 1.4 - fold to 4.3 – fold). 
 
Cell Line Average IC50 (nM) 
A2780 90 
CisA2780 100 
Ovcar3 90 
Ovcar4 340 
Ovcar5 140 
Ovcar8 330 
Igrov-1 230 
Skov-3 950 
Table 15: The single agent activity of obatoclax in reduced oxygen tension conditions. The activity 
of obatoclax against ovarian cancer cell lines was evaluated in cell growth assays in 2% O2. IC50 
and Hill coefficients were determined by the SRB assay following 72 hours exposure to obatoclax, 
n=1.  
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 Trypan blue viability studies 4.3.2
 
 
Measuring the growth of cell cultures does not distinguish between a drug inhibiting cell 
proliferation, inducing cell death, or a combination of the two. To discriminate between 
these two, the viability of cells following exposure to obatoclax for 72 hours was assessed 
by staining with trypan blue. The study was performed on all eight ovarian cancer cell 
lines (Figure 16). In all of the cell lines, exposure to obatoclax (at 10 times the IC50 
measured in cell growth assays) led to a significant increase in the number of dead cells 
compared to the number measured in a sample in which the cells were treated with 
vehicle. However, this increase was less marked in Ovcar-3, Ovcar-4 and Sk-Ov-3 cells. 
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Figure 16: The trypan blue viability assay of obatoclax. Eight ovarian cancer cell lines were treated 
with obatoclax for 72 hours at multiples of the IC50 values for each cell line measured in cell 
growth assays. The results are expressed as a fraction of the total cells present at each time point 
(mean ± S.D., n=2-4). In all of the cell lines, there was a significant increase in dead cells (P < 0.05, 
paired t-test) when cells were treated with the highest concentration of obatoclax compared to 
cells treated with vehicle. Error bars represent S.D.  
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 Colony formation assays 4.3.3
 
 
Colony forming assays were performed to confirm that obatoclax is cytotoxic. Once a cell 
population has been exposed to a drug, if the drug is cytotoxic then it is anticipated than 
only a fraction of the initial population will retain its capacity to produce colonies even 
the drug is subsequently removed [417]. If however, the drug is purely cytostatic, when 
the drug is removed the cells are anticipated to grow again and form colonies. Obatoclax 
dose-dependently reduced the ability of Ovcar-8 cells to form colonies, consistent with it 
causing cell death (Figure 17). Thus, this confirmed the results obtained by trypan blue 
staining.   
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Figure 17: Colony formation assay of obatoclax.  
Cells were treated with the indicated concentration of obatoclax for 48 hours, trypsinized and 
replated. The number of colonies was measured after 2 weeks. The results (mean ± S.D., n=3) 
are expressed as a percentage of the plating efficiency measured in cells treated with vehicle 
alone. The IC50 of obatoclax calculated from these combined experiments (140 nM) is 
comparable to that measured in the cell growth studies (100 nM), although in the later studies 
the duration of exposure was 72 hours. Error bars represent S.D. 
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 Ovcar-8 spheroids treated with obatoclax 4.3.4
 
The experiments so far made use of cells growing as a monolayer. This is not an accurate 
reflection of a tumour which possesses a 3-dimensional architecture.  Growing cells in 3-
dimensional culture has been found to alter their sensitivity to several drugs (for example, 
see Chapter 3). One way in which this can be mimicked in the laboratory is to grow the 
cells as spheroids. Therefore, the activity of obatoclax was evaluated using Ovcar-8 cells 
grown as spheroids.  Spheroids were prepared as previously described [418] and were 
0.47 ± 0.05mm in diameter (E. Robinson & A. Richardson, unpublished observations). The 
cytotoxic activity of obatoclax was confirmed in these studies (Figure 18) although the 
potency was diminished somewhat (IC50 = 610 nM) compared to monolayer cultures.   
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Figure 18: Evaluation of the activity of obatoclax in spheroid cultures.  
Cells were allowed to form spheroids over 1 week, before the indicated concentration of drug 
was added. After 72 hours relative cell number was estimated by measuring intracellular ATP. 
The results (mean ± S.D., n= 3) are expressed as a fraction of the ATP measured in cells treated 
with vehicle alone (marked “C”. Error bars represent S.D. 
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 Single agent studies of obatoclax on primary cultures 4.3.5
 
 
To further validate the usefulness of Obatoclax as a potential treatment for ovarian 
cancer, its activity on primary cultures of ovarian cancer cells (PCOCC) was investigated. 
The process of establishing primary cultures of ovarian cancer cells (PCOCCs) and 
harvesting an adequate number of cells for our experiments remained quite problematic 
throughout the course of this study.  This was mostly due to failure of many of the 
samples to generate a viable culture. The success rate was approximately 33%. Although 
a total of 25 ascitic samples were collected, only 8 samples led to viable cultures. A 
frequent problem was the appearance of cell culture infections, which were resistant to 
antibiotic supplementation. Thus, only a limited number of successful experiments were 
completed. 
 
All the investigations were performed using low passage number of primary cancer cells 
due to the well described problem of senescence after later passages [330].  The initial 
experiments were performed by seeding 5,000 cells per well (PCOCC2 to PCOCC6) and did 
not provide cultures which grew reliably. This was improved by increasing the number of 
cells seeded to 8,000 cells per well. To determine how long the cells could be maintained 
in  culture in either 21% O2 or 2% O2, the time between successive passages (which were 
performed when the cultures became confluent) was recorded  (Figure 19). 
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Figure 19: Growth curve of PCOCC4 cells established in different O2 conditions. 
Both primary cultures were established from the same ascitic sample and were kept in separate 
atmospheric O2 conditions. 
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Figure 20: Primary cultures of ovarian cancer grown in 21% O2 and 2% O2.  
The image on the left shows primary culture PCOCC3 cells in 21% O2 and the image on the right the 
same culture seeded and grown in 2% O2. The normoxic conditions appear to contribute to the cells 
proliferating less and going into a state of senescence. 
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The cobblestone morphology of the cultures (particularly evident in Figure 20, 2% O2) 
provided some reassurance that the cells grown in the primary cultures were of epithelial 
origin and thus likely to be EOC cells. To support this, cells were stained with an antibody 
to detect the epithelial cell marker cytokeratin. More than 90% of the cultured cells were 
stained with the cytokeratin antibody (Figure 21). These images show cells grown on a 
microscope coverslip. Under these conditions the cells did not adopt the typical epithelial 
cell morphology seen on cell culture plasticware. The cytokeratin staining is not 
satisfactory because no cellular morphology is evident, raising concerns about the 
specificity of staining (although no staining was observed with the cells when the primary 
antibody was omitted).  Due to the issues with culturing the ascites cells which led to 
further studies with these cells being abandoned, no further experiments to overcome 
this technical problem were attempted. 
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Figure 21: Staining of ascites cells. PCOCC20 cells were grown on glass coverslips, fixed and 
stained with either Hoechst 33342 (nuclear dye) or anti-cytokeratin (epithelial cell marker). In the 
“negative control” samples Hoechst or the primary antibody were omitted respectively. The 
image is representative of 3 experiments.  
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The sensitivity of PCOCC to carboplatin, paclitaxel and obatoclax was evaluated in cell 
growth assays.  The measured IC50 of carboplatin using 2 primary cultures (PCOCC2 & 
PCOCC3) cells was 8μM. Although in some experiments satisfactory dose response curves 
were obtained using paclitaxel (e.g. Figure 22), in many experiments the drug showed 
poor activity. This may reflect the fact that paclitaxel requires cells to be actively 
progressing through the cell cycle to cause cell death. In Chapter 3, the decreased 
potency of paclitaxel in spheroids was also noted and attributed to the low mitotic index 
likely in spheroids. All of the cell cultures were sensitive to obatoclax (Table 16 and Figure 
23), although an inadequate number of experiments were performed to assess the effect 
of oxygen tension on obatoclax sensitivity. In 21% O2 using the cultures which grew 
sufficiently for the experiments to be replicated, the sensitivity of the cultures to 
obatoclax was approximately 10-fold less than the sensitivity of the ovarian cancer cell 
lines to obatoclax. 
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Figure 22: Activity of carboplatin and paclitaxel in cell growth assays of primary cultures.  Single 
agent studies were conducted in primary cultures of ovarian cancer cells (PCOCC2 & PCOCC3) 
cultured in normoxia and reduced oxygen tension.  Each drug response was measured in 
singlicate, with the exception of the cell number measured in the absence of drug (indicated “C” 
on the x-axis) which was measured in duplicate. 
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Cell Line [O2] IC50 (nM) Hill Slope Number of experiments 
PCOCC2  21% 950 -3.3 n=1 
PCOCC2  2% 46 -1.4 n=1 
PCOCC3  2% 39 -0.8 n=1 
PCOCC4  21% 1500 ± 360 -1.2 ± 0.02 n=1 
PCOCC4  2% 520 ± 510 -1 ± 0.9 n= 4 
PCOCC5  21% 880 ± 680 -1.3 ± 0.4 n=2 
PCOCC8  21% 730 ± 420 -1.1 ± 0.9 n=4 
Table 16: Cell growth assays evaluating the activity of obatoclax against primary cultures of 
ovarian cancer cells in normoxic (21% O2) and reduced oxygen tension (2% O2) conditions. The 
activity of obatoclax was evaluated in cell growth assays using primary cultures of ovarian cancer 
cells obtained from ascites. IC50 values (mean ± S.D.) were determined in all of the cell growth 
assays with primary cultures. In some cultures, the IC50 was only measured once due to the 
problem described in the text. 
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Figure 23: Activity of obatoclax in primary cultures of ovarian cancer cells. The figures show 
representative experiments which are summarized in Table 17. Cells were treated with the 
indicated concentration of obatoclax and the number of cells surviving after 72 hours estimated 
with an SRB assay. “C” denotes cells treated with vehicle alone.  
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 Caspase 3/7 studies of ovarian cancer cells treated with obatoclax 4.3.6
 
 
The foregoing data demonstrated that obatoclax caused cell death in established ovarian 
cancer cell lines and inhibits the growth of cultures of primary EOC derived from ascites 
fluid, presumably also by causing cell death. BH3-mimetics can cause cell death by 
activating the intrinsic apoptosis pathway (Chapter 1). Subsequent experiments were 
performed to confirm that obatoclax induces apoptosis. Caspases 3 and 7 are considered 
effector caspases which are activated by the release of cytochrome c from the 
mitochondria [419]. Their activation provides an indication of the irreversible 
commitment to apoptosis. Caspase 3/7 activity was measured using a commercially 
available kit (Caspase 3/7 Glo) following exposure to two different concentrations of 
obatoclax and compared to apoptosis induced by carboplatin (a drug known to induce 
apoptosis). Obatoclax dose-dependently increased caspase 3/7 activity in most of the cell 
lines (Figure 24). However, no increase was evident in Ovcar-3, Ovcar-4 and Sk-Ov3 cells. 
It is notable that these were the cells in which obatoclax caused the least cell death in the 
trypan blue staining experiments (Figure 24).  Note that the relatively high apparent 
activation of caspases in cisA2780 reflects the fact that the results were normalized to the 
activation induced by carboplatin in each cell line. The cisA2780 cells are relatively 
resistant to carboplatin when the caspase activity induced by obatoclax is expressed as a 
fraction of the carboplatin-induced caspase activity, it consequently appears more 
pronounced than in other cell lines. 
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Figure 24: The activation of caspase 3/7 substrate in after treatment with obatoclax. The study 
was performed using eight ovarian cancer cell lines. The results (mean ±S.D., n=2-3) are expressed 
as a fraction of the caspase 3/7 activity measured in cells exposed to carboplatin at its IC50 
concentration (measured in 72 hour cell growth assays) in each cell line. Obatoclax was evaluated 
at 1x and 10x its IC50 concentration (measured in 72 hour cell growth assays) in each cell line. 
Obatoclax induced significantly increased (P<0.05, paired t-test) caspase 3/7 activity compared to 
carboplatin in cells treated with vehicle in A2780, cisA2780, Ovcar-8 and Igrov-1 cells. Error bars 
represent S.D. 
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 Western blotting studies - The induction of apoptosis and autophagy after 4.3.7
treatment with obatoclax 
 
 
To confirm the results of the caspase 3/7 assays, cleavage of PARP was also measured. 
PARP is a substrate of caspases, and it cleavage therefore provides an additional measure 
of apoptosis. Each of the cell lines was treated with obatoclax at multiples of its 
respective IC50s and PARP cleavage measured by western blotting (Figure 25).  PARP 
cleavage was evident in Ovcar-5, Ovcar-8 and Igrov-1 cells. These cells were the ones in 
which the most significant activation of caspase 3/7 was observed. Relatively modest 
cleavage of PARP was observed in A2780 cells, consistent with the modest activation of 
caspase 3/7 in these cells. Cleavage of PARP was not evident in Ovcar-3, Ovcar-4 and Sk-
Ov-3 cells, consistent both with the trypan blue studies and the lack of activity in the 
caspase 3/7 assay. This suggests that in these cell lines, obatoclax did not induce 
apoptosis.  
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Figure 25: The induction of PARP cleavage and LC3 after treatment with obatoclax. W Cells were 
treated with obatoclax at the indicated multiple of the IC50 measured in cell growth assays. After 
48 hours, cells were lysed and samples processed for western blotting with antibodies directed to 
LC3, PARP or GAPDH. The results shown are representative of 3 experiments. Note that the band 
labelled LC3 represents LC3-II. Unprocessed LC3, which appears as a band 2kd larger, was difficult 
to detect and only visible on prolonged exposure.  
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 Nutlin and obatoclax 4.3.8
 
 
One possible explanation for the lack of induction of apoptosis in some cell lines was that 
these cells had defects in the p53 signalling pathway. Under normal conditions, any type 
of cellular stress can result in the activation of the tumour suppressor p53.Ovarian cancer 
is characterised by deleted or mutated copies of TP53 (the gene encoding p53). The 
transcriptional activity of p53 is regulated by the mouse double minute 2 homolog 
(MDM2) protein, which is encoded by the MDM2 gene [420]. MDM2 acts by binding to 
the N-terminal domain of p53 and catalysing its ubiquitination. MDM2 is very often 
amplified in cancer and its increased expression promotes turnover of p53 and inhibition 
of apoptosis allowing the survival of cancer cells. Nutlin-3 can inhibit the binding of 
MDM2 to p53, preventing ubiquitination and turnover of p53 and effectively cause its re-
activation. Cells which have a functional p53 pathway are relatively sensitive to Nutlin-3, 
whereas cells with defects in the p53 pathway are relatively resistant. Nutlin-3 sensitivity 
can thus be used to estimate the status of the p53 pathway without having to evaluate 
genetic (and potentially epigenetic) abnormalities in all pathway members. 
 
These studies were performed prior to the publication of the cancer genome atlas 
research network which highlighted the high frequency of p53 abnormalities in ovarian 
cancer [123]. With the exception of two cell lines, (A2780 and its daughter line cis-A2780), 
most of the cell lines were relatively insensitive to Nutlin-3 (Figure 26).  This is consistent 
with TGCA data indicating that these cell lines have aberration in the p53 pathway, but 
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A2780 does not [421]. It does not, however, provide an explanation for the differential 
induction of apoptosis in these cells. 
 
 
 
 
Figure 26: Sensitivity of eight ovarian cancer cell lines to nutlin.  
The cells were treated with Nutlin-3 for 72 hours and their sensitivity estimated using an SRB 
assay. Nutlin IC50 values (mean ±S.D. n= 2-3) were determined by non-linear regression to fit a Hill 
equation. Error bars represent S.D.  
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 The formation of autophagosomes after treatment with obatoclax 4.3.9
 
Prior to this work, ABT-737 had been shown to induce autophagy by displacing Beclin-1 
from Bcl-2 [422].  Obatoclax has relatively high affinity for Bcl-2, and this raised the 
possibility that obatoclax might also induce autophagy. Autophagy can be considered to 
be either a protective mechanism which allows the cell to recycle existing structures and 
be energy efficient or a type of death if it becomes excessive. The process of autophagy 
involves the formation of autophagosomes, organelles which captivate cellular 
components and digest them. The recruitment of proteins into autophagosomes is 
regulated by proteolytic processing of LC3 and its subsequent lipidation to generate LC3-
II.  Measurement of LC3-II has been used as a marker of autophagy. The samples analysed 
for PARP cleavage were therefore also analysed to measure the effect of obatoclax on 
LC3-II.  A robust induction of LC3-II was observed in all cell lines raising the possibility that 
this also contributes to cell death.  
 
To confirm the induction of autophagy in these cells we transfected cell lines with an LC 
protein tagged with green fluorescent protein. Live cell imaging was used to visualise 
those cellular organelles that displayed the fluorescent LC3 protein chain. 
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Autophagosomes 
Non-transfected                    MT Non-treated                 WT Non-treated 
 MT treated                           WT Treated 
Figure 27: The formation of autophagosomes in LC3-GFP  transfected Ovcar-8 cells 
treated with obatoclax.  
Ovcar-8 cells were transfected with plasmids encoding wild (“WT”) and mutant 
“MT” LC3-GFP. The mutant LC3 does not undergo lipidation and so is not recruited 
to autophagosomes in an autophagy dependent manner. It therefore provides a  
negative control for autophagy independent staining of autophagosomes. The cells 
were treated with obatoclax before fluorescence microscopy was used to evaluate 
the formation of autophagosomes. The results are representative of 3 experiments. 
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 siRNA inhibition studies 4.3.10
 
 
The foregoing work suggested the possibility that autophagy may contribute to cell death 
induced by obatoclax.  To investigate this, an RNAi approach was taken. The expression of 
two genes known to be essential for the regulation of autophagy, Beclin1 and Atg5 was 
inhibited in Ovcar-4, Ovcar-5 and Ovcar-8 cells by transfection with Dharmacon 
SMARTpools (a pool of 4 siRNAs) directed to the corresponding mRNAs. QPCR studies 
were performed first to identify the appropriate concentration of SMARTpool. The 20nM 
concentration was selected so that mRNAs was significantly reduced 48 hours after 
transfection without significantly reducing cell number (Figure 28). Western blotting 
studies confirmed that the levels of each protein were also reduced 48 hours after 
transfection (Figure 29). 
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Figure 28: Inhibition of Beclin1 and Atg5 using siRNA. Ovcar8 cells were transfected with siRNA to 
Beclin1 or Atg5. After 48 hours mRNA was isolated and the expression measured by Q-RTPCR. The 
results are expressed as a fraction of the mRNA measured in cells transfected with the non-
targeting control siRNA. The experiment is representative of two experiments.  
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Following silencing of Beclin1 and Atg5 changes in sensitivity to obatoclax were 
measured. Knockdown of Beclin1 and Atg5 had a very modest, although statistically 
significant, effect on the sensitivity of Ovcar-5 cells to obatoclax (Figure 30). No significant 
effect was on obatoclax sensitivity was observed in Ovar-4 or Ovcar-8 cells. It should be 
recalled that in Ovcar-4 cells, obatoclax did not induce apoptosis. These data are not 
inconsistent with autophagy playing a role in obatoclax induced cell death, however they 
suggest that autophagy is not necessary for this process.  
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Figure 29: Knockdown of Beclin-1 and Atg-5.  
 Cells were transfected with the indicated siRNA and lysed after 48 hours 
before the samples were processed. Western blotting was performed to 
confirm the knockdown (representative of 2-3 experiments). 
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Figure 30: siRNA inhibition studies. In order to evaluate the contribution of autophagy to the 
activity of obatoclax RNAi studies were performed. Following knockdown of Atg-5 and Beclin, the 
IC50 of obatoclax (mean ± S.D., n= 3-4 separate transfections) was compared to that measured in 
cells treated with a non-targeting (NT) siRNA. *, IC50 significantly different (P<0.05, paired t-test) 
from that measured in cells transfected in the non-targeting control. Error bars represent S.D.  
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 N-acetylcysteine assay rescue experiments of obatoclax 4.3.11
 
 
Recent work has proposed that the combination of obatoclax and lapatinib kills breast 
cancer cell lines through the generation of reactive oxygen species (ROS) [423]. To test 
the possibility that obatoclax killed ovarian cancer cells by generating ROS, the effect of 
N-acetylcysteine on the potency of obatoclax was evaluated in a selection of the ovarian 
cancer cell lines. N-acetyl cysteine protects cells against oxidative stress by scavenging 
ROS [424]. Thus, if obatoclax induces apoptosis through generation of ROS, the measured 
IC50 of obatoclax would be anticipated to increase in the presence of N-acetylcysteine. 
However, when cells were treated with N-acetylcysteine, the potency of obatoclax was 
not significantly altered in 4 of 5 cell lines evaluated (Figure 31). There was a modest, but 
significant, increase (not decrease) in obatoclax potency in cisA2780 cells.  Notably, N-
acetylcysteine had no consistent effect on obatoclax potency even in Ovcar-3 and Ovcar-4 
cells in which apoptosis was not evident following exposure to obatoclax. These data 
suggest that the generation of ROS is not essential for obatoclax-induced cell death. 
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Figure 31: Effect of N-acetylcysteine on the activity of obatoclax. The indicated cells lines were 
treated with a range of concentrations of obatoclax in the presence or absence of 10 mM N-
acetylcysteine (labelled “NAcCys”). After 72 hours, the number of cells surviving was estimated 
with the SRB assay and the IC50 (mean ± S.D., n =2 -3) determined. No consistent change in the 
potency of obatoclax was noted although in cisA2780 cells the change in IC50 was significantly 
reduced (P<0.05, paired t-test). Error bars represent S.D.  
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 Flow cytometry studies 4.3.12
 
The results thus far failed to fully clarify the mechanism by which obatoclax inhibits the 
growth of cultures of ovarian cancer cells. The possibility was considered that obatoclax 
might also cell cycle arrest in addition to inducing apoptosis, and that this might 
contribute to the inhibition of growth of cell cultures treated with obatoclax (Figure 15). 
Precedent for this was provided by the report that at non-cytotoxic concentrations, 
obatoclax can cause S-phase arrest in AML [391]. 
Flow cytometry can be used to measure the proportion of cells in different phases of the 
cell cycle. Following staining with propidium iodide, changes in DNA content can be 
assessed and used to identify cells in G1, S or G2/M phases of the cell cycle [425], [426]. 
Furthermore, the appearance of cells that have a DNA content less than that measured in 
diploid cells (i.e. sub G1) has been taken as a measure of apoptosis [427]. 
 
Each of the ovarian cancer cell lines was treated with obatoclax at a range of drug 
concentrations (Figure 32). There was no consistent pattern of accumulation of cells in S 
or G2/M phases of the cell cycle. In particular, an increase in cells in S-phase, as reported 
for AML cells exposed to a non-cytotoxic concentration of obatoclax, was only observed 
in Ovcar-5 cells [391]. These data suggest that the major mechanism by which obatoclax 
inhibits the growth of cultures of ovarian cancer cell lines is not mediated by cell cycle 
arrest. However,  there was a significant increase in the sub-G1 fraction in several of the 
cell lines, particularly in the Ovcar-5, Ovcar-8 and Igrov-1 cells in which apoptosis was 
observed previously,  consistent with apoptotic cell death[428].  
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Figure 32: Effects of obatoclax on the cell cycle.  
The indicated cell lines were treated with vehicle or obatoclax for 48 hours at the indicated 
multiple of the IC50 measured in cell growth assays. Cells were stained with propidium iodide and 
analysed by flow cytometry. The results (mean ± S.D., n = 2-4) show the % of cells in different 
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phases of the cell cycle. Note that the increase in cells in S phase (1 -10 x IC50) in Ovcar-5 cells was 
significantly different (P < 0.05, paired t-test) from that measured in cells treated with vehicle 
alone. A comparable increase was not observed in the other cell lines. Error bars represent S.D.
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 Synchronous combination studies of obatoclax with carboplatin and paclitaxel 4.3.13
 
 
The use of drug combination therapy in cancer is a long-established practice which has 
evolved greatly over the years. It is based on the concept that inhibiting multiple drug 
targets can lead to synergistic activity of the drugs and potentially overcome 
chemoresistance. Previous work from our group has demonstrated that the BH3-mimetic 
ABT-737 can resensitize ovarian cancer cells to chemotherapy. The work presented in 
chapter 3 demonstrated that navitoclax is also synergistic with carboplatin and paclitaxel. 
This suggested that obatoclax would also show synergy with the standard-of-care drugs 
carboplatin and paclitaxel. Studies were designed to combine obatoclax with these drugs 
in a ratio of their IC50 values. To do this, the obatoclax IC50 values from the single agent 
studies performed previously were used and the IC50 values for carboplatin and paclitaxel 
(Tables 11 & 12, Chapter 4) were obtained from single agent cell growth assays with each 
of the cell lines. The combination studies were conducted using the same ovarian cancer 
cell lines. In order to evaluate the effect of the drug combination, a combination index 
(C.I.) was calculated [429]. A C.I. value <1 is considered indicative of synergy, while values 
over 1 are indicative of antagonism between the two drugs. 
 
Unexpectedly, the results from the combination of obatoclax with carboplatin (Table 17) 
indicated that these drugs have a synergistic activity in only two of the seven cell lines, 
while additivity is observed for the majority of cases. For example, in Igrov-1 cells, the cell 
line in which synergy was most evident between carboplatin and ABT-737 [312] or with 
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navitoclax (Chapter 3), there was no evidence of synergy between carboplatin and 
obatoclax. The results from the obatoclax and paclitaxel combinations (Table 18) 
surprisingly indicated that obatoclax and paclitaxel displayed antagonist activity. These 
results are also shown graphically (Figure 34). 
Combination study of obatoclax and carboplatin 
Cell Line 
Exclusive CI 
values 
t-test 
Non-exclusive 
CI values 
t-test 
Number of 
experiments 
A2780  1.4 ±0.5 P < 0.05 1.9 ±1.0 P < 0.05 n=10 
cisA2780 1.5 ±1.2 P = 0.2 2.2 ±2.4 P < 0.1 n=8  
Ovcar4 1.0 ±0.3 P = 0.7 1.0 ±0.3 P = 0.2 n=7 
Ovcar5 1.0 ±0.1   P = 0.9 1.0 ±0.1 P = 0.2 n=4 
Ovcar8  0.9±0.3 P = 0.5 1.0 ±0.3 P = 0.6 n=10 
Igrov-1  1.0 ±0.1 P = 0.6 1.0 ±0.1 P = 0.1 n=3 
Skov-3  1.2 ±0.2 P = 0.1 1.5 ±0.4 P < 0.05 n=4 
Table 17: Figure 33: The activity of obatoclax and carboplatin in combination. 
The activity of combinations of paclitaxel and obatoclax was evaluated in cell growth assays in 
which the drugs were combined at the ratio of their respective IC50s. C.I. values (mean ± S.D.) 
were calculated as described in section 2.4. C.I. values were calculated assessing exclusivity and 
non-exclusivity. Exclusivity assumes the drugs have similar mechanisms of action while non-
exclusivity assumes that they have different mechanisms. The C.I. values were statistically 
different from unity where indicated (P < 0.05, t-test, with Welch’s correction).   
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Combination study of obatoclax and paclitaxel 
Cell Line 
Exclusive C.I. 
values 
t-test 
Non-exclusive 
C.I. values 
t-test 
Number of 
experiments 
A2780 1.5 ±0.1 P < 0.01 2 ±0.2 P < 0.01 n=6 
cisA2780 1.3 ±0.1 P < 0.05 1.7 ±0.2 P < 0.01 n= 4 
Ovcar3 1.4 ±0.4 P < 0.01 1.9 ±0.7 P < 0.01 n=10 
Ovcar4 1.3 ±0.2 P < 0.05 1.7 ±0.3 P < 0.01 n=5 
Ovcar5 1.5 ±0.1   P < 0.01 1.9 ±0.2 P < 0.01 n=7 
Ovcar8 1.4 ±0.1 P < 0.01 1.8 ±0.2 P < 0.01 n=6 
Igrov-1 1.3 ±0.1 P < 0.01 1.6 ±0.2 P < 0.01 n=5 
Skov-3 1.4 ±0.3 P < 0.05 1.7 ±0.4 P < 0.01 n=8 
Table 18: The activity of obatoclax and paclitaxel in combination against eight ovarian cancer cell 
lines. The activity of combinations of paclitaxel and obatoclax was evaluated in cell growth assays 
in which the drugs were combined at the ratio of their respective IC50s. C.I. values (mean ± S.D.) 
were calculated as described in section 2.4. C.I. values were calculated assessing exclusivity and 
non-exclusivity. Exclusivity assumes the drugs have similar mechanisms of action while non-
exclusivity assumes that they have different mechanisms. The C.I. values were statistically 
different from unity where indicated (P < 0.05, t-test, with Welch’s correction).  
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Figure 34: Activity of obatoclax in combination with carboplatin and paclitaxel in 7 ovarian cancer 
cell lines. A C.I. value <1 is considered indicative of synergy, while values over 1 are indicative of 
antagonism between the two drugs. The C.I. values were statistically different from unity where 
indicated (P < 0.05, t-test, with Welch’s correction). Error bars represent S.D.  
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 Sequenced combination studies of obatoclax & carboplatin  4.3.14
 
The lack of synergy between obatoclax and both carboplatin and paclitaxel was 
unexpected. Work in our group previously found that the order of addition of ABT-737 
and carboplatin substantially affected the extent of synergy.  Addition of carboplatin to 
cells prior to ABT-737 was the most synergistic, presumably because the BH3-only 
proteins induced by carboplatin are subsequently liberated by ABT-737. Furthermore, 
drugs which have effects at different stages of the cell cycle may be antagonistic. For 
example, carboplatin and paclitaxel are also antagonistic (Chapter 3), most likely because 
they exert effects at different stages of the cell cycle, and the antagonism can be altered 
by changing the schedule of addition. The possibility was therefore considered that 
altering the schedule of addition of obatoclax and carboplatin or paclitaxel would increase 
the effectiveness of the drug combinations. 
 
A range of different schedules of administration were evaluated. Obatoclax was 
administered before, during or after exposure to carboplatin. The results (Figure 35) 
suggested that pre-treatment of ovarian cancer cells with carboplatin before obatoclax 
was marginally preferable to other sequence of drug administration. When obatoclax was 
used after carboplatin then a more additive/less antagonistic effect was seen in five of 
the eight cell lines (but none of these reached statistical significance). However, pre-
treatment with carboplatin appeared comparable to synchronous treatment with 
obatoclax and carboplatin for the majority of cell lines evaluated (six out of eight) and 
significant antagonism was still observed in several of the cell lines. Thus, in most of the 
176 
 
cell lines altering the schedule of administration did not substantially improve the 
interaction between these drugs. This is a further surprising result with obatoclax, bearing 
in mind the schedule dependant effects observed with ABT-737 and carboplatin [312]. 
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Figure 35: Scheduled combinations of obatoclax and carboplatin.  
Cells were exposed to: (a) obatoclax for 48 hours then carboplatin for 48 hours; b) carboplatin 
for 48 hours, then obatoclax for 48 hours; c) carboplatin and obatoclax for 48 hours then 
culture medium for a further 48 hours; d) culture medium for 48 hours, then carboplatin and 
obatoclax for 48 hours. In each case, the cells were treated with carboplatin and obatoclax at 
the ratio of the IC50s determined in experiments with the individual drugs.  Results are 
expressed as the mean combination index (mean ± S.D.  n=3-4) and were significantly different 
from 1.0 where indicated (*, P < 0.05, t-test using Welch’s correction). Error bars represent 
S.D. 
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 Obatoclax and lovastatin combinations 4.3.15
 
 
Statins are drugs that have been widely established for the treatment of hyperlipidaemia 
[430]. In many instances they have been shown to contribute to the prevention and 
treatment of cancer [431] and clinical trials have investigated their activity [432]. It is 
believed that this effect of statins is due to their ability to interact with the cellular 
pathways often activated in oncogenesis [433]. In ovarian cancer lovastatin has been 
shown to induce apoptosis as a single agent and to synergize with chemotherapeutic 
drugs such as doxorubicin ,[434] [435]. Results in our laboratory have demonstrated that 
statins have the potential to treat ovarian cancer [436]. 
 
Combination studies of obatoclax and lovastatin were performed to investigate their   
potential in ovarian cancer. The two drugs were combined in a fixed ratio of their 
respective IC50s. The respective C.I. values are described in Table 19. The combination of 
the two drugs was synergistic in one of the cell lines additive in two of the cell lines and 
antagonistic in A2780 cells.  
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Cell Line Exclusive CI values Non-exclusive CI values 
A2780 1.3 1.6 
Ovcar5 0.6 0.6 
Ovcar8 1.1 1.1 
Igrov-1 4.4 5.2 
Table 19: Combination studies of obatoclax and lovastatin in four ovarian cancer cell lines. The 
Combination Index (C.I.) values, n=1.  
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 Xenograft studies of obatoclax 4.3.16
 
The lack of synergy, and in some cases antagonism, between obatoclax and standard-of-
care chemotherapy, together with the potent single agent activity of obatoclax, suggested 
that obatoclax may preferably be used as a single agent in ovarian cancer. Clinical trials 
generally require demonstration of a drug’s activity in animal models.  Xenograft studies 
of obatoclax were not performed by the author but carried out in collaboration with Dr 
Sue Eccles, Institute for Cancer Research. Obatoclax was administered to mice bearing 
Ovcar-8 tumours using a schedule (o.d. days 1-5, i.v.) which had previously been shown to 
be successful in several cancer xenograft models [384]. No statistically significant 
reduction in tumour volume was observed at the end of the treatment. The most 
pronounced differences between vehicle and drug-treated tumours were seen during the 
period of drug administration (days 1-5), and a small (though neither statistically nor 
biologically significant) difference remained throughout most of the period of study 
(Figure 36).  
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Figure 36: The xenograft study of Ovcar8 cell origin tumour treated with obatoclax. Mice were 
injected with Ovcar-8 cells and once the tumours were established, received either vehicle or 
obatoclax (5 mg/kg, i.v.) for days 1-5 of the study. Error bars represent S.D. 
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4.4 Discussion 
 
Since the introduction of platinum agents and taxanes into the treatment of ovarian 
cancer almost forty years ago there has not been any other breakthrough and the 
development of new therapies has not significantly altered the survival rates in ovarian 
cancer. One exception to this may be bevacuzimab, a monoclonal antibody that 
sequesters VEGF and inhibits angiogenesis. Recently completed trials have shown that 
bevacuzimab extends the progression free survival of patients [437]and can result in an 
increase in overall survival for a subgroup patients at high risk of progression [438]. 
Nonetheless, new therapies are still needed. It is reasonable to suggest that overcoming 
the chemoresistance of ovarian cancer is likely to be achieved through the  inclusion of 
targeted agents, especially as our understanding of the molecular pathways underlying 
this disease increases [439].  
 
This work described in this chapter aimed to evaluate obatoclax, a new agent which 
targets the Bcl-2 family of apoptosis regulators and test the hypothesis that obatoclax 
could increase the sensitivity of ovarian cancer cells to existing chemotherapy. Previous 
work from our group in the field of ovarian cancer and by others evaluating similar BH3 
mimetics in a number of malignancies has provided us with evidence that BH3 mimetics 
warrant further investigation as anticancer drugs [376]. 
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The evaluation of obatoclax as a single agent has demonstrated striking nanoMolar 
potency in all the models studied. Obatoclax was significantly more potent than ABT-737 
[312] or Navitoclax (Chapter 3). Although this may be due to several factors such as 
differences in cell permeability, metabolism, protein binding or affinity for its target, it 
may in part also reflect the ability of obatoclax to inhibit all Bcl-2 family members. 
Alternatively obatoclax may have additional, as yet undefined, pharmacological activity 
(discussed below) that contributes to the measured potency. Whatever the cause of the 
notable potency, obatoclax retained its activity in cells which displayed varying degrees of 
resistance to carboplatin. This is perhaps best exemplified by A2780 cells and its 
cisplatin/carboplatin resistant derivative cisA2780. A2780 cells are approximately 10 
times more sensitive to carboplatin than are cisA2780 cells [312] yet they have 
indistinguishable sensitivities to obatoclax. Of the other cell lines, Ovcar-3 is the most 
sensitive to carboplatin and Ovcar-8 the least sensitive. Ovcar-3 cells are approximately 
16-fold more sensitive to carboplatin than are Ovcar-8 cells, yet Ovcar-3 cells are only 2.8 
fold more sensitive than Ovcar-8 cells to obatoclax. The activity of obatoclax in cells which 
are otherwise drug-resistant has implications for the design of clinical trials of obatoclax 
and are discussed below. 
 
The establishment of primary cultures of ovarian cancer cells from the ascitic fluid of 
ovarian cancer patients has in itself at times been delayed or partially hindered because 
of a variety of reasons including new technique and skills being developed, failure of 
samples to establish as a culture and periodic lack of ascitic samples. However, 8 different 
PCOCC were successfully cultured. Excitingly, significant success was obtained culturing 
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the cells in conditions of reduced oxygen tension The primary cultures maintained in 
reduced oxygen tension do not undergo senescence as quickly as those in atmospheric 
oxygen. This supports the use of reduced oxygen tension conditions for culturing both 
permanent ovarian cancer cell lines and primary cultures. Ideally, it was expected that 
some of these primary cultures would overcome their expected senescence and become 
permanent cell lines. Unfortunately, no immortalized cell lines were obtained within the 
period of this project. 
 
It was also anticipated that during the course of this project the majority of patient –
donors of ascitic samples would relapse and die from this disease. This would have 
provided us samples from patients who were initially chemosensitive and who then 
progressed to chemoresistant disease. The availability of paired cell lines under would 
have provided an important model of drug resistance and this is a potential further 
avenue of investigation.  A future aim is to examine the value of primary cultures as 
representative models of this dynamic disease and establish a link between the response 
of primary cultures to treatment in vitro and the clinical response of patients in vivo. 
 
Obatoclax clearly induced cell death – this was supported by both trypan blue staining 
and colony forming assays. However, obatoclax was anticipated to function as a BH3 
mimetic and induce apoptosis through the intrinsic apoptosis pathway. It was striking that 
using two markers of apoptosis (caspase 3/7 activation and PARP cleavage), only 3 of the 
cell lines showed clear apoptosis. In 3 further lines, Ovcar-3, Ovcar-4 and Sk-Ov-3 cells, 
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apoptosis was minimal or undetectable. It was notable that these later cell lines were the 
one in which trypan blue staining was least evident following exposure to obatoclax. Thus 
there appears to be a mechanism in addition to apoptosis that leads to cell death induced 
by obatoclax and the contribution of this mechanism varies between cell lines. In the cell 
lines where apoptosis was observed, it is possible this additional mechanism also 
contributes to cell death alongside apoptosis. The existence of additional mechanism of 
cell death following exposure to obatoclax is supported by the observation that 
obatoclax-induced cell death is only partly blunted in Bak-/-/Bax-/- cells which are unable 
to undergo apoptosis [391]. Our group has also found that the caspase inhibitor ZVAD-
FMK also failed to blunt the activity of obatoclax (V. Stamelos, N. Fisher & A. Richardson, 
unpublished observations). Additionally, synergy between obatoclax and carboplatin was 
anticipated, following the synergy between navitoclax and carboplatin. The lack of 
synergy (see below) may also reflect an additional activity of obatoclax.  
 
A number of experiments were conducted to identify the potential additional mechanism 
of obatoclax induced cell death. The first possibility evaluated was that obatoclax caused 
cell death by activating autophagy. This seems reasonable because the autophagy 
activator beclin-1 is sequestered by Bcl-2 family proteins, and it was anticipated that 
obatoclax would liberate beclin. Although currently debate rages whether autophagy is a 
pathway contributing to cell death or cell survival, at the time these experiments were 
performed it was considered a potential contributor to cell death. Obatoclax did indeed 
induce autophagy, as evidenced by the accumulation of LC3-II and its recruitment to 
autophagosomes. However, inhibition of autophagy using siRNA to Atg5 or beclin did not 
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substantially alter the sensitivity of the cells to obatoclax. In one cell line, a modest 
decrease in sensitivity was observed, suggesting that autophagy may contribute to the 
response to obatoclax, but it does not appear to be essential for obatoclax-induced cell 
death. 
 
Obatoclax has also been reported to cause the generation of reactive oxygen species 
(ROS) [423]. N-Acetylcysteine is a free radical scavenger that can reduce ROS-induced cell 
death. However, there was no clear pattern of altered sensitivity to obatoclax in cells 
simultaneously with N-acetylcysteine. Related to this, obatoclax belongs to a class of 
compounds termed prodiginines. These compounds have been claimed to be proton 
ionophores which could potentially uncouple mitochondrial energy production. In 
preliminary studies, no change in intracellular ATP was observed following short-term 
exposure (24 hours) to obatoclax (data not shown, n=1). Obatoclax has been shown to be 
involved in the induction of another type of cell death named necroptosis [440]. 
However, inclusion of the necroptosis inhibitor necrostatin-1 had no effect on the activity 
of obatoclax (N. Fisher & A. Richardson, unpublished observations). 
 
Obatoclax has also been reported to induce S-phase arrest in AML cells [391]. However, in 
the studies presented here, obatoclax only caused accumulation of cells in S phase in one 
of the cell lines. Cells also did not appear to arrest in other phases of the cell cycle after 
exposure to a range of concentrations of obatoclax that inhibited the growth of cell 
cultures. 
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These observations lead to the rather unsatisfactory conclusion that although obatoclax is 
a bona fide BH3-mimetic, it possesses an additional, as yet unidentified, pharmacological 
activity that contributes to cell death. Nonetheless, the induction of apoptosis in some 
cell lines provides a rationale for the development of obatoclax in ovarian cancer, if 
appropriate patient populations can be identified. 
 
Clinical trials of a new oncology drug are usually evaluated as monotherapy, or in 
combination with the existing standard-of-care treatment. This raised the possibility that 
obatoclax could be evaluated in clinical trials in combination with carboplatin and 
paclitaxel. Previous studies in our laboratory [312] and in the present work (chapter 3) 
have highlighted synergy between BH3-mimetics and carboplatin and created an 
expectation that carboplatin would also be synergistic with obatoclax. However, in the 
studies presented here, the combination of obatoclax with carboplatin was generally 
additive and the combination with paclitaxel was even antagonistic. Altering the schedule 
of administration did not ameliorate these results.  The reasons for the lack of synergy 
between obatoclax and carboplatin are unclear. However, it is possible that the additional 
activity of obatoclax proposed here masks any synergy between carboplatin and 
obatoclax that results from the activity of obatoclax as a BH3-mimetic. 
 
The key significance of these observations of the activity of obatoclax in combination with 
chemotherapy is that they inform the clinical development of obatoclax. From the data 
presented here, it is questionable whether there will be any significant clinical benefit 
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from adding obatoclax to current standard of care regimens. Rather the data suggest any 
clinical trial of obatoclax in ovarian cancer should evaluate it as a single agent treatment. 
Of course such a development carries all the ethical limitations of administering 
experimental treatment to humans as it is known that any investigator is ethically obliged 
to provide only that treatment that is most effective [441]. There are also the toxicity 
related risks, but recent studies show that combinations of obatoclax with topotecan for 
solid tumours have been well tolerated [442].  The results presented here showed that 
obatoclax retained its activity even in cells (e.g. cisA2780, Ovcar-5 and Ovcar-8) which are 
relatively resistant to chemotherapy. It is therefore reasonable to consider obatoclax as 
second line therapy for patients who have relapsed with acquired drug resistant disease 
or as an option for patients with evident intrinsic chemoresistant disease. However, in 
xenograft studies, only minimal activity of obatoclax was noted, and appeared to be 
restricted to the period of drug administration (if indeed activity was present at all). It 
should be noted that this xenograft study was performed with cells which underwent 
apoptosis in vitro following exposure to obatoclax. These data suggest that different 
dosing schedules deserve evaluation (eg daily for several weeks) in xenograft models 
before the clinical evaluation of obatoclax is warranted. 
 
Emerging evidence from on-going preclinical and clinical investigations suggests that the 
full potential of obatoclax mesylate as a novel anticancer agent may be realized as 
monotherapy, in rational combination treatments other than those investigated here and 
guided by molecular predictors of therapeutic response. By understanding the molecular 
underpinnings of obatoclax response, along with optimal therapeutic regimens and 
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indications, the potential of obatoclax mesylate for the treatment of haematological 
malignancies may be further clarified [385]. The issue of which patients should be 
considered for therapy with a BH3 mimetic is the subject of the remaining chapter of this 
thesis.  
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Chapter 5: Conclusion & Future Work 
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Approximately four decades after the introduction of platinum agents in the treatment of 
ovarian cancer, gynaecological oncology is facing the great challenge of discovering novel 
anticancer drugs to overcome the chemoresistance that occurs in this disease. The 
current practice in chemotherapy is to offer treatment based on the tissue of origin of the 
tumour. In advanced ovarian cancer, the standard-of-care for the majority of patients 
comprises surgery followed by chemotherapy, where platinum agents and paclitaxel are 
administered. However, this traditional approach does not fully reflect our understanding 
of the extensive heterogeneity of ovarian cancer which can partially explain why there 
has not been any significant breakthrough in overcoming the chemoresistance of ovarian 
cancer. 
 
The growing body of knowledge of the biology underlying ovarian cancer has contributed 
to the identification of a number of potential therapeutic targets and the development of 
a plethora of targeted cancer therapies. These events can be regarded as the early 
characteristics of the entry into an era of personalized medicine, where the traditional 
chemotherapy approach is replaced by a more patient-tailored treatment. This new 
strategy of personalized medicine, whereby a patient’s treatment is chosen to address 
the molecular defects associated with their personal disease, can allow for the individual 
pharmacodynamic and pharmacokinetic factors to be taken into account as they may 
affect drug safety and efficacy. 
In principle, the process of mapping the genetic (or epigenetic) abnormalities in a 
patient’s tumour and selecting therapy accordingly appears relatively straightforward. 
However, knowledge of the genes affected is often inadequate and does not necessarily 
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translate into a thorough understanding of the signalling pathways involved in 
carcinogenesis. A common feature of ovarian cancer and other malignancies is the 
evasion of apoptosis through the deregulation of the equilibrium between anti- and pro-
apoptotic members of the Bcl-2 family of proteins. For the “primed” cancer cells, whether 
the induction of a BH3-only protein leads to apoptosis depends on whether the repertoire 
of apoptosis inhibitors expressed is adequate to dampen the pro-apoptotic signal. The 
recognition that Bcl-2 family proteins regulate apoptosis has led to the development of 
“BH3-mimetics”. Can we understand what determines whether cancer cells are sensitive 
to BH3-mimetics and use such drugs in the personalized medicine setting? 
 
 
Identifying the factors which increase sensitivity to BH3-mimetics will enable the clinician 
to rationally decide whether to deploy these drugs. Understanding the cancer signalling 
pathways in detail also allows the rational design of drug combinations which may 
improve on the efficacy of a drug. In the case of BH3-mimetics, whose mechanism of 
action is dependent on activation of the intrinsic apoptosis pathway, (such as ABT-737 
and navitoclax), activity has been shown to be limited by the selectivity of these drug for 
some of the anti-apoptotic Bcl-2 proteins. This limitation does not necessarily apply to 
obatoclax, a BH3-mimetic that binds all Bcl-2 family inhibitors and that also elicits 
apparently off-target effects. Expression of Bcl-2 family apoptosis inhibitors that do not 
bind ABT-737/navitoclax confers resistance to these drugs.  Several reports indicate that 
Mcl-1 confers resistance to ABT-737 because of the poor affinity of ABT-737 for Mcl-1 and 
Bfl/A1 also binds ABT-737 weakly [443]. This suggests that the expression of BH3-only 
proteins which can occupy these apoptosis inhibitors should increase the sensitivity of 
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cells to ABT-737. Thus, understanding which patients should receive BH3-mimetics 
requires an understanding of the expression of both Bcl-2 family inhibitors and the BH3-
only proteins that bind to them.  Considering the BH3-only proteins, both activator and 
sensitizer proteins determine the sensitivity of cells to ABT-737/navitoclax.  
 
Bid, Bim and Puma are BH3-only activator proteins that can trigger Bax/Bak to induce 
apoptosis. Early work in the field highlighted the importance of the association of Bim 
with Bcl-2 in determining sensitivity to ABT-737 [444]. The existence of Bcl-2 primed with 
Bim predicted sensitivity to ABT-737, because ABT-737 can displace Bim from Bcl-2 and 
induce apoptosis.  Puma has also recently emerged as an activator BH3-only protein. In 
the presence of ABT-737 to occupy Bcl-2 inhibitors, the expression of Puma may be 
sufficient to induce apoptosis [445]. Puma co-operates with other activators and ABT-737 
to induce apoptosis [446] while loss of Puma reduces the apoptotic activity of ABT-737 
[445, 447]. Bid is an activator BH3-only protein which plays a role in the intrinsic 
apoptosis pathway. Caspase-mediated cleavage of BID promotes its pro-apoptotic 
activity. ABT-737 has been shown to trigger the cleavage of BID in leukaemia [448] and 
neuroblastoma cells [449]. How this occurs is unclear but it suggests cross-talk between 
the intrinsic and extrinsic apoptosis pathways, suggesting it may be necessary to consider 
the status of the extrinsic pathway as well when trying to predict sensitivity to BH3-
mimetics. 
 
BH3-only sensitizer proteins (Figure 7) can also contribute to the sensitivity of cells to 
ABT-737/navitoclax. Noxa is a particularly significant BH3-only protein because it binds to 
both Mcl-1 and Bfl/A1, both of which are insensitive to ABT-737/navitoclax. Noxa 
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increases the sensitivity of cells to ABT-737 by occupying the apoptosis inhibitors to which 
ABT-737/navitoclax does not bind. Bad is classified as a sensitizer which, in contrast to 
Noxa, has a similar binding specificity for Bcl-2 family apoptosis inhibitors similar to that 
of ABT-737. The liberation of BAD by ABT-737 indirectly induces apoptosis by reducing the 
reservoir of apoptosis inhibitors.  
 
The overall conclusion from these observations is that there is no single determinant of 
sensitivity to ABT-737 or navitoclax and the over-arching factor that determines the 
induction apoptosis appears to be whether sufficient pro-apoptotic proteins can be 
released to exceed the buffering capacity of the anti-apoptotic proteins when cells are 
exposed to navitoclax. This is determined by the repertoire of inhibitors, activators and 
sensitizers expressed in a particular cell. Thus, navitoclax may require a broad panel of 
biomarkers to predict accurately its activity in patients.  
 
Can the sensitivity of cells to navitoclax be increased? One obvious strategy that should 
be evaluated further is to decrease the expression of Mcl-1. This approach carries with it 
significant challenges because it has been shown that exposure to ABT-737 can itself 
increase expression of Mcl-1 [450-452] thus providing a mechanism by which ABT-737 
may partly induce “resistance to itself”. Several drugs have been shown to reduce the 
expression of Mcl-1 (Figure 37) and future work should consider their combined use with 
navitoclax. 
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Figure 37: Strategies to increase sensitivity to navitoclax. The sensitivity of cells to navitoclax can 
be increased using drugs which decrease the expression of Mcl-1. The Erk (including Raf and MEK) 
and PI 3-kinase pathways are key regulators of Mcl-1 expression so drugs inhibiting this path show 
synergy with navitoclax.  Drugs inhibiting other regulators of Mcl-1 are also shown, and these 
drugs also increase sensitivity to navitoclax. ARC, 4-amino-6-hydrazino-7-beta-D-ribofuranosyl-7H-
pyrrolo (2, 3-d)-pyrimidine-5-carboxamide; CTX, chemotherapy; EGF-R, EGF receptor; ROS, 
reactive oxygen species; SFK, src family kinase; 
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Future combinations of navitoclax with drugs expected to reduce Mcl-1 expression 
Raf inhibitors. The inhibition of Raf with sorafenib or the inhibition of MEK can reduce the 
expression of Mcl-1. ABT-737 combined with a MEK or Raf inhibitor has been shown to be 
more effective in xenograft studies than the single agents [453-455].  
Src family kinase inhibitors. Desatinib is an inhibitor of BcrAbl and Src-family kinases 
which also reduces the expression of Mcl-1 by inhibiting the src family kinase lyn. Lyn is 
widely expressed, so it will be of interest to evaluate this strategy in ovarian cancer. 
PI 3-kinase inhibitors. The PI-3 kinase pathway is frequently activated in cancer including 
ovarian cancer (Chapter 1). There are several points on the PI3K/Akt/mTORC1 pathway 
that could be inhibited and this is an active area of research, e.g.  GDC-0941 is a PI 3-
kinase inhibitor which reduces expression Mcl-1[450].  
Glycolysis. Mcl-1 expression is maintained in the presence of extracellular glucose, but it 
rapidly diminished in its absence and therefore the inhibition of glycolysis with 2-
deoxyglucose can also inhibit the expression of Mcl-1 [456, 457]. The combination of 2-
DG with ABT-737 or navitoclax improved the survival of animals with an experimental 
model of lymphoma [458] or prostate cancer [459] beyond that seen in animals treated 
with  either agent alone. 
ROS. Navitoclax could also be used together with fenretinide, a synthetic retinoid whose 
cytotoxic activity depends in part on the generation of reactive oxygen species (ROS). 
Subsequent activation of Jnk by ROS leads to phosphorylation and decreased levels of 
Mcl-1 [448]. 
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Transcription and translation inhibitors. Pim kinases are involved in the regulation of 
transcription, translation, cell survival and energy metabolism [460] and it has been seen 
that inhibition of Pim kinases decreases translation of Mcl-1 mRNA, as well as increasing 
degradation of Mcl-1 protein [461].ARC is a nucleoside analogue which inhibits Cdk9 and 
reduces the expression of Mcl-1 [462]. In combination with ABT-737, ARC induces 
apoptosis and causes a synergistic inhibition of cell survival. Transcription of Mcl-1 can 
also be reduced by exposure of cells to roscovitine which inhibits several cyclin 
dependant kinases including cdk9 and this also increases sensitivity to ABT737 [349, 443, 
463]. Synergy with flavopiridol, another pan cdk inhibitor that down-regulates Mcl-1, has 
also been observed [464]. The transcriptional inhibitor actinomycin has been shown to 
reduce Mcl-1[465, 466]. Other agents which have shown synergy with ABT-737 by virtue 
of down-regulating Mcl-1 include Methylseleninic acid [467] and  L-asparaginase [468]. 
Chemotherapy. Several chemotherapeutic agents like etoposide or cisplatin have shown 
synergy with ABT-737 (reviewed in[308]) and in some cases this reflects the down 
regulation of the expression of Mcl-1 by the chemotherapy [469, 470]. Their combined 
use with navitoclax is expected to show further synergistic effects. 
Proteosome inhibitors. The induction of the pro-apoptotic protein Noxa may lead to the 
ubiquitination and proteasomal degradation of Mcl-1 [471] and agents that induce this 
effect should be evaluated in combination studies with navitoclax or obatoclax. 
 
  
198 
 
The alternative approach to decreasing the expression of Mcl-1 is to promote the 
induction of BH3-only proteins which would then occupy Mcl-1 and hence increase 
sensitivity to navitoclax. For the purposes of this both chemotherapeutic and molecularly-
targeted agents have been used successfully and future work in ovarian cancer 
therapeutics should aim to examine their potential uses. 
 
Future combinations with navitoclax with drugs expected to induce BH3-only proteins. 
JAK2 inhibitors. An inhibitor of JAK2 induces Bim and also shows synergy with ABT-737 in 
cells harbouring a JAK2 activating mutation [472].  
Bad. Although Bad does not bind to Mcl-1, it is possible that it could still improve 
sensitivity to ABT-737 by reducing the total capacity of free apoptosis inhibitors. Both 
sorafenib [473, 474] and ABT-737 [475] can increase Bad protein levels. Bad is also likely 
to play a role in the change in sensitivity to ABT-737 when cells are deprived of glucose or 
exposed to 2-DG (discussed above).  In its unphosphorylated state, BAD promotes 
apoptosis, but when phosphorylated it regulates glucose metabolism [476]. 
Dephosphorylation of BAD is promoted by glucose deprivation [477], suggesting that 2-
DG may do the same, and that this may contribute to the synergy observed between ABT-
737 and 2-DG. However, 2-DG also induces the expression of Bim, Bmf and Noxa [478, 
479] and glucose deprivation induces Puma, Bid and Bim [456, 480], again making it 
difficult to assess the contribution of Bad. 
Noxa. The induction of Noxa is one key strategy, because Noxa binds to the Bcl-2 family 
proteins Mcl-1 and Bfl/A1 that are insensitive to antagonism by ABT-737 and Noxa has 
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also been reported to induce the degradation of Mcl-1 [471, 481, 482] but not in all cells 
[483]. Noxa is  induced by exposure to several chemotherapeutic agents including 
fludarabine [443] , CPT11 [484], imiquimod [485], dacarbazine [485] and actinomycin 
[465] and in each of these cases, synergy with ABT-737 has been observed. Expression of 
Noxa is also increased by exposure to targeted agents including several proposed BH3 
mimetics [452], bortezomib [443, 464], a Pim kinase inhibitor [461], and inhibition of 
signalling through the notch pathway using a γ-secretase inhibitor [486]. 
HDAC inhibitors. These agents have been shown to induce expression of Bim and the 
preferential priming by Bim of Bcl-2 and Bcl-XL compared to Mcl-1. Consequently, the 
HDAC inhibitor suberoyl bis-hydroxamic acid was found to induce apoptosis 
synergistically with ABT-737 [487]. ABT-737 released Bim from complexes with Bcl-2 or 
Bcl-XL, and knockdown of Bim substantially blunted the effect of the drug combinations. 
Vorinostat (also known as SAHA) induces histone acetylation, the expression of the genes 
encoding Bmf, Bim and Noxa and consequent priming of Bcl-2 [488]. As a result, 
vorinostat shows synergy with ABT-737 which is reduced by inhibition of Bmf expression 
by shRNA. 
Bim. Bim binds to all known Bcl-2 family proteins, including Mcl-1.  Inhibition of the 
epidermal growth factor receptor (EGFR) with erlotinib or gefitinib leads to increased 
expression of Bim [444, 489, 490], probably through transcriptional and translational 
regulation [489], and apoptosis.  In these experiments, ABT-737 exhibited minimal activity 
when tested on its own, but when combined with erlotinib or gefitinib, a supra-additive 
increase in cell death was observed. Sorafenib (which inhibits several kinases including 
Raf) induces Bim and apoptosis and is synergistic with ABT-737 in AML cells [474].  
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Obatoclax 
Unlike navitoclax, whose activity seems to be principally mediated by on-target effects, 
the evaluation of obatoclax in ovarian cancer in this study and previous work done by 
others for other malignancies has clearly demonstrated that obatoclax has off-target 
effects. Although these can be seen as a problem, this additional activity may be of 
significant value that perhaps should be utilised further. Obatoclax did not measurably 
induce apoptosis in Ovcar-3, Ovar-4 and Sk-Ov-3, despite killing the cells, and it is 
therefore imperative to identify the additional mechanism of action by which these cells 
were killed. The very nature of personalized medicine requires that the mechanism of 
action of a drug is understood, in order to determine which patients should receive it. In 
the case of obatoclax, the data presented in this work makes it clear that our 
understanding is incomplete. One approach worth considering is to perform first 
xenograft studies using cells that respond via apoptosis and compare the results with 
xenografts of cells that respond via the “additional” mechanism. In the present study, 
minimal activity was observed in xenograft studies with Ovcar-8 cells, which do undergo 
apoptosis. From that perspective, it would be worth evaluating the activity of obatoclax 
with xenografts of cells that do not undergo apoptosis in response to obatoclax, such as in 
Sk-Ov-3 xenografts.  It would also be worthwhile simply repeating the studies with 
obatoclax in another cell line (e.g. Igrov) that did undergo apoptosis because significant 
problems were encountered in growing Ovcar-8 as xenografts. Obatoclax also deserves 
further investigation using different schedules of drug administration (as discussed in 
Chapter 4). It seems sensible to conduct these studies to assess the efficacy of obatoclax 
before further studies are performed to identify the additional mechanism of action. 
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Although obatoclax binds to all Bcl-2 family inhibitors, it may be useful to consider some 
of the same drug combinations discussed for ABT-737/navitoclax with obatoclax. 
Decreasing the expression of Bcl-2 family apoptosis inhibitors, or increasing the 
expression of BH3-only proteins, may augment the activity of obatoclax. 
 
The importance of experimental conditions 
The underlying goal of investigating the activity of BH3-mimetics in ovarian cancer at a 
preclinical level is to prepare the ground for these agents to be used in the clinic to 
improve patients’ response. This presupposes that all the in vitro measurements made in 
the laboratory are predictive of clinical outcome. It is therefore reasonable to question 
the value of all of our preclinical models and emphasize the use of those that are as 
realistic as possible, so appropriate hypotheses are tested in clinical studies.  It is without 
doubt that today worldwide the most common setting in which sensitivity to drugs is 
measured is based on the use of cancer cell lines grown in nutrient and growth-factor rich 
media, as a monolayer attached to cell culture plasticware, in 21% O2 (i.e. atmospheric 
oxygen). Over the last few years an increasing amount of evidence shows that this is 
perhaps not the most realistic model, despite its ready availability, convenient access and 
cost-efficiency. In patients, cancer cells may be located in hypoxic, nutrient-poor 
environments, comprising three-dimensional tumours. Each of these factors has already 
been reported to affect cell sensitivity to BH3-mimetics and other antineoplastic drugs.  
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Hypoxia appears to increase the sensitivity of tumour cells to ABT-737 [491-493]. This 
could either be due to down-regulation of Mcl-1 [491], or up-regulation of BH3-only 
proteins including PUMA, Noxa and BNIP3 [493].  It is noteworthy that cells resistant to 
anoxia show increased expression of Bcl-2 family proteins [493]. In xenograft studies, 
ABT-737 induces apoptosis preferentially in hypoxic regions of the tumour [491]. It has 
been seen that the degree of synergy observed in vitro between chemotherapeutic 
agents and ABT-737 is dependent on oxygen concentration [491]. Thus, it may be 
advisable to evaluate the activity of navitoclax and obatoclax in laboratory experiments 
under a more physiological oxygen tension, considerably lower than the one commonly 
applied. An initial step towards this was reported in this thesis. 
 
The utilisation of three-dimensional cultures such as spheroids offers an alternative to the 
conventional monolayer cultures currently in use. These aggregates of proliferating 
cancer cells are prevented from adhering to a solid surface and their formation can mimic 
a small tumour. It can be said that they resemble more closely the cancer cell spheroids 
found in the ascites of advanced ovarian cancer patients. It has already been reported 
that in these models the repertoire of Bcl-2 family proteins appears to change, compared 
to the same cell line grown as a monolayer.  Increases in the expression of Bcl-2 and Bcl-
XL have been observed in spheroids [402, 494-496], and decreases in the expression of 
Mcl-1 have also been reported [402, 494]. This implies a switch towards a BH3-sensitive 
phenotype in cells grown as spheroids. The above observations highlight the usefulness of 
incorporating cancer cell spheroids as tumour models into the laboratory investigations, 
but some caution is appropriate.  The physiology of an avascular cancer cell formation 
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affects the pharmacodynamic properties of any drug and any observed decrease in drug 
sensitivity in a spheroid culture can also be explained by poor diffusion of the drug into 
the spheroid inner mass [497], or a reduced rate of cell proliferation. The changes in the 
expression of both pro- and anti-apoptotic Bcl-2 family members observed in spheroids 
may also be linked to the oxygen gradient between the inside and outside of the spheroid 
[491]. 
 
Implementing personalized medicine with BH3-mimetics 
By definition, the success of tailored anticancer therapy will depend grossly on the 
accurate selection of patients who are most likely to benefit from it.  The choice of drug 
and sequence of administration to the patient should preferably be based on a dynamic 
monitoring of the biological responses of the tumour and the clinical condition of the 
patient. Both of these aspirations imply that for future clinical studies with navitoclax and 
obatoclax we would need to be able to identify which patients should receive the drug(s), 
either alone or in combinations. Bearing in mind the number of factors discussed 
previously which influence the sensitivity to BH3-mimetics, it is no small challenge to 
decide how to address this. 
 
Until today there has not been any evidence to suggest that a correlation exists between 
drug sensitivity and the expression of an individual Bcl-2 family member [443, 483, 498, 
499]. In the case of BH3-mimetics, Mcl-1 does confer resistance and from that point of 
view one strategy for patient selection would be to measure Mcl-1 in order to select 
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which patients should receive navitoclax alone, or which would benefit from a 
combination with a drug that would repress Mcl-1. The predictive value of Mcl-1 
measurements has been investigated and can be improved by measuring multiple anti-
apoptotic Bcl-2 family members [464, 499, 500]. We also have evidence to suggest that 
the pro-apoptotic Bcl2 family members influence the sensitivity of cancer cells to ABT-737 
as it has been shown from reports which describe correlations between Noxa/Mcl-1 
ratios [443, 483] or Bim/Mcl-1 ratios with the activity of ABT-737 [501]. This suggests that 
the process of designing a panel of biomarkers to select patients for treatment should 
consider the inclusion of measurements of all the Bcl-2 family members. For those 
tumours overexpressing more than one of the anti-apoptotic Bcl-2 proteins, determining 
the distribution of pro-apoptotic proteins among the various apoptosis inhibitors is likely 
to be a better predictor of sensitivity to ABT-737 than simply measuring expression [381, 
502]. The dependence of tumours on different apoptosis inhibitors may be measured by a 
test termed “BH-3 profiling”, which has the potential to be used clinically [503]. 
Considering that short-term exposure to ABT-737 has been reported to elevate 
expression of Mcl-1 [450-452], Bfl/A1 [504] as well as Bad [473, 475] and Noxa, [483] it is 
very likely that measurement of Bcl-2 family members prior to drug treatment may 
provide an inaccurate estimation of drug response. One solution to this might be to 
briefly expose patients to navitoclax prior to surgery and measure Bcl-2 family members 
in the excised tumour. Similar biomarker evaluations could very well become part of the 
clinical care even during the course of treatment, in case chemoresistance was suspected. 
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Undoubtedly, the usefulness of any biomarkers will remain to be seen in practice.  If the 
adverse events induced by BH3-mimetics are only modest, then the false-positive 
frequency (the frequency with which patients inappropriately receive the BH3-mimetic) is 
potentially less relevant. However, experience to date suggests thrombocytopenia can be 
a serious issue (Chapter 3), so the false-positive frequency of any biomarker panel should 
be appropriately low to ensure patient safety.  
 
Conclusion 
The discovery of BH3-mimetics has delivered a class of drugs with evidence of promising 
preclinical activity in many types of cancer. Both navitoclax and obatoclax advanced in 
phase I & II clinical trials, where they were found initially to be overall well tolerated by 
patients although thrombocytopenia has been a significant concern. In the case of 
navitoclax, on-going trials have been suspended due to haematological adverse events 
and the results of these trials assessing the efficacy of navitoclax are currently awaited. 
However, the experience with navitoclax has greatly influenced the development of ABT-
199, an agent which avoids Bcl-XL mediated thrombocytopenia through its low affinity for 
Bcl-XL, but unfortunately at the same time this means it is not likely to be effective in 
ovarian cancer [312]. The development of obatoclax, initially produced by GeminX, 
bought by Cephalon and now owned by Teva, has stopped as the current proprietor has 
chosen to focus on different therapeutic areas. These developments have not stopped 
the characterisation of new compounds with improved profiles [505] and currently BH3-
mimetics are being assessed in a wider range of cancers [506]. These updates exemplify 
how rapidly things change in drug discovery and how the discovery of a drug can 
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stimulate interest and eventually lead to a diverse number of newer agents with 
improved profiles and better clinical applicability. 
 
The transition from the conventional model of cytotoxic chemotherapy to the newer 
concept of targeted therapeutics will hopefully result in improved efficacy and will be 
accompanied by a reduction in the incidence of adverse effects. At present, cancer 
therapies are designed based on a ‘one size fits all’ approach with regard to the tumour 
histological type and the stage of disease. The aim of this study is to utilise targeted 
therapeutics such as BH3-mimetics, to increase efficacy and reduce toxicity. This 
proposed change in cancer treatment will inevitably signal the coming of a new era and 
the adjustment of our standard of practice of cancer therapeutics. The concept of 
personalised medicine is an appealing solution to the problem of chemoresistance today, 
but demands a depth of understanding of disease biology that is only just beginning to be 
translated from the laboratory to the clinic. 
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